BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, Powderly JD, Carvajal RD, Sosman JA, Atkins MB, Leming PD, Spigel DR, Antonia SJ, Horn L, Drake CG, Pardoll DM, Chen L, Sharfman WH, Anders RA, Taube JM, McMiller TL, Xu H, Korman AJ, Jure-Kunkel M, Agrawal S, McDonald D, Kollia GD, Gupta A, Wigginton JM, Sznol M. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012;366:2443-54. [PMID: 22658127 DOI: 10.1056/NEJMoa1200690] [Cited by in Crossref: 7634] [Cited by in F6Publishing: 4584] [Article Influence: 763.4] [Reference Citation Analysis]
Number Citing Articles
1 Scognamiglio G, De Chiara A, Di Bonito M, Tatangelo F, Losito NS, Anniciello A, De Cecio R, D'Alterio C, Scala S, Cantile M, Botti G. Variability in Immunohistochemical Detection of Programmed Death Ligand 1 (PD-L1) in Cancer Tissue Types. Int J Mol Sci 2016;17:E790. [PMID: 27213372 DOI: 10.3390/ijms17050790] [Cited by in Crossref: 20] [Cited by in F6Publishing: 23] [Article Influence: 3.3] [Reference Citation Analysis]
2 Vogelstein B, Papadopoulos N, Velculescu VE, Zhou S, Diaz LA, Kinzler KW. Cancer genome landscapes. Science. 2013;339:1546-1558. [PMID: 23539594 DOI: 10.1126/science.1235122] [Cited by in Crossref: 4552] [Cited by in F6Publishing: 3999] [Article Influence: 505.8] [Reference Citation Analysis]
3 Blessin NC, Spriestersbach P, Li W, Mandelkow T, Dum D, Simon R, Hube-Magg C, Lutz F, Viehweger F, Lennartz M, Fraune C, Nickelsen V, Fehrle W, Göbel C, Weidemann S, Clauditz T, Lebok P, Möller K, Steurer S, Izbicki JR, Sauter G, Minner S, Jacobsen F, Luebke AM, Büscheck F, Höflmayer D, Wilczak W, Burandt E, Hinsch A. Prevalence of CD8+ cytotoxic lymphocytes in human neoplasms. Cell Oncol (Dordr) 2020;43:421-30. [PMID: 32141029 DOI: 10.1007/s13402-020-00496-7] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
4 Wang W, Shen G, Wu S, Song S, Ni Y, Suo Z, Meng X, Li D, Zhou L, Hao R, Zhao Y, Bai L, Hou L, Liu B, Liu G. PD-1 mRNA expression in peripheral blood cells and its modulation characteristics in cancer patients. Oncotarget 2017;8:50782-91. [PMID: 28881603 DOI: 10.18632/oncotarget.15006] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
5 Lamarca A, Nonaka D, Breitwieser W, Ashton G, Barriuso J, McNamara MG, Moghadam S, Rogan J, Mansoor W, Hubner RA, Clark C, Chakrabarty B, Valle JW. PD-L1 expression and presence of TILs in small intestinal neuroendocrine tumours. Oncotarget 2018;9:14922-38. [PMID: 29599916 DOI: 10.18632/oncotarget.24464] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 4.3] [Reference Citation Analysis]
6 Feld E, Horn L. Emerging role of nivolumab in the management of patients with non-small-cell lung cancer: current data and future perspectives. Onco Targets Ther 2017;10:3697-708. [PMID: 28769573 DOI: 10.2147/OTT.S97903] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
7 Josefsson SE, Huse K, Kolstad A, Beiske K, Pende D, Steen CB, Inderberg EM, Lingjærde OC, Østenstad B, Smeland EB, Levy R, Irish JM, Myklebust JH. T Cells Expressing Checkpoint Receptor TIGIT Are Enriched in Follicular Lymphoma Tumors and Characterized by Reversible Suppression of T-cell Receptor Signaling. Clin Cancer Res 2018;24:870-81. [PMID: 29217528 DOI: 10.1158/1078-0432.CCR-17-2337] [Cited by in Crossref: 39] [Cited by in F6Publishing: 23] [Article Influence: 7.8] [Reference Citation Analysis]
8 Everts A, Bergeman M, McFadden G, Kemp V. Simultaneous Tumor and Stroma Targeting by Oncolytic Viruses. Biomedicines 2020;8:E474. [PMID: 33167307 DOI: 10.3390/biomedicines8110474] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
9 Kwak G, Kim D, Nam GH, Wang SY, Kim IS, Kim SH, Kwon IC, Yeo Y. Programmed Cell Death Protein Ligand-1 Silencing with Polyethylenimine-Dermatan Sulfate Complex for Dual Inhibition of Melanoma Growth. ACS Nano 2017;11:10135-46. [PMID: 28985469 DOI: 10.1021/acsnano.7b04717] [Cited by in Crossref: 49] [Cited by in F6Publishing: 47] [Article Influence: 9.8] [Reference Citation Analysis]
10 Zalba S, Belsúe V, Topp B, de Alwis D, Alvarez M, Trocóniz IF, Berraondo P, Garrido MJ. Modulation of intratumoural myeloid cells, the hallmark of the anti-tumour efficacy induced by a triple combination: tumour-associated peptide, TLR-3 ligand and α-PD-1. Br J Cancer 2021;124:1275-85. [PMID: 33531689 DOI: 10.1038/s41416-020-01239-z] [Reference Citation Analysis]
11 Lee GA, Lin WL, Kuo DP, Li YT, Chang YW, Chen YC, Huang SW, Hsu JB, Chen CY. Detection of PD-L1 Expression in Temozolomide-Resistant Glioblastoma by Using PD-L1 Antibodies Conjugated with Lipid‑Coated Superparamagnetic Iron Oxide. Int J Nanomedicine 2021;16:5233-46. [PMID: 34366665 DOI: 10.2147/IJN.S310464] [Reference Citation Analysis]
12 Gerner MY, Heltemes-Harris LM, Fife BT, Mescher MF. Cutting edge: IL-12 and type I IFN differentially program CD8 T cells for programmed death 1 re-expression levels and tumor control. J Immunol 2013;191:1011-5. [PMID: 23804712 DOI: 10.4049/jimmunol.1300652] [Cited by in Crossref: 49] [Cited by in F6Publishing: 47] [Article Influence: 5.4] [Reference Citation Analysis]
13 van der Werf N, Redpath SA, Azuma M, Yagita H, Taylor MD. Th2 cell-intrinsic hypo-responsiveness determines susceptibility to helminth infection. PLoS Pathog 2013;9:e1003215. [PMID: 23516361 DOI: 10.1371/journal.ppat.1003215] [Cited by in Crossref: 38] [Cited by in F6Publishing: 39] [Article Influence: 4.2] [Reference Citation Analysis]
14 Jain P, Jain C, Velcheti V. Role of immune-checkpoint inhibitors in lung cancer. Ther Adv Respir Dis 2018;12:1753465817750075. [PMID: 29385894 DOI: 10.1177/1753465817750075] [Cited by in Crossref: 40] [Cited by in F6Publishing: 44] [Article Influence: 13.3] [Reference Citation Analysis]
15 Tsuchiya N, Yoshikawa T, Fujinami N, Saito K, Mizuno S, Sawada Y, Endo I, Nakatsura T. Immunological efficacy of glypican-3 peptide vaccine in patients with advanced hepatocellular carcinoma. Oncoimmunology. 2017;6:e1346764. [PMID: 29123959 DOI: 10.1080/2162402x.2017.1346764] [Cited by in Crossref: 30] [Cited by in F6Publishing: 19] [Article Influence: 6.0] [Reference Citation Analysis]
16 Wan Y, An S, Zhou Y, Zhang J, Zhang Y, Gan T, Liu Q. Is Weak Acid Beneficial for Addressing Checkpoint Inhibitor-Triggered Cancer Hyper Progression in Anti-PD1/PD-L1 Immunotherapies? Cancer Control 2020;27:1073274820944290. [PMID: 32959668 DOI: 10.1177/1073274820944290] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
17 Cai L, Sun Y, Wang K, Guan W, Yue J, Li J, Wang R, Wang L. The Better Survival of MSI Subtype Is Associated With the Oxidative Stress Related Pathways in Gastric Cancer. Front Oncol 2020;10:1269. [PMID: 32850385 DOI: 10.3389/fonc.2020.01269] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
18 Kang J, Jeong JH, Hwang HS, Lee SS, Park DH, Oh DW, Song TJ, Kim KH, Hwang S, Hwang DW, Kim SC, Park JH, Hong SM, Kim KP, Ryoo BY, Yoo C. Efficacy and Safety of Pembrolizumab in Patients with Refractory Advanced Biliary Tract Cancer: Tumor Proportion Score as a Potential Biomarker for Response. Cancer Res Treat 2020;52:594-603. [PMID: 32019287 DOI: 10.4143/crt.2019.493] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 4.7] [Reference Citation Analysis]
19 Twitty CG, Huppert LA, Daud AI. Prognostic Biomarkers for Melanoma Immunotherapy. Curr Oncol Rep 2020;22:25. [PMID: 32048065 DOI: 10.1007/s11912-020-0886-z] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
20 Zhang L, Li L, Zhan Y, Wang J, Zhu Z, Zhang X. Identification of Immune-Related lncRNA Signature to Predict Prognosis and Immunotherapeutic Efficiency in Bladder Cancer. Front Oncol 2020;10:542140. [PMID: 33552945 DOI: 10.3389/fonc.2020.542140] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
21 Lo JA, Fisher DE, Flaherty KT. Prognostic Significance of Cutaneous Adverse Events Associated With Pembrolizumab Therapy. JAMA Oncol 2015;1:1340-1. [PMID: 26270186 DOI: 10.1001/jamaoncol.2015.2274] [Cited by in Crossref: 44] [Cited by in F6Publishing: 41] [Article Influence: 7.3] [Reference Citation Analysis]
22 Jacobs J, Smits E, Lardon F, Pauwels P, Deschoolmeester V. Immune Checkpoint Modulation in Colorectal Cancer: What's New and What to Expect. J Immunol Res 2015;2015:158038. [PMID: 26605342 DOI: 10.1155/2015/158038] [Cited by in Crossref: 30] [Cited by in F6Publishing: 27] [Article Influence: 4.3] [Reference Citation Analysis]
23 Bachireddy P, Hainz U, Rooney M, Pozdnyakova O, Aldridge J, Zhang W, Liao X, Hodi FS, O'Connell K, Haining WN, Goldstein NR, Canning CM, Soiffer RJ, Ritz J, Hacohen N, Alyea EP 3rd, Kim HT, Wu CJ. Reversal of in situ T-cell exhaustion during effective human antileukemia responses to donor lymphocyte infusion. Blood 2014;123:1412-21. [PMID: 24357730 DOI: 10.1182/blood-2013-08-523001] [Cited by in Crossref: 56] [Cited by in F6Publishing: 55] [Article Influence: 6.2] [Reference Citation Analysis]
24 Lee PC, Chao Y, Chen MH, Lan KH, Lee CJ, Lee IC, Chen SC, Hou MC, Huang YH. Predictors of Response and Survival in Immune Checkpoint Inhibitor-Treated Unresectable Hepatocellular Carcinoma. Cancers (Basel) 2020;12:E182. [PMID: 31940757 DOI: 10.3390/cancers12010182] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 9.0] [Reference Citation Analysis]
25 Park TS, Abate-Daga D, Zhang L, Zheng Z, Morgan RA. Gamma-retroviral vector design for the co-expression of artificial microRNAs and therapeutic proteins. Nucleic Acid Ther 2014;24:356-63. [PMID: 25019196 DOI: 10.1089/nat.2014.0486] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
26 Corrales L, Ajona D, Rafail S, Lasarte JJ, Riezu-Boj JI, Lambris JD, Rouzaut A, Pajares MJ, Montuenga LM, Pio R. Anaphylatoxin C5a creates a favorable microenvironment for lung cancer progression. J Immunol 2012;189:4674-83. [PMID: 23028051 DOI: 10.4049/jimmunol.1201654] [Cited by in Crossref: 162] [Cited by in F6Publishing: 148] [Article Influence: 16.2] [Reference Citation Analysis]
27 Jia W, Gao Q, Han A, Zhu H, Yu J. The potential mechanism, recognition and clinical significance of tumor pseudoprogression after immunotherapy. Cancer Biol Med. 2019;16:655-670. [PMID: 31908886 DOI: 10.20892/j.issn.2095-3941.2019.0144] [Cited by in F6Publishing: 15] [Reference Citation Analysis]
28 Linkermann A, Stockwell BR, Krautwald S, Anders HJ. Regulated cell death and inflammation: an auto-amplification loop causes organ failure. Nat Rev Immunol 2014;14:759-67. [PMID: 25324125 DOI: 10.1038/nri3743] [Cited by in Crossref: 258] [Cited by in F6Publishing: 244] [Article Influence: 32.3] [Reference Citation Analysis]
29 Kunert A, Straetemans T, Govers C, Lamers C, Mathijssen R, Sleijfer S, Debets R. TCR-Engineered T Cells Meet New Challenges to Treat Solid Tumors: Choice of Antigen, T Cell Fitness, and Sensitization of Tumor Milieu. Front Immunol 2013;4:363. [PMID: 24265631 DOI: 10.3389/fimmu.2013.00363] [Cited by in Crossref: 54] [Cited by in F6Publishing: 52] [Article Influence: 6.0] [Reference Citation Analysis]
30 Kersten K, Salvagno C, de Visser KE. Exploiting the Immunomodulatory Properties of Chemotherapeutic Drugs to Improve the Success of Cancer Immunotherapy. Front Immunol 2015;6:516. [PMID: 26500653 DOI: 10.3389/fimmu.2015.00516] [Cited by in Crossref: 45] [Cited by in F6Publishing: 42] [Article Influence: 6.4] [Reference Citation Analysis]
31 Jarczak D, Kluge S, Nierhaus A. Sepsis-Pathophysiology and Therapeutic Concepts. Front Med (Lausanne) 2021;8:628302. [PMID: 34055825 DOI: 10.3389/fmed.2021.628302] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
32 Shen L, Guo J, Zhang Q, Pan H, Yuan Y, Bai Y, Liu T, Zhou Q, Zhao J, Shu Y, Huang X, Wang S, Wang J, Zhou A, Ye D, Sun T, Gao Y, Yang S, Wang Z, Li J, Wu YL. Tislelizumab in Chinese patients with advanced solid tumors: an open-label, non-comparative, phase 1/2 study. J Immunother Cancer 2020;8:e000437. [PMID: 32561638 DOI: 10.1136/jitc-2019-000437] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 15.0] [Reference Citation Analysis]
33 Li G, Wang Z, Zhang C, Liu X, Cai J, Wang Z, Hu H, Wu F, Bao Z, Liu Y, Zhao L, Liang T, Yang F, Huang R, Zhang W, Jiang T. Molecular and clinical characterization of TIM-3 in glioma through 1,024 samples. Oncoimmunology 2017;6:e1328339. [PMID: 28919992 DOI: 10.1080/2162402X.2017.1328339] [Cited by in Crossref: 53] [Cited by in F6Publishing: 50] [Article Influence: 10.6] [Reference Citation Analysis]
34 Van der Jeught K, Xu HC, Li YJ, Lu XB, Ji G. Drug resistance and new therapies in colorectal cancer. World J Gastroenterol 2018; 24(34): 3834-3848 [PMID: 30228778 DOI: 10.3748/wjg.v24.i34.3834] [Cited by in CrossRef: 163] [Cited by in F6Publishing: 148] [Article Influence: 40.8] [Reference Citation Analysis]
35 Hailemichael Y, Woods A, Fu T, He Q, Nielsen MC, Hasan F, Roszik J, Xiao Z, Vianden C, Khong H, Singh M, Sharma M, Faak F, Moore D, Dai Z, Anthony SM, Schluns KS, Sharma P, Engelhard VH, Overwijk WW. Cancer vaccine formulation dictates synergy with CTLA-4 and PD-L1 checkpoint blockade therapy. J Clin Invest 2018;128:1338-54. [PMID: 29480817 DOI: 10.1172/JCI93303] [Cited by in Crossref: 41] [Cited by in F6Publishing: 31] [Article Influence: 10.3] [Reference Citation Analysis]
36 Patel PM, Ottensmeier CH, Mulatero C, Lorigan P, Plummer R, Pandha H, Elsheikh S, Hadjimichael E, Villasanti N, Adams SE, Cunnell M, Metheringham RL, Brentville VA, Machado L, Daniels I, Gijon M, Hannaman D, Durrant LG. Targeting gp100 and TRP-2 with a DNA vaccine: Incorporating T cell epitopes with a human IgG1 antibody induces potent T cell responses that are associated with favourable clinical outcome in a phase I/II trial. Oncoimmunology 2018;7:e1433516. [PMID: 29872563 DOI: 10.1080/2162402X.2018.1433516] [Cited by in Crossref: 24] [Cited by in F6Publishing: 17] [Article Influence: 6.0] [Reference Citation Analysis]
37 Zheng X, Wei H. Organ-Specific Immune-Related Adverse Events for PD-1 Antibodies in Lung Cancer Treatment. Front Oncol 2021;11:628243. [PMID: 34094910 DOI: 10.3389/fonc.2021.628243] [Reference Citation Analysis]
38 Hibbert JE, Currie A, Strunk T. Sepsis-Induced Immunosuppression in Neonates. Front Pediatr 2018;6:357. [PMID: 30555806 DOI: 10.3389/fped.2018.00357] [Cited by in Crossref: 23] [Cited by in F6Publishing: 20] [Article Influence: 5.8] [Reference Citation Analysis]
39 Gohil SH, Paredes-Moscosso SR, Harrasser M, Vezzalini M, Scarpa A, Morris E, Davidoff AM, Sorio C, Nathwani AC, Della Peruta M. An ROR1 bi-specific T-cell engager provides effective targeting and cytotoxicity against a range of solid tumors. Oncoimmunology 2017;6:e1326437. [PMID: 28811962 DOI: 10.1080/2162402X.2017.1326437] [Cited by in Crossref: 22] [Cited by in F6Publishing: 15] [Article Influence: 4.4] [Reference Citation Analysis]
40 Taylor A, Rudd CE. Commentary: Small Molecule Inhibition of PD-1 Transcription is an Effective Alternative to Antibody Blockade in Cancer Therapy. J Immunol Sci 2019;3:9-12. [PMID: 31111120 DOI: 10.29245/2578-3009/2019/1.1167] [Reference Citation Analysis]
41 Prieto J, Melero I, Sangro B. Immunological landscape and immunotherapy of hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol. 2015;12:681-700. [PMID: 26484443 DOI: 10.1038/nrgastro.2015.173] [Cited by in Crossref: 252] [Cited by in F6Publishing: 262] [Article Influence: 36.0] [Reference Citation Analysis]
42 Kansy B, Lang S. [Immunotherapy - The New Era of Oncology]. Laryngorhinootologie 2018;97:S3-S47. [PMID: 29905353 DOI: 10.1055/s-0043-121594] [Reference Citation Analysis]
43 Márquez-Rodas I, Cerezuela P, Soria A, Berrocal A, Riso A, González-Cao M, Martín-Algarra S. Immune checkpoint inhibitors: therapeutic advances in melanoma. Ann Transl Med 2015;3:267. [PMID: 26605313 DOI: 10.3978/j.issn.2305-5839.2015.10.27] [Cited by in F6Publishing: 35] [Reference Citation Analysis]
44 Zhao Y, Lee CK, Lin CH, Gassen RB, Xu X, Huang Z, Xiao C, Bonorino C, Lu LF, Bui JD, Hui E. PD-L1:CD80 Cis-Heterodimer Triggers the Co-stimulatory Receptor CD28 While Repressing the Inhibitory PD-1 and CTLA-4 Pathways. Immunity 2019;51:1059-1073.e9. [PMID: 31757674 DOI: 10.1016/j.immuni.2019.11.003] [Cited by in Crossref: 71] [Cited by in F6Publishing: 65] [Article Influence: 23.7] [Reference Citation Analysis]
45 Kang A, Yuen M, Lee DJ. Nivolumab-induced systemic vasculitis. JAAD Case Rep 2018;4:606-8. [PMID: 30003129 DOI: 10.1016/j.jdcr.2018.03.013] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 2.8] [Reference Citation Analysis]
46 . Resection with intraoperative cesium-131 brachytherapy as salvage therapy for recurrent brain tumors. Journal of Neurosurgery 2022. [DOI: 10.3171/2021.10.jns211886] [Reference Citation Analysis]
47 Leitner J, Rieger A, Pickl WF, Zlabinger G, Grabmeier-Pfistershammer K, Steinberger P. TIM-3 does not act as a receptor for galectin-9. PLoS Pathog. 2013;9:e1003253. [PMID: 23555261 DOI: 10.1371/journal.ppat.1003253] [Cited by in Crossref: 62] [Cited by in F6Publishing: 61] [Article Influence: 6.9] [Reference Citation Analysis]
48 Mansour M, Teo ZL, Luen SJ, Loi S. Advancing Immunotherapy in Metastatic Breast Cancer. Curr Treat Options Oncol 2017;18:35. [PMID: 28534250 DOI: 10.1007/s11864-017-0478-9] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
49 Chang J, Tran J, Kamel D, Basu A. Nivolumab-induced hypophysitis leading to hypopituitarism and secondary empty sella syndrome in a patient with non-small cell lung cancer. BMJ Case Rep 2019;12:e228135. [PMID: 30850565 DOI: 10.1136/bcr-2018-228135] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 2.3] [Reference Citation Analysis]
50 Zhao Q, Xie R, Lin S, You X, Weng X. Anti-PD-1/PD-L1 Antibody Therapy for Pretreated Advanced or Metastatic Nonsmall Cell Lung Carcinomas and the Correlation between PD-L1 Expression and Treatment Effectiveness: An Update Meta-Analysis of Randomized Clinical Trials. Biomed Res Int 2018;2018:3820956. [PMID: 30345301 DOI: 10.1155/2018/3820956] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 2.8] [Reference Citation Analysis]
51 Stampouloglou E, Cheng N, Federico A, Slaby E, Monti S, Szeto GL, Varelas X. Yap suppresses T-cell function and infiltration in the tumor microenvironment. PLoS Biol 2020;18:e3000591. [PMID: 31929526 DOI: 10.1371/journal.pbio.3000591] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 6.0] [Reference Citation Analysis]
52 Idorn M, Thor Straten P. Chemokine Receptors and Exercise to Tackle the Inadequacy of T Cell Homing to the Tumor Site. Cells 2018;7:E108. [PMID: 30126117 DOI: 10.3390/cells7080108] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 3.5] [Reference Citation Analysis]
53 Wang DY, Ye F, Zhao S, Johnson DB. Incidence of immune checkpoint inhibitor-related colitis in solid tumor patients: A systematic review and meta-analysis. Oncoimmunology 2017;6:e1344805. [PMID: 29123955 DOI: 10.1080/2162402X.2017.1344805] [Cited by in Crossref: 79] [Cited by in F6Publishing: 42] [Article Influence: 15.8] [Reference Citation Analysis]
54 Fediw M, Lau K. Novel Cancer Therapeutics and Implications for Rehabilitation. Curr Phys Med Rehabil Rep 2021;9:224-9. [DOI: 10.1007/s40141-021-00323-6] [Reference Citation Analysis]
55 Iivanainen S, Alanko T, Vihinen P, Konkola T, Ekstrom J, Virtanen H, Koivunen J. Follow-Up of Cancer Patients Receiving Anti-PD-(L)1 Therapy Using an Electronic Patient-Reported Outcomes Tool (KISS): Prospective Feasibility Cohort Study. JMIR Form Res 2020;4:e17898. [PMID: 33112242 DOI: 10.2196/17898] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
56 D'Angelo SP, Shoushtari AN, Agaram NP, Kuk D, Qin LX, Carvajal RD, Dickson MA, Gounder M, Keohan ML, Schwartz GK, Tap WD. Prevalence of tumor-infiltrating lymphocytes and PD-L1 expression in the soft tissue sarcoma microenvironment. Hum Pathol 2015;46:357-65. [PMID: 25540867 DOI: 10.1016/j.humpath.2014.11.001] [Cited by in Crossref: 151] [Cited by in F6Publishing: 154] [Article Influence: 18.9] [Reference Citation Analysis]
57 Holtzhausen A, Zhao F, Evans KS, Tsutsui M, Orabona C, Tyler DS, Hanks BA. Melanoma-Derived Wnt5a Promotes Local Dendritic-Cell Expression of IDO and Immunotolerance: Opportunities for Pharmacologic Enhancement of Immunotherapy. Cancer Immunol Res 2015;3:1082-95. [PMID: 26041736 DOI: 10.1158/2326-6066.CIR-14-0167] [Cited by in Crossref: 89] [Cited by in F6Publishing: 67] [Article Influence: 12.7] [Reference Citation Analysis]
58 Dong H, Yan Y, Dronca RS, Markovic SN. A T cell equation as a conceptual model of T cell responses for maximizing the efficacy of cancer immunotherapy. SOJ Immunol 2017;5:1-5. [PMID: 29629436 DOI: 10.15226/2372-0948/5/1/00155] [Reference Citation Analysis]
59 Khagi Y, Goodman AM, Daniels GA, Patel SP, Sacco AG, Randall JM, Bazhenova LA, Kurzrock R. Hypermutated Circulating Tumor DNA: Correlation with Response to Checkpoint Inhibitor-Based Immunotherapy. Clin Cancer Res 2017;23:5729-36. [PMID: 28972084 DOI: 10.1158/1078-0432.CCR-17-1439] [Cited by in Crossref: 113] [Cited by in F6Publishing: 78] [Article Influence: 28.3] [Reference Citation Analysis]
60 Zappasodi R, Budhu S, Hellmann MD, Postow MA, Senbabaoglu Y, Manne S, Gasmi B, Liu C, Zhong H, Li Y, Huang AC, Hirschhorn-Cymerman D, Panageas KS, Wherry EJ, Merghoub T, Wolchok JD. Non-conventional Inhibitory CD4+Foxp3-PD-1hi T Cells as a Biomarker of Immune Checkpoint Blockade Activity. Cancer Cell 2018;33:1017-1032.e7. [PMID: 29894689 DOI: 10.1016/j.ccell.2018.05.009] [Cited by in Crossref: 70] [Cited by in F6Publishing: 65] [Article Influence: 23.3] [Reference Citation Analysis]
61 Gerard CL, Delyon J, Wicky A, Homicsko K, Cuendet MA, Michielin O. Turning tumors from cold to inflamed to improve immunotherapy response. Cancer Treat Rev 2021;101:102227. [PMID: 34656019 DOI: 10.1016/j.ctrv.2021.102227] [Reference Citation Analysis]
62 Hollingsworth RE, Jansen K. Turning the corner on therapeutic cancer vaccines. NPJ Vaccines. 2019;4:7. [PMID: 30774998 DOI: 10.1038/s41541-019-0103-y] [Cited by in Crossref: 195] [Cited by in F6Publishing: 173] [Article Influence: 65.0] [Reference Citation Analysis]
63 Pauken KE, Dougan M, Rose NR, Lichtman AH, Sharpe AH. Adverse Events Following Cancer Immunotherapy: Obstacles and Opportunities. Trends Immunol 2019;40:511-23. [PMID: 31053497 DOI: 10.1016/j.it.2019.04.002] [Cited by in Crossref: 74] [Cited by in F6Publishing: 64] [Article Influence: 24.7] [Reference Citation Analysis]
64 Zhou ZX, Zhang HX, Zheng QC. Predicting a Kind of Unusual Multiple-States Dimerization-Modes Transformation in Protein PD-L1 System by Computational Investigation and a Generalized Rate Theory. Front Chem 2021;9:783444. [PMID: 34858950 DOI: 10.3389/fchem.2021.783444] [Reference Citation Analysis]
65 Chen L, Flies DB. Molecular mechanisms of T cell co-stimulation and co-inhibition. Nat Rev Immunol 2013;13:227-42. [PMID: 23470321 DOI: 10.1038/nri3405] [Cited by in Crossref: 1496] [Cited by in F6Publishing: 1380] [Article Influence: 166.2] [Reference Citation Analysis]
66 Lim JS, Soo RA. Nivolumab in the treatment of metastatic squamous non-small cell lung cancer: a review of the evidence. Ther Adv Respir Dis 2016;10:444-54. [PMID: 27480166 DOI: 10.1177/1753465816661091] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 2.5] [Reference Citation Analysis]
67 Zavala VA, Kalergis AM. New clinical advances in immunotherapy for the treatment of solid tumours. Immunology 2015;145:182-201. [PMID: 25826229 DOI: 10.1111/imm.12459] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 2.9] [Reference Citation Analysis]
68 Robert L, Harview C, Emerson R, Wang X, Mok S, Homet B, Comin-Anduix B, Koya RC, Robins H, Tumeh PC, Ribas A. Distinct immunological mechanisms of CTLA-4 and PD-1 blockade revealed by analyzing TCR usage in blood lymphocytes. Oncoimmunology 2014;3:e29244. [PMID: 25083336 DOI: 10.4161/onci.29244] [Cited by in Crossref: 63] [Cited by in F6Publishing: 55] [Article Influence: 7.9] [Reference Citation Analysis]
69 Allen CT, Clavijo PE, Van Waes C, Chen Z. Anti-Tumor Immunity in Head and Neck Cancer: Understanding the Evidence, How Tumors Escape and Immunotherapeutic Approaches. Cancers (Basel) 2015;7:2397-414. [PMID: 26690220 DOI: 10.3390/cancers7040900] [Cited by in Crossref: 45] [Cited by in F6Publishing: 45] [Article Influence: 6.4] [Reference Citation Analysis]
70 Bindal P, Gray JE, Boyle TA, Florou V, Puri S. Biomarkers of therapeutic response with immune checkpoint inhibitors. Ann Transl Med 2021;9:1040. [PMID: 34277840 DOI: 10.21037/atm-20-6396] [Reference Citation Analysis]
71 Lu Y, Hong B, Li H, Zheng Y, Zhang M, Wang S, Qian J, Yi Q. Tumor-specific IL-9-producing CD8+ Tc9 cells are superior effector than type-I cytotoxic Tc1 cells for adoptive immunotherapy of cancers. Proc Natl Acad Sci U S A 2014;111:2265-70. [PMID: 24469818 DOI: 10.1073/pnas.1317431111] [Cited by in Crossref: 73] [Cited by in F6Publishing: 66] [Article Influence: 9.1] [Reference Citation Analysis]
72 Kim H, Ishibashi K, Iijima M, Kuroda S, Nakamura C. Influence of Nivolumab for Intercellular Adhesion Force between a T Cell and a Cancer Cell Evaluated by AFM Force Spectroscopy. Sensors (Basel) 2020;20:E5723. [PMID: 33050090 DOI: 10.3390/s20195723] [Reference Citation Analysis]
73 Hosoi A, Takeda K, Nagaoka K, Iino T, Matsushita H, Ueha S, Aoki S, Matsushima K, Kubo M, Morikawa T, Kitaura K, Suzuki R, Kakimi K. Increased diversity with reduced "diversity evenness" of tumor infiltrating T-cells for the successful cancer immunotherapy. Sci Rep 2018;8:1058. [PMID: 29348598 DOI: 10.1038/s41598-018-19548-y] [Cited by in Crossref: 33] [Cited by in F6Publishing: 30] [Article Influence: 8.3] [Reference Citation Analysis]
74 Harvey CJ, Wucherpfennig KW. Cracking the code of human T-cell immunity. Nat Biotechnol 2013;31:609-10. [PMID: 23839145 DOI: 10.1038/nbt.2626] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
75 Judge SJ, Yanagisawa M, Sturgill IR, Bateni SB, Gingrich AA, Foltz JA, Lee DA, Modiano JF, Monjazeb AM, Culp WTN, Rebhun RB, Murphy WJ, Kent MS, Canter RJ. Blood and tissue biomarker analysis in dogs with osteosarcoma treated with palliative radiation and intra-tumoral autologous natural killer cell transfer. PLoS One 2020;15:e0224775. [PMID: 32084139 DOI: 10.1371/journal.pone.0224775] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
76 Santabarbara G, Maione P, Rossi A, Palazzolo G, Gridelli C. The role of pembrolizumab in the treatment of advanced non-small cell lung cancer. Ann Transl Med 2016;4:215. [PMID: 27386489 DOI: 10.21037/atm.2016.05.64] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.2] [Reference Citation Analysis]
77 Yaddanapudi K, Mitchell RA, Eaton JW. Cancer vaccines: Looking to the future. Oncoimmunology 2013;2:e23403. [PMID: 23802081 DOI: 10.4161/onci.23403] [Cited by in Crossref: 36] [Cited by in F6Publishing: 30] [Article Influence: 4.5] [Reference Citation Analysis]
78 Roh J, Jeon Y, Lee AN, Lee SM, Kim Y, Sung CO, Park CJ, Hong JY, Yoon DH, Suh C, Huh J, Choi I, Park CS. The immune checkpoint molecule V-set Ig domain-containing 4 is an independent prognostic factor for multiple myeloma. Oncotarget 2017;8:58122-32. [PMID: 28938542 DOI: 10.18632/oncotarget.19468] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
79 Lindsay RS, Whitesell JC, Dew KE, Rodriguez E, Sandor AM, Tracy D, Yannacone SF, Basta BN, Jacobelli J, Friedman RS. MERTK on mononuclear phagocytes regulates T cell antigen recognition at autoimmune and tumor sites. J Exp Med 2021;218:e20200464. [PMID: 34415994 DOI: 10.1084/jem.20200464] [Reference Citation Analysis]
80 Sternschein R, Moll M, Ng J, D'Ambrosio C. Immune Checkpoint Inhibitor-related Pneumonitis. Incidence, Risk Factors, and Clinical and Radiographic Features. Am J Respir Crit Care Med 2018;198:951-3. [PMID: 30095979 DOI: 10.1164/rccm.201803-0525RR] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 1.3] [Reference Citation Analysis]
81 Goff SL, Dudley ME, Citrin DE, Somerville RP, Wunderlich JR, Danforth DN, Zlott DA, Yang JC, Sherry RM, Kammula US, Klebanoff CA, Hughes MS, Restifo NP, Langhan MM, Shelton TE, Lu L, Kwong ML, Ilyas S, Klemen ND, Payabyab EC, Morton KE, Toomey MA, Steinberg SM, White DE, Rosenberg SA. Randomized, Prospective Evaluation Comparing Intensity of Lymphodepletion Before Adoptive Transfer of Tumor-Infiltrating Lymphocytes for Patients With Metastatic Melanoma. J Clin Oncol 2016;34:2389-97. [PMID: 27217459 DOI: 10.1200/JCO.2016.66.7220] [Cited by in Crossref: 183] [Cited by in F6Publishing: 111] [Article Influence: 30.5] [Reference Citation Analysis]
82 Xu Y, Cui G, Jiang Z, Li N, Zhang X. Survival analysis with regard to PD-L1 and CD155 expression in human small cell lung cancer and a comparison with associated receptors. Oncol Lett 2019;17:2960-8. [PMID: 30854074 DOI: 10.3892/ol.2019.9910] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 2.7] [Reference Citation Analysis]
83 Koya T, Yanagisawa R, Higuchi Y, Sano K, Shimodaira S. Interferon-α-inducible Dendritic Cells Matured with OK-432 Exhibit TRAIL and Fas Ligand Pathway-mediated Killer Activity. Sci Rep 2017;7:42145. [PMID: 28191816 DOI: 10.1038/srep42145] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
84 Rangamuwa K, Leong T, Weeden C, Asselin-Labat ML, Bozinovski S, Christie M, John T, Antippa P, Irving L, Steinfort D. Thermal ablation in non-small cell lung cancer: a review of treatment modalities and the evidence for combination with immune checkpoint inhibitors. Transl Lung Cancer Res 2021;10:2842-57. [PMID: 34295682 DOI: 10.21037/tlcr-20-1075] [Reference Citation Analysis]
85 Helber HA, Hada AL, Pio RB, Moraes PHZ, Gomes DBD. Immunotherapy-induced pneumonitis: cases report. Einstein (Sao Paulo) 2018;16:eRC4030. [PMID: 29947645 DOI: 10.1590/S1679-45082018RC4030] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
86 Keenan TE, Burke KP, Van Allen EM. Genomic correlates of response to immune checkpoint blockade. Nat Med 2019;25:389-402. [PMID: 30842677 DOI: 10.1038/s41591-019-0382-x] [Cited by in Crossref: 154] [Cited by in F6Publishing: 142] [Article Influence: 51.3] [Reference Citation Analysis]
87 Cerezo M, Rocchi S. Cancer cell metabolic reprogramming: a keystone for the response to immunotherapy. Cell Death Dis 2020;11:964. [PMID: 33177494 DOI: 10.1038/s41419-020-03175-5] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 6.0] [Reference Citation Analysis]
88 Kleponis J, Skelton R, Zheng L. Fueling the engine and releasing the break: combinational therapy of cancer vaccines and immune checkpoint inhibitors. Cancer Biol Med 2015;12:201-8. [PMID: 26487965 DOI: 10.7497/j.issn.2095-3941.2015.0046] [Cited by in F6Publishing: 38] [Reference Citation Analysis]
89 Melief CJ, van Hall T, Arens R, Ossendorp F, van der Burg SH. Therapeutic cancer vaccines. J Clin Invest. 2015;125:3401-3412. [PMID: 26214521 DOI: 10.1172/jci80009] [Cited by in Crossref: 318] [Cited by in F6Publishing: 177] [Article Influence: 45.4] [Reference Citation Analysis]
90 Du W, Yang M, Turner A, Xu C, Ferris RL, Huang J, Kane LP, Lu B. TIM-3 as a Target for Cancer Immunotherapy and Mechanisms of Action. Int J Mol Sci 2017;18:E645. [PMID: 28300768 DOI: 10.3390/ijms18030645] [Cited by in Crossref: 93] [Cited by in F6Publishing: 89] [Article Influence: 18.6] [Reference Citation Analysis]
91 Harter PN, Bernatz S, Scholz A, Zeiner PS, Zinke J, Kiyose M, Blasel S, Beschorner R, Senft C, Bender B, Ronellenfitsch MW, Wikman H, Glatzel M, Meinhardt M, Juratli TA, Steinbach JP, Plate KH, Wischhusen J, Weide B, Mittelbronn M. Distribution and prognostic relevance of tumor-infiltrating lymphocytes (TILs) and PD-1/PD-L1 immune checkpoints in human brain metastases. Oncotarget 2015;6:40836-49. [PMID: 26517811 DOI: 10.18632/oncotarget.5696] [Cited by in Crossref: 72] [Cited by in F6Publishing: 70] [Article Influence: 12.0] [Reference Citation Analysis]
92 Zhu Y, Hwang WT, Li Y. Evaluating the effects of design parameters on the performances of phase I trial designs. Contemp Clin Trials Commun 2019;15:100379. [PMID: 31193764 DOI: 10.1016/j.conctc.2019.100379] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
93 Błach J, Wojas-Krawczyk K, Nicoś M, Krawczyk P. Failure of Immunotherapy-The Molecular and Immunological Origin of Immunotherapy Resistance in Lung Cancer. Int J Mol Sci 2021;22:9030. [PMID: 34445735 DOI: 10.3390/ijms22169030] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
94 Bianchini G, Balko JM, Mayer IA, Sanders ME, Gianni L. Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease. Nat Rev Clin Oncol 2016;13:674-90. [PMID: 27184417 DOI: 10.1038/nrclinonc.2016.66] [Cited by in Crossref: 903] [Cited by in F6Publishing: 888] [Article Influence: 150.5] [Reference Citation Analysis]
95 Okazaki T, Chikuma S, Iwai Y, Fagarasan S, Honjo T. A rheostat for immune responses: the unique properties of PD-1 and their advantages for clinical application. Nat Immunol. 2013;14:1212-1218. [PMID: 24240160 DOI: 10.1038/ni.2762] [Cited by in Crossref: 532] [Cited by in F6Publishing: 487] [Article Influence: 66.5] [Reference Citation Analysis]
96 Igase M, Nemoto Y, Itamoto K, Tani K, Nakaichi M, Sakurai M, Sakai Y, Noguchi S, Kato M, Tsukui T, Mizuno T. A pilot clinical study of the therapeutic antibody against canine PD-1 for advanced spontaneous cancers in dogs. Sci Rep 2020;10:18311. [PMID: 33110170 DOI: 10.1038/s41598-020-75533-4] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
97 Sabbatino F, Villani V, Yearley JH, Deshpande V, Cai L, Konstantinidis IT, Moon C, Nota S, Wang Y, Al-Sukaini A. PD-L1 and HLA Class I Antigen Expression and Clinical Course of the Disease in Intrahepatic Cholangiocarcinoma. Clin Cancer Res. 2016;22:470-478. [PMID: 26373575 DOI: 10.1158/1078-0432.ccr-15-0715] [Cited by in Crossref: 102] [Cited by in F6Publishing: 65] [Article Influence: 14.6] [Reference Citation Analysis]
98 Avogadri F, Zappasodi R, Yang A, Budhu S, Malandro N, Hirschhorn-Cymerman D, Tiwari S, Maughan MF, Olmsted R, Wolchok JD, Merghoub T. Combination of alphavirus replicon particle-based vaccination with immunomodulatory antibodies: therapeutic activity in the B16 melanoma mouse model and immune correlates. Cancer Immunol Res 2014;2:448-58. [PMID: 24795357 DOI: 10.1158/2326-6066.CIR-13-0220] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 2.5] [Reference Citation Analysis]
99 Bai J, Kwok WC, Thiery JP. Traditional Chinese Medicine and regulatory roles on epithelial-mesenchymal transitions. Chin Med 2019;14:34. [PMID: 31558913 DOI: 10.1186/s13020-019-0257-6] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
100 Weiss GJ, Waypa J, Blaydorn L, Coats J, McGahey K, Sangal A, Niu J, Lynch CA, Farley JH, Khemka V. A phase Ib study of pembrolizumab plus chemotherapy in patients with advanced cancer (PembroPlus). Br J Cancer 2017;117:33-40. [PMID: 28588322 DOI: 10.1038/bjc.2017.145] [Cited by in Crossref: 54] [Cited by in F6Publishing: 59] [Article Influence: 10.8] [Reference Citation Analysis]
101 Homet Moreno B, Mok S, Comin-Anduix B, Hu-Lieskovan S, Ribas A. Combined treatment with dabrafenib and trametinib with immune-stimulating antibodies for BRAF mutant melanoma. Oncoimmunology. 2016;5:e1052212. [PMID: 27622011 DOI: 10.1080/2162402x.2015.1052212] [Cited by in Crossref: 54] [Cited by in F6Publishing: 37] [Article Influence: 7.7] [Reference Citation Analysis]
102 Hölzel M, Bovier A, Tüting T. Plasticity of tumour and immune cells: a source of heterogeneity and a cause for therapy resistance? Nat Rev Cancer. 2013;13:365-376. [PMID: 23535846 DOI: 10.1038/nrc3498] [Cited by in Crossref: 166] [Cited by in F6Publishing: 142] [Article Influence: 18.4] [Reference Citation Analysis]
103 Fujisawa Y, Yoshikawa S, Minagawa A, Takenouchi T, Yokota K, Uchi H, Noma N, Nakamura Y, Asai J, Kato J, Fujiwara S, Fukushima S, Uehara J, Hoashi T, Kaji T, Fujimura T, Namikawa K, Yoshioka M, Murao N, Ogata D, Matsuyama K, Hatta N, Shibayama Y, Fujiyama T, Ishikawa M, Yamada D, Kishi A, Nakamura Y, Shimiauchi T, Fujii K, Fujimoto M, Ihn H, Katoh N. Clinical and histopathological characteristics and survival analysis of 4594 Japanese patients with melanoma. Cancer Med 2019;8:2146-56. [PMID: 30932370 DOI: 10.1002/cam4.2110] [Cited by in Crossref: 28] [Cited by in F6Publishing: 26] [Article Influence: 9.3] [Reference Citation Analysis]
104 Beezhold K, Byersdorfer CA. Targeting immuno-metabolism to improve anti-cancer therapies. Cancer Lett 2018;414:127-35. [PMID: 29126914 DOI: 10.1016/j.canlet.2017.11.005] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
105 Roudko V, Greenbaum B, Bhardwaj N. Computational Prediction and Validation of Tumor-Associated Neoantigens. Front Immunol 2020;11:27. [PMID: 32117226 DOI: 10.3389/fimmu.2020.00027] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 10.5] [Reference Citation Analysis]
106 Schweizer MT, Drake CG. Immunotherapy for prostate cancer: recent developments and future challenges. Cancer Metastasis Rev 2014;33:641-55. [PMID: 24477411 DOI: 10.1007/s10555-013-9479-8] [Cited by in Crossref: 43] [Cited by in F6Publishing: 34] [Article Influence: 6.1] [Reference Citation Analysis]
107 Rajani KR, Vile RG. Harnessing the Power of Onco-Immunotherapy with Checkpoint Inhibitors. Viruses 2015;7:5889-901. [PMID: 26580645 DOI: 10.3390/v7112914] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 2.3] [Reference Citation Analysis]
108 Shindo Y, McDonough JS, Chang KC, Ramachandra M, Sasikumar PG, Hotchkiss RS. Anti-PD-L1 peptide improves survival in sepsis. J Surg Res 2017;208:33-9. [PMID: 27993215 DOI: 10.1016/j.jss.2016.08.099] [Cited by in Crossref: 57] [Cited by in F6Publishing: 56] [Article Influence: 9.5] [Reference Citation Analysis]
109 Cui S, Su X, Dong L, Qian J, Ye L, Zhang T, Fu H, Han H, Huang J, Yao Y, Gu Y, Jiang L. Programmed cell death ligand 1 protein levels predicted survival of non-small cell lung cancer. J Cancer 2017;8:4075-82. [PMID: 29187883 DOI: 10.7150/jca.21415] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
110 Zhang J, Zhao X, Ma X, Yuan Z, Hu M. KCNQ1OT1 contributes to sorafenib resistance and programmed death‑ligand‑1‑mediated immune escape via sponging miR‑506 in hepatocellular carcinoma cells. Int J Mol Med 2020;46:1794-804. [PMID: 33000204 DOI: 10.3892/ijmm.2020.4710] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
111 Chehval V, Norian LA. Effects of obesity on immune responses to renal tumors. Immunol Res 2014;59:211-9. [PMID: 24838144 DOI: 10.1007/s12026-014-8533-0] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
112 Concha-Benavente F, Ferris RL. Oncogenic growth factor signaling mediating tumor escape from cellular immunity. Curr Opin Immunol 2017;45:52-9. [PMID: 28208102 DOI: 10.1016/j.coi.2017.01.004] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
113 Vivarelli S, Falzone L, Leonardi GC, Salmeri M, Libra M. Novel insights on gut microbiota manipulation and immune checkpoint inhibition in cancer (Review). Int J Oncol 2021;59:75. [PMID: 34396439 DOI: 10.3892/ijo.2021.5255] [Reference Citation Analysis]
114 Maity A, Mick R, Huang AC, George SM, Farwell MD, Lukens JN, Berman AT, Mitchell TC, Bauml J, Schuchter LM, O'Hara M, Lin LL, Demichele A, Christodouleas JP, Haas NB, Patsch DM, Hahn SM, Minn AJ, Wherry EJ, Vonderheide RH. A phase I trial of pembrolizumab with hypofractionated radiotherapy in patients with metastatic solid tumours. Br J Cancer 2018;119:1200-7. [PMID: 30318516 DOI: 10.1038/s41416-018-0281-9] [Cited by in Crossref: 44] [Cited by in F6Publishing: 43] [Article Influence: 11.0] [Reference Citation Analysis]
115 Balakrishna P, Villegas A. Hypokalemic Paralysis Secondary to Immune Checkpoint Inhibitor Therapy. Case Rep Oncol Med 2017;2017:5063405. [PMID: 29250451 DOI: 10.1155/2017/5063405] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
116 Inoue H, Park JH, Kiyotani K, Zewde M, Miyashita A, Jinnin M, Kiniwa Y, Okuyama R, Tanaka R, Fujisawa Y, Kato H, Morita A, Asai J, Katoh N, Yokota K, Akiyama M, Ihn H, Fukushima S, Nakamura Y. Intratumoral expression levels of PD-L1, GZMA, and HLA-A along with oligoclonal T cell expansion associate with response to nivolumab in metastatic melanoma. Oncoimmunology 2016;5:e1204507. [PMID: 27757299 DOI: 10.1080/2162402X.2016.1204507] [Cited by in Crossref: 74] [Cited by in F6Publishing: 46] [Article Influence: 12.3] [Reference Citation Analysis]
117 Curran E, Corrales L, Kline J. Targeting the innate immune system as immunotherapy for acute myeloid leukemia. Front Oncol 2015;5:83. [PMID: 25914882 DOI: 10.3389/fonc.2015.00083] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 2.4] [Reference Citation Analysis]
118 Sun J, Tao H, Li X, Wang L, Yang J, Wu P, Zhang Y, Guo Y. Clinical significance of novel costimulatory molecule B7-H6 in human breast cancer. Oncol Lett 2017;14:2405-9. [PMID: 28789456 DOI: 10.3892/ol.2017.6417] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 3.0] [Reference Citation Analysis]
119 Karashima T, Udaka K, Niimura M, Suzuki K, Osakabe H, Shimamoto T, Fukata S, Inoue K, Kuroda N, Seiki M, Shuin T. Therapy with transcutaneous administration of imiquimod combined with oral administration of sorafenib suppresses renal cell carcinoma growing in an orthotopic mouse model. Oncol Lett 2017;14:1162-6. [PMID: 28693290 DOI: 10.3892/ol.2017.6235] [Reference Citation Analysis]
120 Neelapu SS, Kwak LW. Rush hour traffic: directing T cells to tumor. J Natl Cancer Inst 2014;106:dju301. [PMID: 25255804 DOI: 10.1093/jnci/dju301] [Reference Citation Analysis]
121 Kim JY, Lee E, Park K, Park WY, Jung HH, Ahn JS, Im YH, Park YH. Immune signature of metastatic breast cancer: Identifying predictive markers of immunotherapy response. Oncotarget 2017;8:47400-11. [PMID: 28537889 DOI: 10.18632/oncotarget.17653] [Cited by in Crossref: 13] [Cited by in F6Publishing: 16] [Article Influence: 3.3] [Reference Citation Analysis]
122 Zhang Z, Liu J, Zhang C, Li F, Li L, Wang D, Chand D, Guan F, Zang X, Zhang Y. Over-Expression and Prognostic Significance of HHLA2, a New Immune Checkpoint Molecule, in Human Clear Cell Renal Cell Carcinoma. Front Cell Dev Biol 2020;8:280. [PMID: 32509772 DOI: 10.3389/fcell.2020.00280] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
123 Carrizosa DR, Gold KA. New strategies in immunotherapy for non-small cell lung cancer. Transl Lung Cancer Res 2015;4:553-9. [PMID: 26629424 DOI: 10.3978/j.issn.2218-6751.2015.06.05] [Cited by in F6Publishing: 16] [Reference Citation Analysis]
124 Tran E, Rosenberg SA. T-cell therapy against cancer mutations. Oncotarget 2014;5:4579-80. [PMID: 25046408 DOI: 10.18632/oncotarget.2234] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 2.1] [Reference Citation Analysis]
125 Nakajima Y, Chamoto K, Oura T, Honjo T. Critical role of the CD44lowCD62Llow CD8+ T cell subset in restoring antitumor immunity in aged mice. Proc Natl Acad Sci U S A 2021;118:e2103730118. [PMID: 34088845 DOI: 10.1073/pnas.2103730118] [Reference Citation Analysis]
126 van der Stegen SJ, Hamieh M, Sadelain M. The pharmacology of second-generation chimeric antigen receptors. Nat Rev Drug Discov 2015;14:499-509. [PMID: 26129802 DOI: 10.1038/nrd4597] [Cited by in Crossref: 246] [Cited by in F6Publishing: 237] [Article Influence: 35.1] [Reference Citation Analysis]
127 Anker JF, Naseem AF, Mok H, Schaeffer AJ, Abdulkadir SA, Thumbikat P. Multi-faceted immunomodulatory and tissue-tropic clinical bacterial isolate potentiates prostate cancer immunotherapy. Nat Commun 2018;9:1591. [PMID: 29686284 DOI: 10.1038/s41467-018-03900-x] [Cited by in Crossref: 32] [Cited by in F6Publishing: 28] [Article Influence: 8.0] [Reference Citation Analysis]
128 Liu J, Westin SN. Rational selection of biomarker driven therapies for gynecologic cancers: The more we know, the more we know we don't know. Gynecol Oncol 2016;141:65-71. [PMID: 27016231 DOI: 10.1016/j.ygyno.2016.01.003] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
129 Oda K, Hamanishi J, Matsuo K, Hasegawa K. Genomics to immunotherapy of ovarian clear cell carcinoma: Unique opportunities for management. Gynecol Oncol 2018;151:381-9. [PMID: 30217369 DOI: 10.1016/j.ygyno.2018.09.001] [Cited by in Crossref: 50] [Cited by in F6Publishing: 47] [Article Influence: 12.5] [Reference Citation Analysis]
130 Nishimori A, Konnai S, Okagawa T, Maekawa N, Ikebuchi R, Goto S, Sajiki Y, Suzuki Y, Kohara J, Ogasawara S, Kato Y, Murata S, Ohashi K. In vitro and in vivo antivirus activity of an anti-programmed death-ligand 1 (PD-L1) rat-bovine chimeric antibody against bovine leukemia virus infection. PLoS One 2017;12:e0174916. [PMID: 28445479 DOI: 10.1371/journal.pone.0174916] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 4.0] [Reference Citation Analysis]
131 Xia AL, Xu Y, Lu XJ. Functional genomics in the era of cancer immunotherapy: challenges and clinical implications. Brief Funct Genomics 2019;18:83-5. [PMID: 30901384 DOI: 10.1093/bfgp/elz003] [Reference Citation Analysis]
132 Girotra M, Hansen A, Farooki A, Byun DJ, Min L, Creelan BC, Callahan MK, Atkins MB, Sharon E, Antonia SJ, West P, Gravell AE; Investigational Drug Steering Committee (IDSC) Immunotherapy Task Force collaboration. The Current Understanding of the Endocrine Effects From Immune Checkpoint Inhibitors and Recommendations for Management. JNCI Cancer Spectr 2018;2:pky021. [PMID: 30057972 DOI: 10.1093/jncics/pky021] [Cited by in Crossref: 57] [Cited by in F6Publishing: 43] [Article Influence: 14.3] [Reference Citation Analysis]
133 DeVette CI, Andreatta M, Bardet W, Cate SJ, Jurtz VI, Jackson KW, Welm AL, Nielsen M, Hildebrand WH. NetH2pan: A Computational Tool to Guide MHC Peptide Prediction on Murine Tumors. Cancer Immunol Res 2018;6:636-44. [PMID: 29615400 DOI: 10.1158/2326-6066.CIR-17-0298] [Cited by in Crossref: 12] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
134 Nishino M, Chambers ES, Chong CR, Ramaiya NH, Gray SW, Marcoux JP, Hatabu H, Jänne PA, Hodi FS, Awad MM. Anti-PD-1 Inhibitor-Related Pneumonitis in Non-Small Cell Lung Cancer. Cancer Immunol Res 2016;4:289-93. [PMID: 26865455 DOI: 10.1158/2326-6066.CIR-15-0267] [Cited by in Crossref: 90] [Cited by in F6Publishing: 54] [Article Influence: 15.0] [Reference Citation Analysis]
135 Katsuta E, DeMasi SC, Terracina KP, Spiegel S, Phan GQ, Bear HD, Takabe K. Modified breast cancer model for preclinical immunotherapy studies. J Surg Res 2016;204:467-74. [PMID: 27565084 DOI: 10.1016/j.jss.2016.06.003] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.8] [Reference Citation Analysis]
136 Peng Q, Qiu X, Zhang Z, Zhang S, Zhang Y, Liang Y, Guo J, Peng H, Chen M, Fu YX, Tang H. PD-L1 on dendritic cells attenuates T cell activation and regulates response to immune checkpoint blockade. Nat Commun 2020;11:4835. [PMID: 32973173 DOI: 10.1038/s41467-020-18570-x] [Cited by in Crossref: 43] [Cited by in F6Publishing: 46] [Article Influence: 21.5] [Reference Citation Analysis]
137 Missiaen R, Mazzone M, Bergers G. The reciprocal function and regulation of tumor vessels and immune cells offers new therapeutic opportunities in cancer. Semin Cancer Biol 2018;52:107-16. [PMID: 29935312 DOI: 10.1016/j.semcancer.2018.06.002] [Cited by in Crossref: 34] [Cited by in F6Publishing: 28] [Article Influence: 8.5] [Reference Citation Analysis]
138 Adachi K, Tamada K. Immune checkpoint blockade opens an avenue of cancer immunotherapy with a potent clinical efficacy. Cancer Sci. 2015;106:945-950. [PMID: 25981182 DOI: 10.1111/cas.12695] [Cited by in Crossref: 55] [Cited by in F6Publishing: 48] [Article Influence: 7.9] [Reference Citation Analysis]
139 Ziv E, Durack JC, Solomon SB. The Importance of Biopsy in the Era of Molecular Medicine. Cancer J 2016;22:418-22. [PMID: 27870685 DOI: 10.1097/PPO.0000000000000228] [Cited by in Crossref: 12] [Cited by in F6Publishing: 6] [Article Influence: 2.4] [Reference Citation Analysis]
140 Luke JJ, Bao R, Sweis RF, Spranger S, Gajewski TF. WNT/β-catenin Pathway Activation Correlates with Immune Exclusion across Human Cancers. Clin Cancer Res 2019;25:3074-83. [PMID: 30635339 DOI: 10.1158/1078-0432.CCR-18-1942] [Cited by in Crossref: 201] [Cited by in F6Publishing: 133] [Article Influence: 67.0] [Reference Citation Analysis]
141 Grabie N, Lichtman AH, Padera R. T cell checkpoint regulators in the heart. Cardiovasc Res 2019;115:869-77. [PMID: 30721928 DOI: 10.1093/cvr/cvz025] [Cited by in Crossref: 24] [Cited by in F6Publishing: 25] [Article Influence: 12.0] [Reference Citation Analysis]
142 Zhao W, Jiang W, Wang H, He J, Su C, Yu Q. Impact of Smoking History on Response to Immunotherapy in Non-Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis. Front Oncol 2021;11:703143. [PMID: 34497760 DOI: 10.3389/fonc.2021.703143] [Reference Citation Analysis]
143 Tumeh PC, Harview CL, Yearley JH, Shintaku IP, Taylor EJ, Robert L, Chmielowski B, Spasic M, Henry G, Ciobanu V. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature. 2014;515:568-571. [PMID: 25428505 DOI: 10.1038/nature13954] [Cited by in Crossref: 3422] [Cited by in F6Publishing: 3190] [Article Influence: 488.9] [Reference Citation Analysis]
144 Bose CK. Immune Checkpoint Blockers and Ovarian Cancer. Indian J Med Paediatr Oncol 2017;38:182-9. [PMID: 28900328 DOI: 10.4103/ijmpo.ijmpo_73_16] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
145 Baronzio G, Parmar G, Shubina IZh, Cassutti V, Giuli S, Ballerini M, Kiselevsky M. Update on the challenges and recent advances in cancer immunotherapy. Immunotargets Ther 2013;2:39-49. [PMID: 27471687 DOI: 10.2147/ITT.S30818] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
146 Su R, Jin C, Zhou L, Cao Y, Kuang M, Li L, Xiang J. Construction of a ceRNA network of hub genes affecting immune infiltration in ovarian cancer identified by WGCNA. BMC Cancer 2021;21:970. [PMID: 34461858 DOI: 10.1186/s12885-021-08711-w] [Reference Citation Analysis]
147 Tesone AJ, Svoronos N, Allegrezza MJ, Conejo-Garcia JR. Pathological mobilization and activities of dendritic cells in tumor-bearing hosts: challenges and opportunities for immunotherapy of cancer. Front Immunol 2013;4:435. [PMID: 24339824 DOI: 10.3389/fimmu.2013.00435] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 1.4] [Reference Citation Analysis]
148 Cappuccini F, Pollock E, Stribbling S, Hill AVS, Redchenko I. 5T4 oncofoetal glycoprotein: an old target for a novel prostate cancer immunotherapy. Oncotarget 2017;8:47474-89. [PMID: 28537896 DOI: 10.18632/oncotarget.17666] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.5] [Reference Citation Analysis]
149 Nakanishi Y, Diaz-Meco MT, Moscat J. Serrated Colorectal Cancer: The Road Less Travelled? Trends Cancer. 2019;5:742-754. [PMID: 31735291 DOI: 10.1016/j.trecan.2019.09.004] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 4.7] [Reference Citation Analysis]
150 Delafoy A, Uguen A, Lemasson G, Conan-Charlet V, Pradier O, Lucia F, Schick U. PD-L1 expression in recurrent head and neck squamous cell carcinoma. Eur Arch Otorhinolaryngol 2021. [PMID: 33796940 DOI: 10.1007/s00405-021-06777-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
151 Watson HA, Dolton G, Ohme J, Ladell K, Vigar M, Wehenkel S, Hindley J, Mohammed RN, Miners K, Luckwell RA, Price DA, Matthews RJ, Ager A. Purity of transferred CD8(+) T cells is crucial for safety and efficacy of combinatorial tumor immunotherapy in the absence of SHP-1. Immunol Cell Biol 2016;94:802-8. [PMID: 27430370 DOI: 10.1038/icb.2016.45] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.7] [Reference Citation Analysis]
152 Adjiri A. Identifying and Targeting the Cause of Cancer is Needed to Cure Cancer. Oncol Ther 2016;4:17-33. [PMID: 28261638 DOI: 10.1007/s40487-015-0015-6] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
153 Hepgur M, Sadeghi S, Dorff TB, Quinn DI. Tivozanib in the treatment of renal cell carcinoma. Biologics 2013;7:139-48. [PMID: 23788831 DOI: 10.2147/BTT.S32958] [Cited by in Crossref: 2] [Cited by in F6Publishing: 8] [Article Influence: 0.2] [Reference Citation Analysis]
154 Mansfield AS, Roden AC, Peikert T, Sheinin YM, Harrington SM, Krco CJ, Dong H, Kwon ED. B7-H1 expression in malignant pleural mesothelioma is associated with sarcomatoid histology and poor prognosis. J Thorac Oncol 2014;9:1036-40. [PMID: 24926549 DOI: 10.1097/JTO.0000000000000177] [Cited by in Crossref: 150] [Cited by in F6Publishing: 70] [Article Influence: 21.4] [Reference Citation Analysis]
155 Pérez-Romero K, Rodríguez RM, Amedei A, Barceló-Coblijn G, Lopez DH. Immune Landscape in Tumor Microenvironment: Implications for Biomarker Development and Immunotherapy. Int J Mol Sci 2020;21:E5521. [PMID: 32752264 DOI: 10.3390/ijms21155521] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
156 You W, Shang B, Sun J, Liu X, Su L, Jiang S. Mechanistic insight of predictive biomarkers for antitumor PD‑1/PD‑L1 blockade: A paradigm shift towards immunome evaluation (Review). Oncol Rep 2020;44:424-37. [PMID: 32627031 DOI: 10.3892/or.2020.7643] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
157 Lin S, Huang G, Cheng L, Li Z, Xiao Y, Deng Q, Jiang Y, Li B, Lin S, Wang S, Wu Q, Yao H, Cao S, Li Y, Liu P, Wei W, Pei D, Yao Y, Wen Z, Zhang X, Wu Y, Zhang Z, Cui S, Sun X, Qian X, Li P. Establishment of peripheral blood mononuclear cell-derived humanized lung cancer mouse models for studying efficacy of PD-L1/PD-1 targeted immunotherapy. MAbs 2018;10:1301-11. [PMID: 30204048 DOI: 10.1080/19420862.2018.1518948] [Cited by in Crossref: 28] [Cited by in F6Publishing: 25] [Article Influence: 7.0] [Reference Citation Analysis]
158 Niu X, Wang W, Liang T, Li S, Yang C, Xu X, Li L, Liu S. CPI-203 improves the efficacy of anti-PD-1 therapy by inhibiting the induced PD-L1 overexpression in liver cancer. Cancer Sci 2021. [PMID: 34727389 DOI: 10.1111/cas.15190] [Reference Citation Analysis]
159 Oh T, Ivan ME, Sun MZ, Safaee M, Fakurnejad S, Clark AJ, Sayegh ET, Bloch O, Parsa AT. PI3K pathway inhibitors: potential prospects as adjuncts to vaccine immunotherapy for glioblastoma. Immunotherapy 2014;6:737-53. [PMID: 25186604 DOI: 10.2217/imt.14.35] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 1.7] [Reference Citation Analysis]
160 Betzler AC, Theodoraki MN, Schuler PJ, Döscher J, Laban S, Hoffmann TK, Brunner C. NF-κB and Its Role in Checkpoint Control. Int J Mol Sci 2020;21:E3949. [PMID: 32486375 DOI: 10.3390/ijms21113949] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 7.5] [Reference Citation Analysis]
161 Idorn M, Skadborg SK, Kellermann L, Halldórsdóttir HR, Holmen Olofsson G, Met Ö, Thor Straten P. Chemokine receptor engineering of T cells with CXCR2 improves homing towards subcutaneous human melanomas in xenograft mouse model. Oncoimmunology 2018;7:e1450715. [PMID: 30221044 DOI: 10.1080/2162402X.2018.1450715] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 4.8] [Reference Citation Analysis]
162 Leto SM, Trusolino L. Primary and acquired resistance to EGFR-targeted therapies in colorectal cancer: impact on future treatment strategies. J Mol Med (Berl) 2014;92:709-22. [PMID: 24811491 DOI: 10.1007/s00109-014-1161-2] [Cited by in Crossref: 58] [Cited by in F6Publishing: 51] [Article Influence: 7.3] [Reference Citation Analysis]
163 Xu X, Xie K, Li B, Xu L, Huang L, Feng Y, Pi C, Zhang J, Huang T, Jiang M, Gu H, Fang J. Adaptive resistance in tumors to anti-PD-1 therapy through re-immunosuppression by upregulation of GPNMB expression. Int Immunopharmacol 2021;101:108199. [PMID: 34673297 DOI: 10.1016/j.intimp.2021.108199] [Reference Citation Analysis]
164 Huang MH, Zhang XB, Wang HL, Li LX, Zeng YM, Wang M, Zeng HQ. Intermittent hypoxia enhances the tumor programmed death ligand 1 expression in a mouse model of sleep apnea. Ann Transl Med 2019;7:97. [PMID: 31019947 DOI: 10.21037/atm.2019.01.44] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
165 Goswami S, Aparicio A, Subudhi SK. Immune Checkpoint Therapies in Prostate Cancer. Cancer J 2016;22:117-20. [PMID: 27111907 DOI: 10.1097/PPO.0000000000000176] [Cited by in Crossref: 28] [Cited by in F6Publishing: 14] [Article Influence: 5.6] [Reference Citation Analysis]
166 Beer A, Taghizadeh H, Schiefer AI, Puhr HC, Karner AK, Jomrich G, Schoppmann SF, Kain R, Preusser M, Ilhan-Mutlu A. PD-L1 and HER2 Expression in Gastroesophageal Cancer: a Matched Case Control Study. Pathol Oncol Res 2020;26:2225-35. [PMID: 32372174 DOI: 10.1007/s12253-020-00814-2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
167 He J, Hu Y, Hu M, Li B. Development of PD-1/PD-L1 Pathway in Tumor Immune Microenvironment and Treatment for Non-Small Cell Lung Cancer. Sci Rep 2015;5:13110. [PMID: 26279307 DOI: 10.1038/srep13110] [Cited by in Crossref: 198] [Cited by in F6Publishing: 204] [Article Influence: 28.3] [Reference Citation Analysis]
168 Abida W, Cheng ML, Armenia J, Middha S, Autio KA, Vargas HA, Rathkopf D, Morris MJ, Danila DC, Slovin SF, Carbone E, Barnett ES, Hullings M, Hechtman JF, Zehir A, Shia J, Jonsson P, Stadler ZK, Srinivasan P, Laudone VP, Reuter V, Wolchok JD, Socci ND, Taylor BS, Berger MF, Kantoff PW, Sawyers CL, Schultz N, Solit DB, Gopalan A, Scher HI. Analysis of the Prevalence of Microsatellite Instability in Prostate Cancer and Response to Immune Checkpoint Blockade. JAMA Oncol 2019;5:471-8. [PMID: 30589920 DOI: 10.1001/jamaoncol.2018.5801] [Cited by in Crossref: 173] [Cited by in F6Publishing: 166] [Article Influence: 86.5] [Reference Citation Analysis]
169 Rapoport BL, Shannon VR, Cooksley T, Johnson DB, Anderson L, Blidner AG, Tintinger GR, Anderson R. Pulmonary Toxicities Associated With the Use of Immune Checkpoint Inhibitors: An Update From the Immuno-Oncology Subgroup of the Neutropenia, Infection & Myelosuppression Study Group of the Multinational Association for Supportive Care in Cancer. Front Pharmacol 2021;12:743582. [PMID: 34675810 DOI: 10.3389/fphar.2021.743582] [Reference Citation Analysis]
170 Baylin SB, Jones PA. Epigenetic Determinants of Cancer. Cold Spring Harb Perspect Biol 2016;8:a019505. [PMID: 27194046 DOI: 10.1101/cshperspect.a019505] [Cited by in Crossref: 371] [Cited by in F6Publishing: 318] [Article Influence: 61.8] [Reference Citation Analysis]
171 Nishino M, Giobbie-Hurder A, Ramaiya NH, Hodi FS. Response assessment in metastatic melanoma treated with ipilimumab and bevacizumab: CT tumor size and density as markers for response and outcome. J Immunother Cancer 2014;2:40. [PMID: 25411640 DOI: 10.1186/s40425-014-0040-2] [Cited by in Crossref: 40] [Cited by in F6Publishing: 32] [Article Influence: 5.0] [Reference Citation Analysis]
172 Cui C, Wang J, Fagerberg E, Chen PM, Connolly KA, Damo M, Cheung JF, Mao T, Askari AS, Chen S, Fitzgerald B, Foster GG, Eisenbarth SC, Zhao H, Craft J, Joshi NS. Neoantigen-driven B cell and CD4 T follicular helper cell collaboration promotes anti-tumor CD8 T cell responses. Cell 2021;184:6101-6118.e13. [PMID: 34852236 DOI: 10.1016/j.cell.2021.11.007] [Reference Citation Analysis]
173 Hsueh CT, Selim JH, Tsai JY, Hsueh CT. Nanovectors for anti-cancer drug delivery in the treatment of advanced pancreatic adenocarcinoma. World J Gastroenterol 2016; 22(31): 7080-7090 [PMID: 27610018 DOI: 10.3748/wjg.v22.i31.7080] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
174 Tunger A, Sommer U, Wehner R, Kubasch AS, Grimm MO, Bachmann MP, Platzbecker U, Bornhäuser M, Baretton G, Schmitz M. The Evolving Landscape of Biomarkers for Anti-PD-1 or Anti-PD-L1 Therapy. J Clin Med 2019;8:E1534. [PMID: 31557787 DOI: 10.3390/jcm8101534] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 7.7] [Reference Citation Analysis]
175 Zeng W, Qin S, Wang R, Zhang Y, Ma X, Tian F, Liu XR, Qin X, Liao S, Sun L, Lin Y. PDL1 blockage increases fetal resorption and Tfr cells but does not affect Tfh/Tfr ratio and B-cell maturation during allogeneic pregnancy. Cell Death Dis 2020;11:119. [PMID: 32051396 DOI: 10.1038/s41419-020-2313-7] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
176 Liu Y, Yan X, Zhang F, Zhang X, Tang F, Han Z, Li Y. TCR-T Immunotherapy: The Challenges and Solutions. Front Oncol 2022;11:794183. [DOI: 10.3389/fonc.2021.794183] [Reference Citation Analysis]
177 Finkelstein SE, Fishman M. Clinical opportunities in combining immunotherapy with radiation therapy. Front Oncol 2012;2:169. [PMID: 23233905 DOI: 10.3389/fonc.2012.00169] [Cited by in Crossref: 27] [Cited by in F6Publishing: 25] [Article Influence: 2.7] [Reference Citation Analysis]
178 Vandeven N, Nghiem P. Rationale for immune-based therapies in Merkel polyomavirus-positive and -negative Merkel cell carcinomas. Immunotherapy 2016;8:907-21. [PMID: 27381685 DOI: 10.2217/imt-2016-0009] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 3.4] [Reference Citation Analysis]
179 Zhu L, Hu S, Chen Q, Zhang H, Fu J, Zhou Y, Bai Y, Pan Y, Shao C. Macrophage contributes to radiation-induced anti-tumor abscopal effect on transplanted breast cancer by HMGB1/TNF-α signaling factors. Int J Biol Sci 2021;17:926-41. [PMID: 33867819 DOI: 10.7150/ijbs.57445] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
180 van Poelgeest MI, Welters MJ, van Esch EM, Stynenbosch LF, Kerpershoek G, van Persijn van Meerten EL, van den Hende M, Löwik MJ, Berends-van der Meer DM, Fathers LM. HPV16 synthetic long peptide (HPV16-SLP) vaccination therapy of patients with advanced or recurrent HPV16-induced gynecological carcinoma, a phase II trial. J Transl Med. 2013;11:88. [PMID: 23557172 DOI: 10.1186/1479-5876-11-88] [Cited by in Crossref: 114] [Cited by in F6Publishing: 99] [Article Influence: 12.7] [Reference Citation Analysis]
181 Fenwick C, Loredo-Varela JL, Joo V, Pellaton C, Farina A, Rajah N, Esteves-Leuenberger L, Decaillon T, Suffiotti M, Noto A, Ohmiti K, Gottardo R, Weissenhorn W, Pantaleo G. Tumor suppression of novel anti-PD-1 antibodies mediated through CD28 costimulatory pathway. J Exp Med 2019;216:1525-41. [PMID: 31123083 DOI: 10.1084/jem.20182359] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 3.7] [Reference Citation Analysis]
182 Kwok G, Yau TC, Chiu JW, Tse E, Kwong YL. Pembrolizumab (Keytruda). Hum Vaccin Immunother 2016;12:2777-89. [PMID: 27398650 DOI: 10.1080/21645515.2016.1199310] [Cited by in Crossref: 70] [Cited by in F6Publishing: 72] [Article Influence: 11.7] [Reference Citation Analysis]
183 Park IH, Yang HN, Lee KJ, Kim TS, Lee ES, Jung SY, Kwon Y, Kong SY. Tumor-derived IL-18 induces PD-1 expression on immunosuppressive NK cells in triple-negative breast cancer. Oncotarget 2017;8:32722-30. [PMID: 28415798 DOI: 10.18632/oncotarget.16281] [Cited by in Crossref: 40] [Cited by in F6Publishing: 40] [Article Influence: 10.0] [Reference Citation Analysis]
184 Kirk R. From ASCO-immunotherapy: programming cancer cell death. Nat Rev Clin Oncol 2012;9:427. [PMID: 22710340 DOI: 10.1038/nrclinonc.2012.104] [Reference Citation Analysis]
185 Fang W, Zhou H, Shen J, Li J, Zhang Y, Hong S, Zhang L. MDM2/4 amplification predicts poor response to immune checkpoint inhibitors: a pan-cancer analysis. ESMO Open 2020;5:e000614. [PMID: 33551066 DOI: 10.1136/esmoopen-2019-000614] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
186 Osoegawa A, Hiraishi H, Hashimoto T, Takumi Y, Abe M, Takeuchi H, Miyawaki M, Okamoto T, Sugio K. The Positive Relationship Between γH2AX and PD-L1 Expression in Lung Squamous Cell Carcinoma. In Vivo 2018;32:171-7. [PMID: 29275316 DOI: 10.21873/invivo.11221] [Cited by in Crossref: 2] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
187 Savas P, Hughes B, Solomon B. Targeted therapy in lung cancer: IPASS and beyond, keeping abreast of the explosion of targeted therapies for lung cancer. J Thorac Dis 2013;5 Suppl 5:S579-92. [PMID: 24163750 DOI: 10.3978/j.issn.2072-1439.2013.08.52] [Cited by in F6Publishing: 22] [Reference Citation Analysis]
188 Grant MJ, Herbst RS, Goldberg SB. Selecting the optimal immunotherapy regimen in driver-negative metastatic NSCLC. Nat Rev Clin Oncol 2021. [PMID: 34168333 DOI: 10.1038/s41571-021-00520-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
189 Mimura N, Hideshima T, Anderson KC. Novel therapeutic strategies for multiple myeloma. Exp Hematol 2015;43:732-41. [PMID: 26118499 DOI: 10.1016/j.exphem.2015.04.010] [Cited by in Crossref: 62] [Cited by in F6Publishing: 62] [Article Influence: 8.9] [Reference Citation Analysis]
190 Gebremeskel S, Johnston B. Concepts and mechanisms underlying chemotherapy induced immunogenic cell death: impact on clinical studies and considerations for combined therapies. Oncotarget. 2015;6:41600-41619. [PMID: 26486085 DOI: 10.18632/oncotarget.6113] [Cited by in Crossref: 72] [Cited by in F6Publishing: 72] [Article Influence: 12.0] [Reference Citation Analysis]
191 Erdogdu IH. MHC Class 1 and PDL-1 Status of Primary Tumor and Lymph Node Metastatic Tumor Tissue in Gastric Cancers. Gastroenterol Res Pract 2019;2019:4785098. [PMID: 30881447 DOI: 10.1155/2019/4785098] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
192 Wang B, Wang X, Wen Y, Fu J, Wang H, Ma Z, Shi Y, Wang B. Suppression of established hepatocarcinoma in adjuvant only immunotherapy: alum triggers anti-tumor CD8+ T cell response. Sci Rep 2015;5:17695. [PMID: 26647964 DOI: 10.1038/srep17695] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
193 He W, Xiao K, Fang M, Xie L. Immune Cell Number, Phenotype, and Function in the Elderly with Sepsis. Aging Dis 2021;12:277-96. [PMID: 33532141 DOI: 10.14336/AD.2020.0627] [Reference Citation Analysis]
194 Tsao CK, Liaw B, He C, Galsky MD, Sfakianos J, Oh WK. Moving beyond vascular endothelial growth factor-targeted therapy in renal cell cancer: latest evidence and therapeutic implications. Ther Adv Med Oncol 2017;9:287-98. [PMID: 28491148 DOI: 10.1177/1758834016687261] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
195 Martinov T, Fife BT. Type 1 diabetes pathogenesis and the role of inhibitory receptors in islet tolerance. Ann N Y Acad Sci 2020;1461:73-103. [PMID: 31025378 DOI: 10.1111/nyas.14106] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
196 Melero I, Gaudernack G, Gerritsen W, Huber C, Parmiani G, Scholl S, Thatcher N, Wagstaff J, Zielinski C, Faulkner I. Therapeutic vaccines for cancer: an overview of clinical trials. Nat Rev Clin Oncol. 2014;11:509-524. [PMID: 25001465 DOI: 10.1038/nrclinonc.2014.111] [Cited by in Crossref: 454] [Cited by in F6Publishing: 426] [Article Influence: 56.8] [Reference Citation Analysis]
197 Weiss A, Gill J, Goldberg J, Lagmay J, Spraker-Perlman H, Venkatramani R, Reed D. Advances in therapy for pediatric sarcomas. Curr Oncol Rep. 2014;16:395. [PMID: 24894064 DOI: 10.1007/s11912-014-0395-z] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 2.9] [Reference Citation Analysis]
198 Nishino M, Giobbie-Hurder A, Gargano M, Suda M, Ramaiya NH, Hodi FS. Developing a common language for tumor response to immunotherapy: immune-related response criteria using unidimensional measurements. Clin Cancer Res. 2013;19:3936-3943. [PMID: 23743568 DOI: 10.1158/1078-0432.ccr-13-0895] [Cited by in Crossref: 291] [Cited by in F6Publishing: 142] [Article Influence: 32.3] [Reference Citation Analysis]
199 Winograd R, Byrne KT, Evans RA, Odorizzi PM, Meyer AR, Bajor DL, Clendenin C, Stanger BZ, Furth EE, Wherry EJ, Vonderheide RH. Induction of T-cell Immunity Overcomes Complete Resistance to PD-1 and CTLA-4 Blockade and Improves Survival in Pancreatic Carcinoma. Cancer Immunol Res. 2015;3:399-411. [PMID: 25678581 DOI: 10.1158/2326-6066.cir-14-0215] [Cited by in Crossref: 242] [Cited by in F6Publishing: 171] [Article Influence: 34.6] [Reference Citation Analysis]
200 Wong PF, Wei W, Smithy JW, Acs B, Toki MI, Blenman KRM, Zelterman D, Kluger HM, Rimm DL. Multiplex Quantitative Analysis of Tumor-Infiltrating Lymphocytes and Immunotherapy Outcome in Metastatic Melanoma. Clin Cancer Res 2019;25:2442-9. [PMID: 30617133 DOI: 10.1158/1078-0432.CCR-18-2652] [Cited by in Crossref: 39] [Cited by in F6Publishing: 28] [Article Influence: 13.0] [Reference Citation Analysis]
201 Sayour EJ, Mitchell DA. Immunotherapy for Pediatric Brain Tumors. Brain Sci. 2017;7. [PMID: 29065490 DOI: 10.3390/brainsci7100137] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
202 Irving M, Vuillefroy de Silly R, Scholten K, Dilek N, Coukos G. Engineering Chimeric Antigen Receptor T-Cells for Racing in Solid Tumors: Don't Forget the Fuel. Front Immunol 2017;8:267. [PMID: 28421069 DOI: 10.3389/fimmu.2017.00267] [Cited by in Crossref: 40] [Cited by in F6Publishing: 37] [Article Influence: 8.0] [Reference Citation Analysis]
203 Baine MK, Turcu G, Zito CR, Adeniran AJ, Camp RL, Chen L, Kluger HM, Jilaveanu LB. Characterization of tumor infiltrating lymphocytes in paired primary and metastatic renal cell carcinoma specimens. Oncotarget 2015;6:24990-5002. [PMID: 26317902 DOI: 10.18632/oncotarget.4572] [Cited by in Crossref: 32] [Cited by in F6Publishing: 34] [Article Influence: 5.3] [Reference Citation Analysis]
204 Imafuku K, Yoshino K, Yamaguchi K, Tsuboi S, Ohara K, Hata H. Two Cases of Nivolumab Re-Administration after Pneumonitis as Immune-Related Adverse Events. Case Rep Oncol 2017;10:296-300. [PMID: 28512413 DOI: 10.1159/000463379] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
205 Feldman R, Gatalica Z, Knezetic J, Reddy S, Nathan CA, Javadi N, Teknos T. Molecular profiling of head and neck squamous cell carcinoma. Head Neck 2016;38 Suppl 1:E1625-38. [PMID: 26614708 DOI: 10.1002/hed.24290] [Cited by in Crossref: 57] [Cited by in F6Publishing: 59] [Article Influence: 8.1] [Reference Citation Analysis]
206 Kim JE, Lim M. The role of checkpoints in the treatment of GBM. J Neurooncol 2015;123:413-23. [PMID: 25749875 DOI: 10.1007/s11060-015-1747-8] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.6] [Reference Citation Analysis]
207 Duan J, Cui L, Zhao X, Bai H, Cai S, Wang G, Zhao Z, Zhao J, Chen S, Song J, Qi C, Wang Q, Huang M, Zhang Y, Huang D, Bai Y, Sun F, Lee JJ, Wang Z, Wang J. Use of Immunotherapy With Programmed Cell Death 1 vs Programmed Cell Death Ligand 1 Inhibitors in Patients With Cancer: A Systematic Review and Meta-analysis. JAMA Oncol 2020;6:375-84. [PMID: 31876895 DOI: 10.1001/jamaoncol.2019.5367] [Cited by in Crossref: 73] [Cited by in F6Publishing: 73] [Article Influence: 36.5] [Reference Citation Analysis]
208 Amrein MA, Bührer ED, Amrein ML, Li Q, Rothschild S, Riether C, Jaggi R, Savic-Prince S, Bubendorf L, Gautschi O, Ochsenbein AF. Chemotherapy negatively impacts the tumor immune microenvironment in NSCLC: an analysis of pre- and post-treatment biopsies in the multi-center SAKK19/09 study. Cancer Immunol Immunother 2021;70:405-15. [PMID: 32767058 DOI: 10.1007/s00262-020-02688-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
209 Seifert L, Miller G. Molecular Pathways: The Necrosome-A Target for Cancer Therapy. Clin Cancer Res 2017;23:1132-6. [PMID: 27932417 DOI: 10.1158/1078-0432.CCR-16-0968] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
210 Awadalla M, Golden DLA, Mahmood SS, Alvi RM, Mercaldo ND, Hassan MZO, Banerji D, Rokicki A, Mulligan C, Murphy SPT, Jones-O'Connor M, Cohen JV, Heinzerling LM, Armanious M, Sullivan RJ, Damrongwatanasuk R, Chen CL, Gupta D, Kirchberger MC, Moslehi JJ, Shah SP, Ganatra S, Thavendiranathan P, Rizvi MA, Sahni G, Lyon AR, Tocchetti CG, Mercurio V, Thuny F, Ederhy S, Mahmoudi M, Lawrence DP, Groarke JD, Nohria A, Fradley MG, Reynolds KL, Neilan TG. Influenza vaccination and myocarditis among patients receiving immune checkpoint inhibitors. J Immunother Cancer 2019;7:53. [PMID: 30795818 DOI: 10.1186/s40425-019-0535-y] [Cited by in Crossref: 39] [Cited by in F6Publishing: 32] [Article Influence: 13.0] [Reference Citation Analysis]
211 Frebel H, Oxenius A. The risks of targeting co-inhibitory pathways to modulate pathogen-directed T cell responses. Trends Immunol 2013;34:193-9. [PMID: 23333205 DOI: 10.1016/j.it.2012.12.002] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 1.6] [Reference Citation Analysis]
212 Evans T, Ciunci C, Hertan L, Gomez D. Special topics in immunotherapy and radiation therapy: reirradiation and palliation. Transl Lung Cancer Res 2017;6:119-30. [PMID: 28529895 DOI: 10.21037/tlcr.2017.04.03] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
213 Penaloza-MacMaster P. CD8 T-cell regulation by T regulatory cells and the programmed cell death protein 1 pathway. Immunology 2017;151:146-53. [PMID: 28375543 DOI: 10.1111/imm.12739] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.6] [Reference Citation Analysis]
214 Rajan A, Kim C, Heery CR, Guha U, Gulley JL. Nivolumab, anti-programmed death-1 (PD-1) monoclonal antibody immunotherapy: Role in advanced cancers. Hum Vaccin Immunother 2016;12:2219-31. [PMID: 27135835 DOI: 10.1080/21645515.2016.1175694] [Cited by in Crossref: 23] [Cited by in F6Publishing: 27] [Article Influence: 3.8] [Reference Citation Analysis]
215 Magee MS, Snook AE, Marszalowicz GP, Waldman SA. Immunotherapeutic strategies to target prognostic and predictive markers of cancer. Biomark Med 2013;7:23-35. [PMID: 23387482 DOI: 10.2217/bmm.12.110] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
216 Porichis F, Hart MG, Zupkosky J, Barblu L, Kwon DS, McMullen A, Brennan T, Ahmed R, Freeman GJ, Kavanagh DG, Kaufmann DE. Differential impact of PD-1 and/or interleukin-10 blockade on HIV-1-specific CD4 T cell and antigen-presenting cell functions. J Virol 2014;88:2508-18. [PMID: 24352453 DOI: 10.1128/JVI.02034-13] [Cited by in Crossref: 38] [Cited by in F6Publishing: 36] [Article Influence: 4.2] [Reference Citation Analysis]
217 Joseph RW, Chatta G, Vaishampayan U. Nivolumab treatment for advanced renal cell carcinoma: Considerations for clinical practice. Urol Oncol 2017;35:142-8. [PMID: 28259541 DOI: 10.1016/j.urolonc.2017.01.017] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 2.2] [Reference Citation Analysis]
218 Callahan MK, Kluger H, Postow MA, Segal NH, Lesokhin A, Atkins MB, Kirkwood JM, Krishnan S, Bhore R, Horak C, Wolchok JD, Sznol M. Nivolumab Plus Ipilimumab in Patients With Advanced Melanoma: Updated Survival, Response, and Safety Data in a Phase I Dose-Escalation Study. J Clin Oncol 2018;36:391-8. [PMID: 29040030 DOI: 10.1200/JCO.2017.72.2850] [Cited by in Crossref: 101] [Cited by in F6Publishing: 53] [Article Influence: 20.2] [Reference Citation Analysis]
219 Martinez-Morilla S, McGuire J, Gaule P, Moore L, Acs B, Cougot D, Gown AM, Yaziji H, Wang WL, Cartun RW, Hornick JL, Sholl LM, Qiu J, Mino-Kenudson M, Yi ES, Beasley MB, Merrick DT, Ambaye AB, Zhang ZJ, Walker J, Rimm DL. Quantitative assessment of PD-L1 as an analyte in immunohistochemistry diagnostic assays using a standardized cell line tissue microarray. Lab Invest 2020;100:4-15. [PMID: 31409885 DOI: 10.1038/s41374-019-0295-9] [Cited by in Crossref: 22] [Cited by in F6Publishing: 24] [Article Influence: 7.3] [Reference Citation Analysis]
220 Im JS, Herrmann AC, Bernatchez C, Haymaker C, Molldrem JJ, Hong WK, Perez-Soler R. Immune-Modulation by Epidermal Growth Factor Receptor Inhibitors: Implication on Anti-Tumor Immunity in Lung Cancer. PLoS One 2016;11:e0160004. [PMID: 27467256 DOI: 10.1371/journal.pone.0160004] [Cited by in Crossref: 19] [Cited by in F6Publishing: 23] [Article Influence: 3.2] [Reference Citation Analysis]
221 Iasonos A, O'Quigley J. Clinical trials: Early phase clinical trials-are dose expansion cohorts needed? Nat Rev Clin Oncol 2015;12:626-8. [PMID: 26441082 DOI: 10.1038/nrclinonc.2015.174] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 2.6] [Reference Citation Analysis]
222 Lv P, Chen X, Fu S, Ren E, Liu C, Liu X, Jiang L, Zeng Y, Wang X, Liu G. Surface engineering of oncolytic adenovirus for a combination of immune checkpoint blockade and virotherapy. Biomater Sci 2021;9:7392-401. [PMID: 34751685 DOI: 10.1039/d1bm00928a] [Reference Citation Analysis]
223 Bedke J, Gouttefangeas C, Singh-Jasuja H, Stevanović S, Behnes CL, Stenzl A. Targeted therapy in renal cell carcinoma: moving from molecular agents to specific immunotherapy. World J Urol 2014;32:31-8. [PMID: 23404195 DOI: 10.1007/s00345-013-1033-3] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 2.1] [Reference Citation Analysis]
224 Morrot A, da Fonseca LM, Salustiano EJ, Gentile LB, Conde L, Filardy AA, Franklim TN, da Costa KM, Freire-de-Lima CG, Freire-de-Lima L. Metabolic Symbiosis and Immunomodulation: How Tumor Cell-Derived Lactate May Disturb Innate and Adaptive Immune Responses. Front Oncol 2018;8:81. [PMID: 29629338 DOI: 10.3389/fonc.2018.00081] [Cited by in Crossref: 40] [Cited by in F6Publishing: 35] [Article Influence: 10.0] [Reference Citation Analysis]
225 Zheng X, Xu K, Chen L, Zhou Y, Jiang J. Prognostic value of TIM-1 expression in human non-small-cell lung cancer. J Transl Med 2019;17:178. [PMID: 31138322 DOI: 10.1186/s12967-019-1931-2] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
226 Blomberg OS, Spagnuolo L, de Visser KE. Immune regulation of metastasis: mechanistic insights and therapeutic opportunities. Dis Model Mech 2018;11:dmm036236. [PMID: 30355585 DOI: 10.1242/dmm.036236] [Cited by in Crossref: 48] [Cited by in F6Publishing: 39] [Article Influence: 12.0] [Reference Citation Analysis]
227 Zhou J, Liu L, Yang T, Lu B. Prognostic and therapeutic value of CD103+ cells in renal cell carcinoma. Exp Ther Med 2018;15:4979-86. [PMID: 29805521 DOI: 10.3892/etm.2018.6025] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
228 Cullis J, Das S, Bar-Sagi D. Kras and Tumor Immunity: Friend or Foe? Cold Spring Harb Perspect Med. 2018;8. [PMID: 29229670 DOI: 10.1101/cshperspect.a031849] [Cited by in Crossref: 29] [Cited by in F6Publishing: 29] [Article Influence: 7.3] [Reference Citation Analysis]
229 Xing W, Dresser K, Zhang R, Evens AM, Yu H, Woda BA, Chen BJ. PD-L1 expression in EBV-negative diffuse large B-cell lymphoma: clinicopathologic features and prognostic implications. Oncotarget 2016;7:59976-86. [PMID: 27527850 DOI: 10.18632/oncotarget.11045] [Cited by in Crossref: 37] [Cited by in F6Publishing: 37] [Article Influence: 9.3] [Reference Citation Analysis]
230 Hanna SC, Krishnan B, Bailey ST, Moschos SJ, Kuan PF, Shimamura T, Osborne LD, Siegel MB, Duncan LM, O'Brien ET 3rd, Superfine R, Miller CR, Simon MC, Wong KK, Kim WY. HIF1α and HIF2α independently activate SRC to promote melanoma metastases. J Clin Invest 2013;123:2078-93. [PMID: 23563312 DOI: 10.1172/JCI66715] [Cited by in Crossref: 104] [Cited by in F6Publishing: 78] [Article Influence: 11.6] [Reference Citation Analysis]
231 Thomas A, Giaccone G. Why has active immunotherapy not worked in lung cancer? Ann Oncol 2015;26:2213-20. [PMID: 26232492 DOI: 10.1093/annonc/mdv323] [Cited by in Crossref: 27] [Cited by in F6Publishing: 27] [Article Influence: 3.9] [Reference Citation Analysis]
232 李伟东, 孙学英. 恶性肿瘤缺氧酸性微环境对免疫治疗影响机制的研究进展. 世界华人消化杂志 2017; 25(21): 1934-1944 [DOI: 10.11569/wcjd.v25.i21.1934] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
233 Yasuma T, Toda M, Kobori H, Tada N, D'Alessandro-Gabazza CN, Gabazza EC. Subcritical Water Extracts from Agaricus blazei Murrill's Mycelium Inhibit the Expression of Immune Checkpoint Molecules and Axl Receptor. J Fungi (Basel) 2021;7:590. [PMID: 34436128 DOI: 10.3390/jof7080590] [Reference Citation Analysis]
234 Bidnur S, Savdie R, Black PC. Inhibiting Immune Checkpoints for the Treatment of Bladder Cancer. Bladder Cancer 2016;2:15-25. [PMID: 27376121 DOI: 10.3233/BLC-150026] [Cited by in Crossref: 18] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
235 Zhang J, Sanghavi K, Shen J, Zhao X, Feng Y, Statkevich P, Sheng J, Roy A, Zhu L. Population Pharmacokinetics of Nivolumab in Combination With Ipilimumab in Patients With Advanced Malignancies. CPT Pharmacometrics Syst Pharmacol 2019;8:962-70. [PMID: 31710163 DOI: 10.1002/psp4.12476] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
236 Nakamura K, Ashida A, Kiniwa Y, Okuyama R. Chemokine level predicts the therapeutic effect of anti-PD-1 antibody (nivolumab) therapy for malignant melanoma. Arch Dermatol Res 2021. [PMID: 34842960 DOI: 10.1007/s00403-021-02305-z] [Reference Citation Analysis]
237 Papadopoulos KP, Harb W, Peer CJ, Hua Q, Xu S, Lu H, Lu N, He Y, Xu T, Dong R, Gong J, Liu D. First-in-Human Phase I Study of Envafolimab, a Novel Subcutaneous Single-Domain Anti-PD-L1 Antibody, in Patients with Advanced Solid Tumors. Oncologist 2021;26:e1514-25. [PMID: 33973293 DOI: 10.1002/onco.13817] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
238 Zamora AE, Crawford JC, Allen EK, Guo XJ, Bakke J, Carter RA, Abdelsamed HA, Moustaki A, Li Y, Chang TC, Awad W, Dallas MH, Mullighan CG, Downing JR, Geiger TL, Chen T, Green DR, Youngblood BA, Zhang J, Thomas PG. Pediatric patients with acute lymphoblastic leukemia generate abundant and functional neoantigen-specific CD8+ T cell responses. Sci Transl Med 2019;11:eaat8549. [PMID: 31243155 DOI: 10.1126/scitranslmed.aat8549] [Cited by in Crossref: 34] [Cited by in F6Publishing: 30] [Article Influence: 17.0] [Reference Citation Analysis]
239 Hu-Lieskovan S, Robert L, Homet Moreno B, Ribas A. Combining targeted therapy with immunotherapy in BRAF-mutant melanoma: promise and challenges. J Clin Oncol. 2014;32:2248-2254. [PMID: 24958825 DOI: 10.1200/jco.2013.52.1377] [Cited by in Crossref: 144] [Cited by in F6Publishing: 81] [Article Influence: 18.0] [Reference Citation Analysis]
240 Okamoto M, Kobayashi M, Yonemitsu Y, Koido S, Homma S. Dendritic cell-based vaccine for pancreatic cancer in Japan. World J Gastrointest Pharmacol Ther 2016; 7(1): 133-138 [PMID: 26855819 DOI: 10.4292/wjgpt.v7.i1.133] [Cited by in CrossRef: 12] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
241 Rizvi NA, Hellmann MD, Brahmer JR, Juergens RA, Borghaei H, Gettinger S, Chow LQ, Gerber DE, Laurie SA, Goldman JW. Nivolumab in Combination With Platinum-Based Doublet Chemotherapy for First-Line Treatment of Advanced Non-Small-Cell Lung Cancer. J Clin Oncol. 2016;34:2969-2979. [PMID: 27354481 DOI: 10.1200/jco.2016.66.9861] [Cited by in Crossref: 258] [Cited by in F6Publishing: 161] [Article Influence: 43.0] [Reference Citation Analysis]
242 Zhang B, Wu Q, Li B, Wang D, Wang L, Zhou YL. m6A regulator-mediated methylation modification patterns and tumor microenvironment infiltration characterization in gastric cancer. Mol Cancer 2020;19:53. [PMID: 32164750 DOI: 10.1186/s12943-020-01170-0] [Cited by in Crossref: 86] [Cited by in F6Publishing: 104] [Article Influence: 43.0] [Reference Citation Analysis]
243 Overwijk WW, Wang E, Marincola FM, Rammensee HG, Restifo NP. Mining the mutanome: developing highly personalized Immunotherapies based on mutational analysis of tumors. J Immunother Cancer 2013;1:11. [PMID: 24829748 DOI: 10.1186/2051-1426-1-11] [Cited by in Crossref: 43] [Cited by in F6Publishing: 39] [Article Influence: 4.8] [Reference Citation Analysis]
244 Feucht J, Kayser S, Gorodezki D, Hamieh M, Döring M, Blaeschke F, Schlegel P, Bösmüller H, Quintanilla-Fend L, Ebinger M, Lang P, Handgretinger R, Feuchtinger T. T-cell responses against CD19+ pediatric acute lymphoblastic leukemia mediated by bispecific T-cell engager (BiTE) are regulated contrarily by PD-L1 and CD80/CD86 on leukemic blasts. Oncotarget 2016;7:76902-19. [PMID: 27708227 DOI: 10.18632/oncotarget.12357] [Cited by in Crossref: 79] [Cited by in F6Publishing: 76] [Article Influence: 19.8] [Reference Citation Analysis]
245 van de Kerkhof PC. Dermatology: Where are We Coming from and Where are We Going to? Front Med (Lausanne) 2014;1:40. [PMID: 25593913 DOI: 10.3389/fmed.2014.00040] [Reference Citation Analysis]
246 Kim HJ, Oh SC. Novel Systemic Therapies for Advanced Gastric Cancer. J Gastric Cancer 2018;18:1-19. [PMID: 29629216 DOI: 10.5230/jgc.2018.18.e3] [Cited by in Crossref: 12] [Cited by in F6Publishing: 20] [Article Influence: 3.0] [Reference Citation Analysis]
247 Trono P, Sistigu A, Palermo B, Ciliberto G, Nisticò P. Mesenchymal traits at the convergence of tumor-intrinsic and -extrinsic mechanisms of resistance to immune checkpoint blockers. Emerg Top Life Sci 2017;1:471-86. [PMID: 33525801 DOI: 10.1042/ETLS20170068] [Cited by in Crossref: 2] [Article Influence: 0.4] [Reference Citation Analysis]
248 Salerno EP, Bedognetti D, Mauldin IS, Deacon DH, Shea SM, Pinczewski J, Obeid JM, Coukos G, Wang E, Gajewski TF, Marincola FM, Slingluff CL Jr. Human melanomas and ovarian cancers overexpressing mechanical barrier molecule genes lack immune signatures and have increased patient mortality risk. Oncoimmunology 2016;5:e1240857. [PMID: 28123876 DOI: 10.1080/2162402X.2016.1240857] [Cited by in Crossref: 37] [Cited by in F6Publishing: 24] [Article Influence: 6.2] [Reference Citation Analysis]
249 Pfannenstiel LW, McNeilly C, Xiang C, Kang K, Diaz-Montero CM, Yu JS, Gastman BR. Combination PD-1 blockade and irradiation of brain metastasis induces an effective abscopal effect in melanoma. Oncoimmunology 2019;8:e1507669. [PMID: 30546944 DOI: 10.1080/2162402X.2018.1507669] [Cited by in Crossref: 28] [Cited by in F6Publishing: 19] [Article Influence: 7.0] [Reference Citation Analysis]
250 Hoefsmit EP, Rozeman EA, Van TM, Dimitriadis P, Krijgsman O, Conway JW, Pires da Silva I, van der Wal JE, Ketelaars SLC, Bresser K, Broeks A, Kerkhoven RM, Reeves JW, Warren S, Kvistborg P, Scolyer RA, Kapiteijn EW, Peeper DS, Long GV, Schumacher TNM, Blank CU. Comprehensive analysis of cutaneous and uveal melanoma liver metastases. J Immunother Cancer 2020;8:e001501. [PMID: 33262254 DOI: 10.1136/jitc-2020-001501] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
251 Filley AC, Henriquez M, Dey M. Recurrent glioma clinical trial, CheckMate-143: the game is not over yet. Oncotarget 2017;8:91779-94. [PMID: 29207684 DOI: 10.18632/oncotarget.21586] [Cited by in Crossref: 164] [Cited by in F6Publishing: 156] [Article Influence: 32.8] [Reference Citation Analysis]
252 Horton BL, Morgan DM, Momin N, Zagorulya M, Torres-Mejia E, Bhandarkar V, Wittrup KD, Love JC, Spranger S. Lack of CD8+ T cell effector differentiation during priming mediates checkpoint blockade resistance in non-small cell lung cancer. Sci Immunol 2021;6:eabi8800. [PMID: 34714687 DOI: 10.1126/sciimmunol.abi8800] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
253 Tseng WW, Malu S, Zhang M, Chen J, Sim GC, Wei W, Ingram D, Somaiah N, Lev DC, Pollock RE, Lizée G, Radvanyi L, Hwu P. Analysis of the intratumoral adaptive immune response in well differentiated and dedifferentiated retroperitoneal liposarcoma. Sarcoma 2015;2015:547460. [PMID: 25705114 DOI: 10.1155/2015/547460] [Cited by in Crossref: 26] [Cited by in F6Publishing: 30] [Article Influence: 3.7] [Reference Citation Analysis]
254 Le Louedec F, Leenhardt F, Marin C, Chatelut É, Evrard A, Ciccolini J. Cancer Immunotherapy Dosing: A Pharmacokinetic/Pharmacodynamic Perspective. Vaccines (Basel) 2020;8:E632. [PMID: 33142728 DOI: 10.3390/vaccines8040632] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
255 Mender I, Zhang A, Ren Z, Han C, Deng Y, Siteni S, Li H, Zhu J, Vemula A, Shay JW, Fu YX. Telomere Stress Potentiates STING-Dependent Anti-tumor Immunity. Cancer Cell 2020;38:400-411.e6. [PMID: 32619407 DOI: 10.1016/j.ccell.2020.05.020] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 3.5] [Reference Citation Analysis]
256 An YS, Kim SH, Roh TH, Park SH, Kim TG, Kim JH. Correlation Between 18F-FDG Uptake and Immune Cell Infiltration in Metastatic Brain Lesions. Front Oncol 2021;11:618705. [PMID: 34249674 DOI: 10.3389/fonc.2021.618705] [Reference Citation Analysis]
257 Wen J, Yan M, Liu Y, Li J, Xie Y, Lu Y, Kamata M, Chen IS. Specific Elimination of Latently HIV-1 Infected Cells Using HIV-1 Protease-Sensitive Toxin Nanocapsules. PLoS One 2016;11:e0151572. [PMID: 27049645 DOI: 10.1371/journal.pone.0151572] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
258 Carbone DP, Gandara DR, Antonia SJ, Zielinski C, Paz-Ares L. Non-Small-Cell Lung Cancer: Role of the Immune System and Potential for Immunotherapy. J Thorac Oncol 2015;10:974-84. [PMID: 26134219 DOI: 10.1097/JTO.0000000000000551] [Cited by in Crossref: 65] [Cited by in F6Publishing: 37] [Article Influence: 10.8] [Reference Citation Analysis]
259 Freiberger SN, Turko P, Hüllner M, Dummer R, Morand GB, Levesque MP, Holzmann D, Rupp NJ. Who's Driving? Switch of Drivers in Immunotherapy-Treated Progressing Sinonasal Melanoma. Cancers (Basel) 2021;13:2725. [PMID: 34072863 DOI: 10.3390/cancers13112725] [Reference Citation Analysis]
260 Mott KR, Allen SJ, Zandian M, Akbari O, Hamrah P, Maazi H, Wechsler SL, Sharpe AH, Freeman GJ, Ghiasi H. Inclusion of CD80 in HSV targets the recombinant virus to PD-L1 on DCs and allows productive infection and robust immune responses. PLoS One 2014;9:e87617. [PMID: 24475315 DOI: 10.1371/journal.pone.0087617] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 2.0] [Reference Citation Analysis]
261 Le Du F, Eckhardt BL, Lim B, Litton JK, Moulder S, Meric-Bernstam F, Gonzalez-Angulo AM, Ueno NT. Is the future of personalized therapy in triple-negative breast cancer based on molecular subtype? Oncotarget 2015;6:12890-908. [PMID: 25973541 DOI: 10.18632/oncotarget.3849] [Cited by in Crossref: 67] [Cited by in F6Publishing: 60] [Article Influence: 11.2] [Reference Citation Analysis]
262 Pezzuto F, Fortarezza F, Lunardi F, Calabrese F. Are there any theranostic biomarkers in small cell lung carcinoma? J Thorac Dis 2019;11:S102-12. [PMID: 30775033 DOI: 10.21037/jtd.2018.12.14] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
263 Tocchetti CG, Cadeddu C, Di Lisi D, Femminò S, Madonna R, Mele D, Monte I, Novo G, Penna C, Pepe A, Spallarossa P, Varricchi G, Zito C, Pagliaro P, Mercuro G. From Molecular Mechanisms to Clinical Management of Antineoplastic Drug-Induced Cardiovascular Toxicity: A Translational Overview. Antioxid Redox Signal 2019;30:2110-53. [PMID: 28398124 DOI: 10.1089/ars.2016.6930] [Cited by in Crossref: 52] [Cited by in F6Publishing: 48] [Article Influence: 10.4] [Reference Citation Analysis]
264 Moran AE, Kovacsovics-Bankowski M, Weinberg AD. The TNFRs OX40, 4-1BB, and CD40 as targets for cancer immunotherapy. Curr Opin Immunol. 2013;25:230-237. [PMID: 23414607 DOI: 10.1016/j.coi.2013.01.004] [Cited by in Crossref: 101] [Cited by in F6Publishing: 97] [Article Influence: 11.2] [Reference Citation Analysis]
265 Sumimoto H, Takano A, Teramoto K, Daigo Y. RAS-Mitogen-Activated Protein Kinase Signal Is Required for Enhanced PD-L1 Expression in Human Lung Cancers. PLoS One 2016;11:e0166626. [PMID: 27846317 DOI: 10.1371/journal.pone.0166626] [Cited by in Crossref: 80] [Cited by in F6Publishing: 79] [Article Influence: 13.3] [Reference Citation Analysis]
266 Jia Y, Liu L, Shan B. Future of immune checkpoint inhibitors: focus on tumor immune microenvironment. Ann Transl Med 2020;8:1095. [PMID: 33145314 DOI: 10.21037/atm-20-3735] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
267 Xu C, Chen YP, Du XJ, Liu JQ, Huang CL, Chen L, Zhou GQ, Li WF, Mao YP, Hsu C, Liu Q, Lin AH, Tang LL, Sun Y, Ma J. Comparative safety of immune checkpoint inhibitors in cancer: systematic review and network meta-analysis. BMJ. 2018;363:k4226. [PMID: 30409774 DOI: 10.1136/bmj.k4226] [Cited by in Crossref: 124] [Cited by in F6Publishing: 119] [Article Influence: 31.0] [Reference Citation Analysis]
268 Gaillard SL, Secord AA, Monk B. The role of immune checkpoint inhibition in the treatment of ovarian cancer. Gynecol Oncol Res Pract 2016;3:11. [PMID: 27904752 DOI: 10.1186/s40661-016-0033-6] [Cited by in Crossref: 89] [Cited by in F6Publishing: 82] [Article Influence: 14.8] [Reference Citation Analysis]
269 Palicelli A, Bonacini M, Croci S, Magi-Galluzzi C, Cañete-Portillo S, Chaux A, Bisagni A, Zanetti E, De Biase D, Melli B, Sanguedolce F, Ragazzi M, Bonasoni MP, Soriano A, Ascani S, Zizzo M, Castro Ruiz C, De Leo A, Giordano G, Landriscina M, Carrieri G, Cormio L, Berney DM, Athanazio D, Gandhi J, Cavazza A, Santandrea G, Tafuni A, Zanelli M. What Do We Have to Know about PD-L1 Expression in Prostate Cancer? A Systematic Literature Review. Part 1: Focus on Immunohistochemical Results with Discussion of Pre-Analytical and Interpretation Variables. Cells 2021;10:3166. [PMID: 34831389 DOI: 10.3390/cells10113166] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 5.0] [Reference Citation Analysis]
270 Zheng H, Siddharth S, Parida S, Wu X, Sharma D. Tumor Microenvironment: Key Players in Triple Negative Breast Cancer Immunomodulation. Cancers (Basel) 2021;13:3357. [PMID: 34283088 DOI: 10.3390/cancers13133357] [Reference Citation Analysis]
271 Fuller MJ, Callendret B, Zhu B, Freeman GJ, Hasselschwert DL, Satterfield W, Sharpe AH, Dustin LB, Rice CM, Grakoui A, Ahmed R, Walker CM. Immunotherapy of chronic hepatitis C virus infection with antibodies against programmed cell death-1 (PD-1). Proc Natl Acad Sci USA. 2013;110:15001-15006. [PMID: 23980172 DOI: 10.1073/pnas.1312772110] [Cited by in Crossref: 133] [Cited by in F6Publishing: 126] [Article Influence: 14.8] [Reference Citation Analysis]
272 Khoja L, Butler MO, Kang SP, Ebbinghaus S, Joshua AM. Pembrolizumab. J Immunother Cancer 2015;3:36. [PMID: 26288737 DOI: 10.1186/s40425-015-0078-9] [Cited by in Crossref: 111] [Cited by in F6Publishing: 101] [Article Influence: 15.9] [Reference Citation Analysis]
273 Maeng H, Terabe M, Berzofsky JA. Cancer vaccines: translation from mice to human clinical trials. Curr Opin Immunol 2018;51:111-22. [PMID: 29554495 DOI: 10.1016/j.coi.2018.03.001] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 5.8] [Reference Citation Analysis]
274 Litak J, Mazurek M, Grochowski C, Kamieniak P, Roliński J. PD-L1/PD-1 Axis in Glioblastoma Multiforme. Int J Mol Sci 2019;20:E5347. [PMID: 31661771 DOI: 10.3390/ijms20215347] [Cited by in Crossref: 37] [Cited by in F6Publishing: 31] [Article Influence: 12.3] [Reference Citation Analysis]
275 Turcotte S, Gros A, Tran E, Lee CC, Wunderlich JR, Robbins PF, Rosenberg SA. Tumor-reactive CD8+ T cells in metastatic gastrointestinal cancer refractory to chemotherapy. Clin Cancer Res. 2014;20:331-343. [PMID: 24218514 DOI: 10.1158/1078-0432.ccr-13-1736] [Cited by in Crossref: 41] [Cited by in F6Publishing: 28] [Article Influence: 4.6] [Reference Citation Analysis]
276 Shiuan E, Chen J. Eph Receptor Tyrosine Kinases in Tumor Immunity. Cancer Res 2016;76:6452-7. [PMID: 27811149 DOI: 10.1158/0008-5472.CAN-16-1521] [Cited by in Crossref: 30] [Cited by in F6Publishing: 23] [Article Influence: 5.0] [Reference Citation Analysis]
277 Blair AB, Kim VM, Muth ST, Saung MT, Lokker N, Blouw B, Armstrong TD, Jaffee EM, Tsujikawa T, Coussens LM, He J, Burkhart RA, Wolfgang CL, Zheng L. Dissecting the Stromal Signaling and Regulation of Myeloid Cells and Memory Effector T Cells in Pancreatic Cancer. Clin Cancer Res 2019;25:5351-63. [PMID: 31186314 DOI: 10.1158/1078-0432.CCR-18-4192] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 6.3] [Reference Citation Analysis]
278 Madan RA, Antonarakis ES, Drake CG, Fong L, Yu EY, McNeel DG, Lin DW, Chang NN, Sheikh NA, Gulley JL. Putting the Pieces Together: Completing the Mechanism of Action Jigsaw for Sipuleucel-T. J Natl Cancer Inst 2020;112:562-73. [PMID: 32145020 DOI: 10.1093/jnci/djaa021] [Cited by in Crossref: 15] [Cited by in F6Publishing: 10] [Article Influence: 15.0] [Reference Citation Analysis]
279 Jilaveanu LB, Shuch B, Zito CR, Parisi F, Barr M, Kluger Y, Chen L, Kluger HM. PD-L1 Expression in Clear Cell Renal Cell Carcinoma: An Analysis of Nephrectomy and Sites of Metastases. J Cancer 2014;5:166-72. [PMID: 24563671 DOI: 10.7150/jca.8167] [Cited by in Crossref: 102] [Cited by in F6Publishing: 93] [Article Influence: 12.8] [Reference Citation Analysis]
280 Kim PS, Kwilas AR, Xu W, Alter S, Jeng EK, Wong HC, Schlom J, Hodge JW. IL-15 superagonist/IL-15RαSushi-Fc fusion complex (IL-15SA/IL-15RαSu-Fc; ALT-803) markedly enhances specific subpopulations of NK and memory CD8+ T cells, and mediates potent anti-tumor activity against murine breast and colon carcinomas. Oncotarget 2016;7:16130-45. [PMID: 26910920 DOI: 10.18632/oncotarget.7470] [Cited by in Crossref: 95] [Cited by in F6Publishing: 89] [Article Influence: 19.0] [Reference Citation Analysis]
281 Gompertz-Mattar M, Perales J, Sahu A, Mondaca S, Gonzalez S, Uribe P, Navarrete-Dechent C. Differential expression of programmed cell death ligand 1 (PD-L1) and inflammatory cells in basal cell carcinoma subtypes. Arch Dermatol Res 2021. [PMID: 34647186 DOI: 10.1007/s00403-021-02289-w] [Reference Citation Analysis]
282 Tomela K, Pietrzak B, Schmidt M, Mackiewicz A. The Tumor and Host Immune Signature, and the Gut Microbiota as Predictive Biomarkers for Immune Checkpoint Inhibitor Response in Melanoma Patients. Life (Basel) 2020;10:E219. [PMID: 32992737 DOI: 10.3390/life10100219] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
283 Fontugne J, Augustin J, Pujals A, Compagnon P, Rousseau B, Luciani A, Tournigand C, Cherqui D, Azoulay D, Pawlotsky JM, Calderaro J. PD-L1 expression in perihilar and intrahepatic cholangiocarcinoma. Oncotarget 2017;8:24644-51. [PMID: 28445951 DOI: 10.18632/oncotarget.15602] [Cited by in Crossref: 78] [Cited by in F6Publishing: 77] [Article Influence: 19.5] [Reference Citation Analysis]
284 Szeponik L, Akeus P, Rodin W, Raghavan S, Quiding-Järbrink M. Regulatory T cells specifically suppress conventional CD8αβ T cells in intestinal tumors of APCMin/+ mice. Cancer Immunol Immunother 2020;69:1279-92. [PMID: 32185408 DOI: 10.1007/s00262-020-02540-9] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
285 Boussiotis VA. Somatic mutations and immunotherapy outcome with CTLA-4 blockade in melanoma. N Engl J Med 2014;371:2230-2. [PMID: 25409261 DOI: 10.1056/NEJMe1413061] [Cited by in Crossref: 34] [Cited by in F6Publishing: 14] [Article Influence: 4.3] [Reference Citation Analysis]
286 Drakes ML, Stiff PJ. Ovarian Cancer: Therapeutic Strategies to Overcome Immune Suppression. Adv Exp Med Biol 2021;1330:33-54. [PMID: 34339029 DOI: 10.1007/978-3-030-73359-9_3] [Reference Citation Analysis]
287 Guo B, Zang Y. BIPSE: A biomarker-based phase I/II design for immunotherapy trials with progression-free survival endpoint. Stat Med 2021. [PMID: 34821409 DOI: 10.1002/sim.9265] [Reference Citation Analysis]
288 Takaya K, Sonoda M, Fuchigami A, Hiyoshi T. Isolated Adrenocorticotropic Hormone Deficiency Caused by Nivolumab in a Patient with Metastatic Lung Cancer. Intern Med 2017;56:2463-9. [PMID: 28824067 DOI: 10.2169/internalmedicine.8548-16] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 4.2] [Reference Citation Analysis]
289 Shen D, Chen Q, Wu J, Li J, Tao K, Jiang Y. The safety and efficacy of neoadjuvant PD-1 inhibitor with chemotherapy for locally advanced esophageal squamous cell carcinoma. J Gastrointest Oncol 2021;12:1-10. [PMID: 33708420 DOI: 10.21037/jgo-20-599] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
290 Lin H, Wei S, Hurt EM, Green MD, Zhao L, Vatan L, Szeliga W, Herbst R, Harms PW, Fecher LA, Vats P, Chinnaiyan AM, Lao CD, Lawrence TS, Wicha M, Hamanishi J, Mandai M, Kryczek I, Zou W. Host expression of PD-L1 determines efficacy of PD-L1 pathway blockade-mediated tumor regression. J Clin Invest 2018;128:805-15. [PMID: 29337305 DOI: 10.1172/JCI96113] [Cited by in Crossref: 207] [Cited by in F6Publishing: 147] [Article Influence: 51.8] [Reference Citation Analysis]
291 Schmitz-Winnenthal FH, Hohmann N, Schmidt T, Podola L, Friedrich T, Lubenau H, Springer M, Wieckowski S, Breiner KM, Mikus G, Büchler MW, Keller AV, Koc R, Springfeld C, Knebel P, Bucur M, Grenacher L, Haefeli WE, Beckhove P. A phase 1 trial extension to assess immunologic efficacy and safety of prime-boost vaccination with VXM01, an oral T cell vaccine against VEGFR2, in patients with advanced pancreatic cancer. Oncoimmunology 2018;7:e1303584. [PMID: 29632710 DOI: 10.1080/2162402X.2017.1303584] [Cited by in Crossref: 14] [Cited by in F6Publishing: 9] [Article Influence: 3.5] [Reference Citation Analysis]
292 Tang J, Jiang W, Liu D, Luo J, Wu X, Pan Z, Ding P, Li Y. The comprehensive molecular landscape of the immunologic co-stimulator B7 and TNFR ligand receptor families in colorectal cancer: immunotherapeutic implications with microsatellite instability. Oncoimmunology. 2018;7:e1488566. [PMID: 30288357 DOI: 10.1080/2162402x.2018.1488566] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
293 Odunsi A, McGray AJR, Miliotto A, Zhang Y, Wang J, Abiola A, Eppolito C, Huang RY. Fidelity of human ovarian cancer patient-derived xenografts in a partially humanized mouse model for preclinical testing of immunotherapies. J Immunother Cancer 2020;8:e001237. [PMID: 33177175 DOI: 10.1136/jitc-2020-001237] [Reference Citation Analysis]
294 Qiu YF, Liu ZG, Yang WJ, Zhao Y, Tang J, Tang WZ, Jin Y, Li F, Zhong R, Wang H. Research progress in the treatment of small cell lung cancer. J Cancer 2017;8:29-38. [PMID: 28123595 DOI: 10.7150/jca.16822] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.8] [Reference Citation Analysis]
295 Johnson DB, Rioth MJ, Horn L. Immune checkpoint inhibitors in NSCLC. Curr Treat Options Oncol 2014;15:658-69. [PMID: 25096781 DOI: 10.1007/s11864-014-0305-5] [Cited by in Crossref: 46] [Cited by in F6Publishing: 45] [Article Influence: 6.6] [Reference Citation Analysis]
296 Ilié M, Lantéri E, Chamorey E, Thamphya B, Hamila M, Montaudié H, Picard-Gauci A, Gardrat S, Passeron T, Lassalle S, Long-Mira E, Cherfils-Vicini J, Gilson E, Hofman V, Hofman P. Association of TRF2 expression and myeloid-derived suppressor cells infiltration with clinical outcome of patients with cutaneous melanoma. Oncoimmunology 2021;10:1901446. [PMID: 33796413 DOI: 10.1080/2162402X.2021.1901446] [Reference Citation Analysis]
297 Sobottka B, Pestalozzi B, Fink D, Moch H, Varga Z. Similar lymphocytic infiltration pattern in primary breast cancer and their corresponding distant metastases. Oncoimmunology 2016;5:e1153208. [PMID: 27471624 DOI: 10.1080/2162402X.2016.1153208] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 3.7] [Reference Citation Analysis]
298 Wang X, Xiong H, Liang D, Chen Z, Li X, Zhang K. The role of SRGN in the survival and immune infiltrates of skin cutaneous melanoma (SKCM) and SKCM-metastasis patients. BMC Cancer 2020;20:378. [PMID: 32370744 DOI: 10.1186/s12885-020-06849-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
299 Läubli H, Balmelli C, Bossard M, Pfister O, Glatz K, Zippelius A. Acute heart failure due to autoimmune myocarditis under pembrolizumab treatment for metastatic melanoma. J Immunother Cancer 2015;3:11. [PMID: 25901283 DOI: 10.1186/s40425-015-0057-1] [Cited by in Crossref: 184] [Cited by in F6Publishing: 174] [Article Influence: 26.3] [Reference Citation Analysis]
300 Otano I, Escors D, Schurich A, Singh H, Robertson F, Davidson BR, Fusai G, Vargas FA, Tan ZMD, Aw JYJ, Hansi N, Kennedy PTF, Xue SA, Stauss HJ, Bertoletti A, Pavesi A, Maini MK. Molecular Recalibration of PD-1+ Antigen-Specific T Cells from Blood and Liver. Mol Ther 2018;26:2553-66. [PMID: 30217730 DOI: 10.1016/j.ymthe.2018.08.013] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 3.3] [Reference Citation Analysis]
301 Garber ST, Hashimoto Y, Weathers SP, Xiu J, Gatalica Z, Verhaak RG, Zhou S, Fuller GN, Khasraw M, de Groot J, Reddy SK, Spetzler D, Heimberger AB. Immune checkpoint blockade as a potential therapeutic target: surveying CNS malignancies. Neuro Oncol 2016;18:1357-66. [PMID: 27370400 DOI: 10.1093/neuonc/now132] [Cited by in Crossref: 83] [Cited by in F6Publishing: 79] [Article Influence: 13.8] [Reference Citation Analysis]
302 Mino-Kenudson M. Programmed cell death ligand-1 (PD-L1) expression by immunohistochemistry: could it be predictive and/or prognostic in non-small cell lung cancer? Cancer Biol Med 2016;13:157-70. [PMID: 27458525 DOI: 10.20892/j.issn.2095-3941.2016.0009] [Cited by in Crossref: 57] [Cited by in F6Publishing: 50] [Article Influence: 9.5] [Reference Citation Analysis]
303 Price JG, Idoyaga J, Salmon H, Hogstad B, Bigarella CL, Ghaffari S, Leboeuf M, Merad M. CDKN1A regulates Langerhans cell survival and promotes Treg cell generation upon exposure to ionizing irradiation. Nat Immunol 2015;16:1060-8. [PMID: 26343536 DOI: 10.1038/ni.3270] [Cited by in Crossref: 84] [Cited by in F6Publishing: 76] [Article Influence: 12.0] [Reference Citation Analysis]
304 Patel JN, Ersek JL, Kim ES. Lung cancer biomarkers, targeted therapies and clinical assays. Transl Lung Cancer Res 2015;4:503-14. [PMID: 26629419 DOI: 10.3978/j.issn.2218-6751.2015.06.02] [Cited by in F6Publishing: 9] [Reference Citation Analysis]
305 Myklebust JH, Irish JM, Brody J, Czerwinski DK, Houot R, Kohrt HE, Timmerman J, Said J, Green MR, Delabie J, Kolstad A, Alizadeh AA, Levy R. High PD-1 expression and suppressed cytokine signaling distinguish T cells infiltrating follicular lymphoma tumors from peripheral T cells. Blood 2013;121:1367-76. [PMID: 23297127 DOI: 10.1182/blood-2012-04-421826] [Cited by in Crossref: 114] [Cited by in F6Publishing: 108] [Article Influence: 12.7] [Reference Citation Analysis]
306 Acheampong E, Spencer I, Lin W, Ziman M, Millward M, Gray E. Is the Blood an Alternative for Programmed Cell Death Ligand 1 Assessment in Non-Small Cell Lung Cancer? Cancers (Basel) 2019;11:E920. [PMID: 31262041 DOI: 10.3390/cancers11070920] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
307 Spurrell EL, Lockley M. Adaptive immunity in cancer immunology and therapeutics. Ecancermedicalscience 2014;8:441. [PMID: 25075215 DOI: 10.3332/ecancer.2014.441] [Cited by in F6Publishing: 19] [Reference Citation Analysis]
308 Deng R, Cassady K, Li X, Yao S, Zhang M, Racine J, Lin J, Chen L, Zeng D. B7H1/CD80 interaction augments PD-1-dependent T cell apoptosis and ameliorates graft-versus-host disease. J Immunol 2015;194:560-74. [PMID: 25488990 DOI: 10.4049/jimmunol.1402157] [Cited by in Crossref: 43] [Cited by in F6Publishing: 43] [Article Influence: 5.4] [Reference Citation Analysis]
309 Ellebaek E, Iversen TZ, Junker N, Donia M, Engell-Noerregaard L, Met Ö, Hölmich LR, Andersen RS, Hadrup SR, Andersen MH, thor Straten P, Svane IM. Adoptive cell therapy with autologous tumor infiltrating lymphocytes and low-dose Interleukin-2 in metastatic melanoma patients. J Transl Med 2012;10:169. [PMID: 22909342 DOI: 10.1186/1479-5876-10-169] [Cited by in Crossref: 105] [Cited by in F6Publishing: 94] [Article Influence: 10.5] [Reference Citation Analysis]
310 Al-Mansour Z, Pang L, Bathini V. Novel Cancer Therapeutics in Geriatrics: What is Unique to the Aging Patient? Drugs Aging 2019;36:1-11. [PMID: 30478744 DOI: 10.1007/s40266-018-0619-2] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
311 Brahmer JR, Pardoll DM. Immune checkpoint inhibitors: making immunotherapy a reality for the treatment of lung cancer. Cancer Immunol Res 2013;1:85-91. [PMID: 24777499 DOI: 10.1158/2326-6066.CIR-13-0078] [Cited by in Crossref: 112] [Cited by in F6Publishing: 66] [Article Influence: 12.4] [Reference Citation Analysis]
312 Gurbatri CR, Lia I, Vincent R, Coker C, Castro S, Treuting PM, Hinchliffe TE, Arpaia N, Danino T. Engineered probiotics for local tumor delivery of checkpoint blockade nanobodies. Sci Transl Med 2020;12:eaax0876. [PMID: 32051224 DOI: 10.1126/scitranslmed.aax0876] [Cited by in Crossref: 66] [Cited by in F6Publishing: 53] [Article Influence: 66.0] [Reference Citation Analysis]
313 Samstein RM, Lee CH, Shoushtari AN, Hellmann MD, Shen R, Janjigian YY, Barron DA, Zehir A, Jordan EJ, Omuro A, Kaley TJ, Kendall SM, Motzer RJ, Hakimi AA, Voss MH, Russo P, Rosenberg J, Iyer G, Bochner BH, Bajorin DF, Al-Ahmadie HA, Chaft JE, Rudin CM, Riely GJ, Baxi S, Ho AL, Wong RJ, Pfister DG, Wolchok JD, Barker CA, Gutin PH, Brennan CW, Tabar V, Mellinghoff IK, DeAngelis LM, Ariyan CE, Lee N, Tap WD, Gounder MM, D'Angelo SP, Saltz L, Stadler ZK, Scher HI, Baselga J, Razavi P, Klebanoff CA, Yaeger R, Segal NH, Ku GY, DeMatteo RP, Ladanyi M, Rizvi NA, Berger MF, Riaz N, Solit DB, Chan TA, Morris LGT. Tumor mutational load predicts survival after immunotherapy across multiple cancer types. Nat Genet. 2019;51:202-206. [PMID: 30643254 DOI: 10.1038/s41588-018-0312-8] [Cited by in Crossref: 967] [Cited by in F6Publishing: 931] [Article Influence: 322.3] [Reference Citation Analysis]
314 Schmid-Bindert G, Jiang T. First-line nivolumab (anti-PD-1) monotherapy in advanced NSCLC: the story of immune checkpoint inhibitors and "the sorcerers apprentice". Transl Lung Cancer Res 2015;4:215-6. [PMID: 26207206 DOI: 10.3978/j.issn.2218-6751.2015.01.12] [Cited by in F6Publishing: 7] [Reference Citation Analysis]
315 Wages NA, Chiuzan C, Panageas KS. Design considerations for early-phase clinical trials of immune-oncology agents. J Immunother Cancer 2018;6:81. [PMID: 30134959 DOI: 10.1186/s40425-018-0389-8] [Cited by in Crossref: 27] [Cited by in F6Publishing: 26] [Article Influence: 6.8] [Reference Citation Analysis]
316 Liu W, Wang Y, Xie Y, Dai T, Fan M, Li C, Zou Y. Cisplatin remodels the tumor immune microenvironment via the transcription factor EB in ovarian cancer. Cell Death Discov 2021;7:136. [PMID: 34091590 DOI: 10.1038/s41420-021-00519-8] [Reference Citation Analysis]
317 Pannier D, Philippin-Lauridant G, Baranzelli MC, Bertin D, Bogart E, Delprat V, Villain G, Mattot V, Bonneterre J, Soncin F. High expression levels of egfl7 correlate with low endothelial cell activation in peritumoral vessels of human breast cancer. Oncol Lett 2016;12:1422-8. [PMID: 27446447 DOI: 10.3892/ol.2016.4791] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.2] [Reference Citation Analysis]
318 Fankhauser CD, Schüffler PJ, Gillessen S, Omlin A, Rupp NJ, Rueschoff JH, Hermanns T, Poyet C, Sulser T, Moch H, Wild PJ. Comprehensive immunohistochemical analysis of PD-L1 shows scarce expression in castration-resistant prostate cancer. Oncotarget 2018;9:10284-93. [PMID: 29535806 DOI: 10.18632/oncotarget.22888] [Cited by in Crossref: 25] [Cited by in F6Publishing: 20] [Article Influence: 5.0] [Reference Citation Analysis]
319 Zimmermannova O, Caiado I, Ferreira AG, Pereira CF. Cell Fate Reprogramming in the Era of Cancer Immunotherapy. Front Immunol 2021;12:714822. [PMID: 34367185 DOI: 10.3389/fimmu.2021.714822] [Reference Citation Analysis]
320 Peng W, Lizée G, Hwu P. Blockade of the PD-1 pathway enhances the efficacy of adoptive cell therapy against cancer. Oncoimmunology 2013;2:e22691. [PMID: 23524510 DOI: 10.4161/onci.22691] [Cited by in Crossref: 26] [Cited by in F6Publishing: 22] [Article Influence: 3.3] [Reference Citation Analysis]
321 Boonstra PS, Braun TM, Taylor JMG, Kidwell KM, Bellile EL, Daignault S, Zhao L, Griffith KA, Lawrence TS, Kalemkerian GP, Schipper MJ. Statistical controversies in clinical research: building the bridge to phase II-efficacy estimation in dose-expansion cohorts. Ann Oncol 2017;28:1427-35. [PMID: 28200082 DOI: 10.1093/annonc/mdx045] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
322 Li X, Wang X, Ito A, Tsuji NM. A nanoscale metal organic frameworks-based vaccine synergises with PD-1 blockade to potentiate anti-tumour immunity. Nat Commun 2020;11:3858. [PMID: 32737343 DOI: 10.1038/s41467-020-17637-z] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 5.0] [Reference Citation Analysis]
323 Allegra A, Di Salvo E, Casciaro M, Musolino C, Pioggia G, Gangemi S. The Impact of Immunological Checkpoint Inhibitors and Targeted Therapy on Chronic Pruritus in Cancer Patients. Biomedicines 2020;9:2. [PMID: 33375183 DOI: 10.3390/biomedicines9010002] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
324 Martens A, Wistuba-Hamprecht K, Geukes Foppen M, Yuan J, Postow MA, Wong P, Romano E, Khammari A, Dreno B, Capone M, Ascierto PA, Di Giacomo AM, Maio M, Schilling B, Sucker A, Schadendorf D, Hassel JC, Eigentler TK, Martus P, Wolchok JD, Blank C, Pawelec G, Garbe C, Weide B. Baseline Peripheral Blood Biomarkers Associated with Clinical Outcome of Advanced Melanoma Patients Treated with Ipilimumab. Clin Cancer Res 2016;22:2908-18. [PMID: 26787752 DOI: 10.1158/1078-0432.CCR-15-2412] [Cited by in Crossref: 318] [Cited by in F6Publishing: 200] [Article Influence: 53.0] [Reference Citation Analysis]
325 Yu XH, Huang J, Ge NJ, Yang YF, Zhao JY. Recurrent undifferentiated embryonal sarcoma of the liver in adult patient treated by pembrolizumab: A case report. World J Clin Cases 2021; 9(10): 2281-2288 [PMID: 33869604 DOI: 10.12998/wjcc.v9.i10.2281] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
326 Cooper ZA, Frederick DT, Ahmed Z, Wargo JA. Combining checkpoint inhibitors and BRAF-targeted agents against metastatic melanoma. Oncoimmunology 2013;2:e24320. [PMID: 23762807 DOI: 10.4161/onci.24320] [Cited by in Crossref: 35] [Cited by in F6Publishing: 33] [Article Influence: 4.4] [Reference Citation Analysis]
327 Mikucki ME, Fisher DT, Matsuzaki J, Skitzki JJ, Gaulin NB, Muhitch JB, Ku AW, Frelinger JG, Odunsi K, Gajewski TF, Luster AD, Evans SS. Non-redundant requirement for CXCR3 signalling during tumoricidal T-cell trafficking across tumour vascular checkpoints. Nat Commun 2015;6:7458. [PMID: 26109379 DOI: 10.1038/ncomms8458] [Cited by in Crossref: 225] [Cited by in F6Publishing: 220] [Article Influence: 32.1] [Reference Citation Analysis]
328 Hiniker SM, Maecker HT, Knox SJ. Predictors of clinical response to immunotherapy with or without radiotherapy. J Radiat Oncol. 2015;4:339-345. [PMID: 26709361 DOI: 10.1007/s13566-015-0219-2] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.4] [Reference Citation Analysis]
329 Deng B, Park JH, Ren L, Yew PY, Kiyotani K, Antic T, O'Connor K, O'Donnell PH, Nakamura Y. CD8 lymphocytes in tumors and nonsynonymous mutational load correlate with prognosis of bladder cancer patients treated with immune checkpoint inhibitors. Cancer Rep (Hoboken) 2018;1:e1002. [PMID: 32729250 DOI: 10.1002/cnr2.1002] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
330 Shi X, Wu S, Sun J, Liu Y, Zeng X, Liang Z. PD-L1 expression in lung adenosquamous carcinomas compared with the more common variants of non-small cell lung cancer. Sci Rep 2017;7:46209. [PMID: 28387300 DOI: 10.1038/srep46209] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 3.8] [Reference Citation Analysis]
331 D'Alincourt Salazar M, Manuel ER, Tsai W, D'Apuzzo M, Goldstein L, Blazar BR, Diamond DJ. Evaluation of innate and adaptive immunity contributing to the antitumor effects of PD1 blockade in an orthotopic murine model of pancreatic cancer. Oncoimmunology 2016;5:e1160184. [PMID: 27471630 DOI: 10.1080/2162402X.2016.1160184] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.7] [Reference Citation Analysis]
332 Jang BS, Kim IA. A Radiosensitivity Gene Signature and PD-L1 Status Predict Clinical Outcome of Patients with Glioblastoma Multiforme in The Cancer Genome Atlas Dataset. Cancer Res Treat 2020;52:530-42. [PMID: 31801317 DOI: 10.4143/crt.2019.440] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
333 Qiao YM, Zhang Y. Immunotherapy for esophageal cancer: Current studies and future perspectives. Shijie Huaren Xiaohua Zazhi 2016; 24(36): 4739-4751 [DOI: 10.11569/wcjd.v24.i36.4739] [Reference Citation Analysis]
334 Ji S, Lee J, Lee ES, Kim DH, Sin JI. B16 melanoma control by anti-PD-L1 requires CD8+ T cells and NK cells: application of anti-PD-L1 Abs and Trp2 peptide vaccines. Hum Vaccin Immunother 2021;17:1910-22. [PMID: 33522416 DOI: 10.1080/21645515.2020.1866951] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
335 Homet Moreno B, Zaretsky JM, Garcia-Diaz A, Tsoi J, Parisi G, Robert L, Meeth K, Ndoye A, Bosenberg M, Weeraratna AT, Graeber TG, Comin-Anduix B, Hu-Lieskovan S, Ribas A. Response to Programmed Cell Death-1 Blockade in a Murine Melanoma Syngeneic Model Requires Costimulation, CD4, and CD8 T Cells. Cancer Immunol Res 2016;4:845-57. [PMID: 27589875 DOI: 10.1158/2326-6066.CIR-16-0060] [Cited by in Crossref: 59] [Cited by in F6Publishing: 48] [Article Influence: 9.8] [Reference Citation Analysis]
336 Ya Z, Hailemichael Y, Overwijk W, Restifo NP. Mouse model for pre-clinical study of human cancer immunotherapy. Curr Protoc Immunol 2015;108:20.1.1-20.1.43. [PMID: 25640991 DOI: 10.1002/0471142735.im2001s108] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 1.7] [Reference Citation Analysis]
337 Calinescu AA, Kamran N, Baker G, Mineharu Y, Lowenstein PR, Castro MG. Overview of current immunotherapeutic strategies for glioma. Immunotherapy 2015;7:1073-104. [PMID: 26598957 DOI: 10.2217/imt.15.75] [Cited by in Crossref: 32] [Cited by in F6Publishing: 32] [Article Influence: 5.3] [Reference Citation Analysis]
338 Bai X, Wu DH, Ma SC, Wang J, Tang XR, Kang S, Fu QJ, Cao CH, Luo HS, Chen YH, Zhu HB, Yan HH, Wu YL, Dong ZY. Development and validation of a genomic mutation signature to predict response to PD-1 inhibitors in non-squamous NSCLC: a multicohort study. J Immunother Cancer 2020;8:e000381. [PMID: 32606052 DOI: 10.1136/jitc-2019-000381] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 6.0] [Reference Citation Analysis]
339 Dillman RO, Depriest C, McClure SE. High-dose IL2 in metastatic melanoma: better survival in patients immunized with antigens from autologous tumor cell lines. Cancer Biother Radiopharm 2014;29:53-7. [PMID: 24380630 DOI: 10.1089/cbr.2013.1565] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.1] [Reference Citation Analysis]
340 Oya Y, Yoshida T, Kuroda H, Mikubo M, Kondo C, Shimizu J, Horio Y, Sakao Y, Hida T, Yatabe Y. Predictive clinical parameters for the response of nivolumab in pretreated advanced non-small-cell lung cancer. Oncotarget 2017;8:103117-28. [PMID: 29262550 DOI: 10.18632/oncotarget.21602] [Cited by in Crossref: 37] [Cited by in F6Publishing: 45] [Article Influence: 7.4] [Reference Citation Analysis]
341 Beckermann KE, Dudzinski SO, Rathmell JC. Dysfunctional T cell metabolism in the tumor microenvironment. Cytokine Growth Factor Rev 2017;35:7-14. [PMID: 28456467 DOI: 10.1016/j.cytogfr.2017.04.003] [Cited by in Crossref: 43] [Cited by in F6Publishing: 43] [Article Influence: 8.6] [Reference Citation Analysis]
342 Mills AM, Bullock TN, Ring KL. Targeting immune checkpoints in gynecologic cancer: updates & perspectives for pathologists. Mod Pathol 2021. [PMID: 34493822 DOI: 10.1038/s41379-021-00882-y] [Reference Citation Analysis]
343 Kamran N, Calinescu A, Candolfi M, Chandran M, Mineharu Y, Asad AS, Koschmann C, Nunez FJ, Lowenstein PR, Castro MG. Recent advances and future of immunotherapy for glioblastoma. Expert Opin Biol Ther 2016;16:1245-64. [PMID: 27411023 DOI: 10.1080/14712598.2016.1212012] [Cited by in Crossref: 45] [Cited by in F6Publishing: 43] [Article Influence: 7.5] [Reference Citation Analysis]
344 Curry WT, Lim M. Immunomodulation: checkpoint blockade etc. Neuro Oncol. 2015;17 Suppl 7:vii26-vii31. [PMID: 26516223 DOI: 10.1093/neuonc/nov174] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 3.0] [Reference Citation Analysis]
345 Nagahara K, Arikawa T, Oomizu S, Kontani K, Nobumoto A, Tateno H, Watanabe K, Niki T, Katoh S, Miyake M. Galectin-9 increases Tim-3+ dendritic cells and CD8+ T cells and enhances antitumor immunity via galectin-9-Tim-3 interactions. J Immunol. 2008;181:7660-7669. [PMID: 19017954 DOI: 10.4049/jimmunol.181.11.7660] [Cited by in Crossref: 132] [Cited by in F6Publishing: 125] [Article Influence: 9.4] [Reference Citation Analysis]
346 Stankovic B, Bjørhovde HAK, Skarshaug R, Aamodt H, Frafjord A, Müller E, Hammarström C, Beraki K, Bækkevold ES, Woldbæk PR, Helland Å, Brustugun OT, Øynebråten I, Corthay A. Immune Cell Composition in Human Non-small Cell Lung Cancer. Front Immunol 2018;9:3101. [PMID: 30774636 DOI: 10.3389/fimmu.2018.03101] [Cited by in Crossref: 59] [Cited by in F6Publishing: 64] [Article Influence: 19.7] [Reference Citation Analysis]
347 van Rooij N, van Buuren MM, Philips D, Velds A, Toebes M, Heemskerk B, van Dijk LJ, Behjati S, Hilkmann H, El Atmioui D, Nieuwland M, Stratton MR, Kerkhoven RM, Kesmir C, Haanen JB, Kvistborg P, Schumacher TN. Tumor exome analysis reveals neoantigen-specific T-cell reactivity in an ipilimumab-responsive melanoma. J Clin Oncol 2013;31:e439-42. [PMID: 24043743 DOI: 10.1200/JCO.2012.47.7521] [Cited by in Crossref: 575] [Cited by in F6Publishing: 367] [Article Influence: 63.9] [Reference Citation Analysis]
348 Qu S, Jiao Z, Lu G, Yao B, Wang T, Rong W, Xu J, Fan T, Sun X, Yang R, Wang J, Yao Y, Xu G, Yan X, Wang T, Liang H, Zen K. PD-L1 lncRNA splice isoform promotes lung adenocarcinoma progression via enhancing c-Myc activity. Genome Biol 2021;22:104. [PMID: 33849634 DOI: 10.1186/s13059-021-02331-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
349 Fang X, Xiu B, Yang Z, Qiu W, Zhang L, Zhang S, Wu Y, Zhu X, Chen X, Xie S, Yi X, Liang A, Zeng Y. The expression and clinical relevance of PD-1, PD-L1, and TP63 in patients with diffuse large B-cell lymphoma. Medicine (Baltimore) 2017;96:e6398. [PMID: 28403071 DOI: 10.1097/MD.0000000000006398] [Cited by in Crossref: 28] [Cited by in F6Publishing: 16] [Article Influence: 5.6] [Reference Citation Analysis]
350 Brown SD, Warren RL, Gibb EA, Martin SD, Spinelli JJ, Nelson BH, Holt RA. Neo-antigens predicted by tumor genome meta-analysis correlate with increased patient survival. Genome Res. 2014;24:743-750. [PMID: 24782321 DOI: 10.1101/gr.165985.113] [Cited by in Crossref: 399] [Cited by in F6Publishing: 372] [Article Influence: 49.9] [Reference Citation Analysis]
351 Choudhry P, Galligan D, Wiita AP. Seeking Convergence and Cure with New Myeloma Therapies. Trends Cancer 2018;4:567-82. [PMID: 30064664 DOI: 10.1016/j.trecan.2018.05.005] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
352 McCaw TR, Randall TD, Forero A, Buchsbaum DJ. Modulation of antitumor immunity with histone deacetylase inhibitors. Immunotherapy 2017;9:1359-72. [PMID: 29185390 DOI: 10.2217/imt-2017-0134] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 4.5] [Reference Citation Analysis]
353 Kim JS, Kim YG, Pyo M, Lee HK, Hong JT, Kim Y, Han SB. Adoptive Cell Therapy of Melanoma with Cytokine-induced Killer Cells. Immune Netw 2015;15:58-65. [PMID: 25922594 DOI: 10.4110/in.2015.15.2.58] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
354 Placke JM, Soun C, Bottek J, Herbst R, Terheyden P, Utikal J, Pföhler C, Ulrich J, Kreuter A, Pfeiffer C, Mohr P, Gutzmer R, Meier F, Dippel E, Weichenthal M, Zimmer L, Livingstone E, Becker JC, Lodde G, Sucker A, Griewank K, Horn S, Hadaschik E, Roesch A, Schadendorf D, Engel DR, Ugurel S. Digital Quantification of Tumor PD-L1 Predicts Outcome of PD-1-Based Immune Checkpoint Therapy in Metastatic Melanoma. Front Oncol 2021;11:741993. [PMID: 34621681 DOI: 10.3389/fonc.2021.741993] [Reference Citation Analysis]
355 Youngblood B, Noto A, Porichis F, Akondy RS, Ndhlovu ZM, Austin JW, Bordi R, Procopio FA, Miura T, Allen TM, Sidney J, Sette A, Walker BD, Ahmed R, Boss JM, Sékaly RP, Kaufmann DE. Cutting edge: Prolonged exposure to HIV reinforces a poised epigenetic program for PD-1 expression in virus-specific CD8 T cells. J Immunol 2013;191:540-4. [PMID: 23772031 DOI: 10.4049/jimmunol.1203161] [Cited by in Crossref: 105] [Cited by in F6Publishing: 99] [Article Influence: 11.7] [Reference Citation Analysis]
356 Redman JM, Gulley JL, Madan RA. Combining immunotherapies for the treatment of prostate cancer. Urol Oncol 2017;35:694-700. [PMID: 29146441 DOI: 10.1016/j.urolonc.2017.09.024] [Cited by in Crossref: 14] [Cited by in F6Publishing: 17] [Article Influence: 3.5] [Reference Citation Analysis]
357 Wei H, Zhao L, Li W, Fan K, Qian W, Hou S, Wang H, Dai M, Hellstrom I, Hellstrom KE, Guo Y. Combinatorial PD-1 blockade and CD137 activation has therapeutic efficacy in murine cancer models and synergizes with cisplatin. PLoS One 2013;8:e84927. [PMID: 24367702 DOI: 10.1371/journal.pone.0084927] [Cited by in Crossref: 67] [Cited by in F6Publishing: 61] [Article Influence: 7.4] [Reference Citation Analysis]
358 Eggermont A, Robert C, Soria JC, Zitvogel L. Harnessing the immune system to provide long-term survival in patients with melanoma and other solid tumors. Oncoimmunology. 2014;3:e27560. [PMID: 24719793 DOI: 10.4161/onci.27560] [Cited by in Crossref: 32] [Cited by in F6Publishing: 28] [Article Influence: 4.0] [Reference Citation Analysis]
359 Bloom AC, Bender LH, Tiwary S, Pasquet L, Clark K, Jiang T, Xia Z, Morales-Kastresana A, Jones JC, Walters I, Terabe M, Berzofsky JA. Intratumorally delivered formulation, INT230-6, containing potent anticancer agents induces protective T cell immunity and memory. Oncoimmunology 2019;8:e1625687. [PMID: 31646070 DOI: 10.1080/2162402X.2019.1625687] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.7] [Reference Citation Analysis]
360 Hossain DMS, Javaid S, Cai M, Zhang C, Sawant A, Hinton M, Sathe M, Grein J, Blumenschein W, Pinheiro EM, Chackerian A. Dinaciclib induces immunogenic cell death and enhances anti-PD1-mediated tumor suppression. J Clin Invest 2018;128:644-54. [PMID: 29337311 DOI: 10.1172/JCI94586] [Cited by in Crossref: 51] [Cited by in F6Publishing: 31] [Article Influence: 12.8] [Reference Citation Analysis]
361 Kamada T, Togashi Y, Tay C, Ha D, Sasaki A, Nakamura Y, Sato E, Fukuoka S, Tada Y, Tanaka A, Morikawa H, Kawazoe A, Kinoshita T, Shitara K, Sakaguchi S, Nishikawa H. PD-1+ regulatory T cells amplified by PD-1 blockade promote hyperprogression of cancer. Proc Natl Acad Sci U S A 2019;116:9999-10008. [PMID: 31028147 DOI: 10.1073/pnas.1822001116] [Cited by in Crossref: 254] [Cited by in F6Publishing: 246] [Article Influence: 84.7] [Reference Citation Analysis]
362 Kawazoe A, Shitara K, Fukuoka S, Noguchi M, Kuboki Y, Bando H, Okamoto W, Kojima T, Fuse N, Yoshino T, Ohtsu A, Doi T. Clinical outcomes in 66 patients with advanced gastric cancer treated in phase I trials: the NCCHE experience. Invest New Drugs 2015;33:664-70. [PMID: 25773493 DOI: 10.1007/s10637-015-0231-9] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
363 Maritaz C, Broutin S, Chaput N, Marabelle A, Paci A. Immune checkpoint-targeted antibodies: a room for dose and schedule optimization? J Hematol Oncol 2022;15:6. [PMID: 35033167 DOI: 10.1186/s13045-021-01182-3] [Reference Citation Analysis]
364 Lind H, Gameiro SR, Jochems C, Donahue RN, Strauss J, Gulley JL MD,, Palena C, Schlom J. Dual targeting of TGF-β and PD-L1 via a bifunctional anti-PD-L1/TGF-βRII agent: status of preclinical and clinical advances. J Immunother Cancer 2020;8:e000433. [PMID: 32079617 DOI: 10.1136/jitc-2019-000433] [Cited by in Crossref: 57] [Cited by in F6Publishing: 51] [Article Influence: 57.0] [Reference Citation Analysis]
365 Yeung SJ, Qdaisat A, Chaftari P, Lipe D, Merlin J, Rajha E, Wechsler A, Sandoval M, Viets J, Al-Breiki A, Shah M, Pandey R, Kamal M, Khattab O, Toale K, Wattana M, Elsayem A, Gaeta S, Brock P, Reyes-Gibby C, Alagappan K. Diagnosis and management of immune-related adverse effects of immune checkpoint therapy in the emergency department. J Am Coll Emerg Physicians Open 2020;1:1637-59. [PMID: 33392573 DOI: 10.1002/emp2.12209] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
366 AiErken N, Shi HJ, Zhou Y, Shao N, Zhang J, Shi Y, Yuan ZY, Lin Y. High PD-L1 Expression Is Closely Associated With Tumor-Infiltrating Lymphocytes and Leads to Good Clinical Outcomes in Chinese Triple Negative Breast Cancer Patients. Int J Biol Sci 2017;13:1172-9. [PMID: 29104508 DOI: 10.7150/ijbs.20868] [Cited by in Crossref: 18] [Cited by in F6Publishing: 20] [Article Influence: 3.6] [Reference Citation Analysis]
367 Tanaka K, Miyata H, Sugimura K, Kanemura T, Hamada-Uematsu M, Mizote Y, Yamasaki M, Wada H, Nakajima K, Takiguchi S, Mori M, Doki Y, Tahara H. Negative influence of programmed death-1-ligands on the survival of esophageal cancer patients treated with chemotherapy. Cancer Sci 2016;107:726-33. [PMID: 27015293 DOI: 10.1111/cas.12938] [Cited by in Crossref: 30] [Cited by in F6Publishing: 32] [Article Influence: 5.0] [Reference Citation Analysis]
368 Molon B, Calì B, Viola A. T Cells and Cancer: How Metabolism Shapes Immunity. Front Immunol 2016;7:20. [PMID: 26870036 DOI: 10.3389/fimmu.2016.00020] [Cited by in Crossref: 57] [Cited by in F6Publishing: 58] [Article Influence: 9.5] [Reference Citation Analysis]
369 Zhang J, Li Y, Yang S, Zhang L, Wang W. Anti-CD40 mAb enhanced efficacy of anti-PD1 against osteosarcoma. J Bone Oncol 2019;17:100245. [PMID: 31293882 DOI: 10.1016/j.jbo.2019.100245] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
370 Naik PP. Cemiplimab in advanced cutaneous squamous cell carcinoma. Dermatol Ther 2021;:e15184. [PMID: 34716727 DOI: 10.1111/dth.15184] [Reference Citation Analysis]
371 Shi H, Li K, Ni Y, Liang X, Zhao X. Myeloid-Derived Suppressor Cells: Implications in the Resistance of Malignant Tumors to T Cell-Based Immunotherapy. Front Cell Dev Biol 2021;9:707198. [PMID: 34336860 DOI: 10.3389/fcell.2021.707198] [Reference Citation Analysis]
372 Liu S, Kong P, Wang X, Yang L, Jiang C, He W, Quan Q, Huang J, Xie Q, Xia X, Zhang B, Xia L. Tumor microenvironment classification based on T-cell infiltration and PD-L1 in patients with mismatch repair-proficient and -deficient colorectal cancer. Oncol Lett 2019;17:2335-43. [PMID: 30675299 DOI: 10.3892/ol.2018.9826] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
373 Liu X, Zhang N, Shi H. Driving better and safer HER2-specific CARs for cancer therapy. Oncotarget 2017;8:62730-41. [PMID: 28977984 DOI: 10.18632/oncotarget.17528] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 3.8] [Reference Citation Analysis]
374 Gedye C, Hogg D, Butler M, Joshua AM. New treatments for metastatic melanoma. CMAJ 2014;186:754-60. [PMID: 24549129 DOI: 10.1503/cmaj.130989] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
375 Lu L, Yan H, Shyam-Sundar V, Janowitz T. Cross-sectional and longitudinal analysis of cancer vaccination trials registered on the US Clinical Trials Database demonstrates paucity of immunological trial endpoints and decline in registration since 2008. Drug Des Devel Ther 2014;8:1539-53. [PMID: 25302014 DOI: 10.2147/DDDT.S65963] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
376 Singh BH, Gulley JL. Immunotherapy and therapeutic vaccines in prostate cancer: an update on current strategies and clinical implications. Asian J Androl 2014;16:364-71. [PMID: 24435055 DOI: 10.4103/1008-682X.122585] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
377 Jiang Z, Pan Z, Ren X. [Progress of PD-1/PD-L1 Inhibitors in Non-small Cell Lung Cancer]. Zhongguo Fei Ai Za Zhi 2017;20:138-42. [PMID: 28228226 DOI: 10.3779/j.issn.1009-3419.2017.02.09] [Reference Citation Analysis]
378 Kosaka N, Yoshioka Y, Fujita Y, Ochiya T. Versatile roles of extracellular vesicles in cancer. J Clin Invest. 2016;126:1163-1172. [PMID: 26974161 DOI: 10.1172/jci81130] [Cited by in Crossref: 165] [Cited by in F6Publishing: 110] [Article Influence: 27.5] [Reference Citation Analysis]
379 Thompson ED, Zahurak M, Murphy A, Cornish T, Cuka N, Abdelfatah E, Yang S, Duncan M, Ahuja N, Taube JM, Anders RA, Kelly RJ. Patterns of PD-L1 expression and CD8 T cell infiltration in gastric adenocarcinomas and associated immune stroma. Gut. 2017;66:794-801. [PMID: 26801886 DOI: 10.1136/gutjnl-2015-310839] [Cited by in Crossref: 206] [Cited by in F6Publishing: 217] [Article Influence: 34.3] [Reference Citation Analysis]
380 O'Kane GM, Leighl NB. Are immune checkpoint blockade monoclonal antibodies active against CNS metastases from NSCLC?-current evidence and future perspectives. Transl Lung Cancer Res 2016;5:628-36. [PMID: 28149757 DOI: 10.21037/tlcr.2016.09.05] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.7] [Reference Citation Analysis]
381 Salinas RD, Durgin JS, O'Rourke DM. Potential of Glioblastoma-Targeted Chimeric Antigen Receptor (CAR) T-Cell Therapy. CNS Drugs 2020;34:127-45. [PMID: 31916100 DOI: 10.1007/s40263-019-00687-3] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 7.0] [Reference Citation Analysis]
382 Smith AD, Roda D, Yap TA. Strategies for modern biomarker and drug development in oncology. J Hematol Oncol 2014;7:70. [PMID: 25277503 DOI: 10.1186/s13045-014-0070-8] [Cited by in Crossref: 84] [Cited by in F6Publishing: 81] [Article Influence: 10.5] [Reference Citation Analysis]
383 Carvalho M, Sepodes B, Martins AP. Regulatory and Scientific Advancements in Gene Therapy: State-of-the-Art of Clinical Applications and of the Supporting European Regulatory Framework. Front Med (Lausanne) 2017;4:182. [PMID: 29124055 DOI: 10.3389/fmed.2017.00182] [Cited by in Crossref: 23] [Cited by in F6Publishing: 16] [Article Influence: 4.6] [Reference Citation Analysis]
384 Kato S, Okamura R, Kumaki Y, Ikeda S, Nikanjam M, Eskander R, Goodman A, Lee S, Glenn ST, Dressman D, Papanicolau-Sengos A, Lenzo FL, Morrison C, Kurzrock R. Expression of TIM3/VISTA checkpoints and the CD68 macrophage-associated marker correlates with anti-PD1/PDL1 resistance: implications of immunogram heterogeneity. Oncoimmunology 2020;9:1708065. [PMID: 32117584 DOI: 10.1080/2162402X.2019.1708065] [Cited by in Crossref: 15] [Cited by in F6Publishing: 9] [Article Influence: 7.5] [Reference Citation Analysis]
385 Gajewski TF, Schreiber H, Fu YX. Innate and adaptive immune cells in the tumor microenvironment. Nat Immunol 2013;14:1014-22. [PMID: 24048123 DOI: 10.1038/ni.2703] [Cited by in Crossref: 1775] [Cited by in F6Publishing: 1724] [Article Influence: 197.2] [Reference Citation Analysis]
386 Spranger S, Gajewski T. Rational combinations of immunotherapeutics that target discrete pathways. J Immunother Cancer 2013;1:16. [PMID: 24829752 DOI: 10.1186/2051-1426-1-16] [Cited by in Crossref: 51] [Cited by in F6Publishing: 48] [Article Influence: 5.7] [Reference Citation Analysis]
387 Yang H, Wang Y, Jia Z, Wang Y, Yang X, Wu P, Song Y, Xu H, Gu D, Chen R, Xia X, Bing Z, Gao C, Cao L, Li S, Cao Z, Liang N. Characteristics of T-Cell Receptor Repertoire and Correlation With EGFR Mutations in All Stages of Lung Cancer. Front Oncol 2021;11:537735. [PMID: 33777727 DOI: 10.3389/fonc.2021.537735] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
388 Lv L, Zhang Y, Zhao Y, Wei Q, Zhao Y, Yi Q. Effects of 1p/19q Codeletion on Immune Phenotype in Low Grade Glioma. Front Cell Neurosci 2021;15:704344. [PMID: 34335194 DOI: 10.3389/fncel.2021.704344] [Reference Citation Analysis]
389 Pu X, Wu L, Su D, Mao W, Fang B. Immunotherapy for non-small cell lung cancers: biomarkers for predicting responses and strategies to overcome resistance. BMC Cancer 2018;18:1082. [PMID: 30409126 DOI: 10.1186/s12885-018-4990-5] [Cited by in Crossref: 25] [Cited by in F6Publishing: 29] [Article Influence: 6.3] [Reference Citation Analysis]
390 Rubin MA. Insights into the mechanism of organ-specific cancer metastasis. Cancer Discov 2014;4:1262-4. [PMID: 25367948 DOI: 10.1158/2159-8290.CD-14-1075] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.9] [Reference Citation Analysis]
391 Long GV, Tykodi SS, Schneider JG, Garbe C, Gravis G, Rashford M, Agrawal S, Grigoryeva E, Bello A, Roy A, Rollin L, Zhao X. Assessment of nivolumab exposure and clinical safety of 480 mg every 4 weeks flat-dosing schedule in patients with cancer. Ann Oncol 2018;29:2208-13. [PMID: 30215677 DOI: 10.1093/annonc/mdy408] [Cited by in Crossref: 75] [Cited by in F6Publishing: 70] [Article Influence: 25.0] [Reference Citation Analysis]
392 Mushtaq MU, Papadas A, Pagenkopf A, Flietner E, Morrow Z, Chaudhary SG, Asimakopoulos F. Tumor matrix remodeling and novel immunotherapies: the promise of matrix-derived immune biomarkers. J Immunother Cancer 2018;6:65. [PMID: 29970158 DOI: 10.1186/s40425-018-0376-0] [Cited by in Crossref: 54] [Cited by in F6Publishing: 56] [Article Influence: 13.5] [Reference Citation Analysis]
393 Liao Y, Chen L, Feng Y, Shen J, Gao Y, Cote G, Choy E, Harmon D, Mankin H, Hornicek F, Duan Z. Targeting programmed cell death ligand 1 by CRISPR/Cas9 in osteosarcoma cells. Oncotarget 2017;8:30276-87. [PMID: 28415820 DOI: 10.18632/oncotarget.16326] [Cited by in Crossref: 37] [Cited by in F6Publishing: 36] [Article Influence: 9.3] [Reference Citation Analysis]
394 Lattanzi M, Deng FM, Chiriboga LA, Femia AN, Meehan SA, Iyer G, Voss MH, Sundatova Y, Huang WC, Balar AV. Durable response to anti-PD-1 immunotherapy in epithelioid angiomyolipoma: a report on the successful treatment of a rare malignancy. J Immunother Cancer 2018;6:97. [PMID: 30285856 DOI: 10.1186/s40425-018-0415-x] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
395 Yamazaki N, Takenouchi T, Nakamura Y, Takahashi A, Namikawa K, Kitano S, Fujita T, Kubota K, Yamanaka T, Kawakami Y. Prospective observational study of the efficacy of nivolumab in Japanese patients with advanced melanoma (CREATIVE study). Jpn J Clin Oncol 2021;51:1232-41. [PMID: 34115870 DOI: 10.1093/jjco/hyab064] [Reference Citation Analysis]
396 Chen YY, Ge JY, Ma D, Yu KD. Immune-Activated Regional Lymph Nodes Predict Favorable Survival in Early-Stage Triple-Negative Breast Cancer. Front Oncol 2020;10:570981. [PMID: 33163401 DOI: 10.3389/fonc.2020.570981] [Reference Citation Analysis]
397 Chen M, Andreozzi M, Pockaj B, Barrett MT, Ocal IT, McCullough AE, Linnaus ME, Chang JM, Yearley JH, Annamalai L, Anderson KS. Development and validation of a novel clinical fluorescence in situ hybridization assay to detect JAK2 and PD-L1 amplification: a fluorescence in situ hybridization assay for JAK2 and PD-L1 amplification. Mod Pathol 2017;30:1516-26. [PMID: 28752839 DOI: 10.1038/modpathol.2017.86] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 3.0] [Reference Citation Analysis]
398 Lee SJ, Yang A, Wu TC, Hung CF. Immunotherapy for human papillomavirus-associated disease and cervical cancer: review of clinical and translational research. J Gynecol Oncol 2016;27:e51. [PMID: 27329199 DOI: 10.3802/jgo.2016.27.e51] [Cited by in Crossref: 57] [Cited by in F6Publishing: 53] [Article Influence: 9.5] [Reference Citation Analysis]
399 Lo JA, Kawakubo M, Juneja VR, Su MY, Erlich TH, LaFleur MW, Kemeny LV, Rashid M, Malehmir M, Rabi SA, Raghavan R, Allouche J, Kasumova G, Frederick DT, Pauken KE, Weng QY, Pereira da Silva M, Xu Y, van der Sande AAJ, Silkworth W, Roider E, Browne EP, Lieb DJ, Wang B, Garraway LA, Wu CJ, Flaherty KT, Brinckerhoff CE, Mullins DW, Adams DJ, Hacohen N, Hoang MP, Boland GM, Freeman GJ, Sharpe AH, Manstein D, Fisher DE. Epitope spreading toward wild-type melanocyte-lineage antigens rescues suboptimal immune checkpoint blockade responses. Sci Transl Med 2021;13:eabd8636. [PMID: 33597266 DOI: 10.1126/scitranslmed.abd8636] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 9.0] [Reference Citation Analysis]
400 Syed Khaja AS, Toor SM, El Salhat H, Ali BR, Elkord E. Intratumoral FoxP3+Helios+ Regulatory T Cells Upregulating Immunosuppressive Molecules Are Expanded in Human Colorectal Cancer. Front Immunol 2017;8:619. [PMID: 28603527 DOI: 10.3389/fimmu.2017.00619] [Cited by in Crossref: 43] [Cited by in F6Publishing: 46] [Article Influence: 8.6] [Reference Citation Analysis]
401 Sweis RF, Luke JJ. Mechanistic and pharmacologic insights on immune checkpoint inhibitors. Pharmacol Res 2017;120:1-9. [PMID: 28323141 DOI: 10.1016/j.phrs.2017.03.012] [Cited by in Crossref: 26] [Cited by in F6Publishing: 24] [Article Influence: 5.2] [Reference Citation Analysis]
402 White AL, Chan HT, French RR, Willoughby J, Mockridge CI, Roghanian A, Penfold CA, Booth SG, Dodhy A, Polak ME, Potter EA, Ardern-Jones MR, Verbeek JS, Johnson PW, Al-Shamkhani A, Cragg MS, Beers SA, Glennie MJ. Conformation of the human immunoglobulin G2 hinge imparts superagonistic properties to immunostimulatory anticancer antibodies. Cancer Cell 2015;27:138-48. [PMID: 25500122 DOI: 10.1016/j.ccell.2014.11.001] [Cited by in Crossref: 95] [Cited by in F6Publishing: 83] [Article Influence: 11.9] [Reference Citation Analysis]
403 Mahmoud F, Shields B, Makhoul I, Avaritt N, Wong HK, Hutchins LF, Shalin S, Tackett AJ. Immune surveillance in melanoma: From immune attack to melanoma escape and even counterattack. Cancer Biol Ther 2017;18:451-69. [PMID: 28513269 DOI: 10.1080/15384047.2017.1323596] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 3.6] [Reference Citation Analysis]
404 Fernandez MF, Qiao G, Tulla K, Prabhakar BS, Maker AV. Combination Immunotherapy With LIGHT and Interleukin-2 Increases CD8 Central Memory T-Cells In Vivo. J Surg Res 2021;263:44-52. [PMID: 33631377 DOI: 10.1016/j.jss.2021.01.010] [Reference Citation Analysis]
405 Tang PA, Heng DY. Programmed death 1 pathway inhibition in metastatic renal cell cancer and prostate cancer. Curr Oncol Rep 2013;15:98-104. [PMID: 23263823 DOI: 10.1007/s11912-012-0284-2] [Cited by in Crossref: 31] [Cited by in F6Publishing: 31] [Article Influence: 3.4] [Reference Citation Analysis]
406 Karachi A, Yang C, Dastmalchi F, Sayour EJ, Huang J, Azari H, Long Y, Flores C, Mitchell DA, Rahman M. Modulation of temozolomide dose differentially affects T-cell response to immune checkpoint inhibition. Neuro Oncol 2019;21:730-41. [PMID: 30668768 DOI: 10.1093/neuonc/noz015] [Cited by in Crossref: 25] [Cited by in F6Publishing: 25] [Article Influence: 12.5] [Reference Citation Analysis]
407 Liu M, Gao S, Elhassan RM, Hou X, Fang H. Strategies to overcome drug resistance using SHP2 inhibitors. Acta Pharmaceutica Sinica B 2021;11:3908-24. [DOI: 10.1016/j.apsb.2021.03.037] [Reference Citation Analysis]
408 Rao J, Wu X, Zhou X, Deng R, Ma Y. TMEM205 Is an Independent Prognostic Factor and Is Associated With Immune Cell Infiltrates in Hepatocellular Carcinoma. Front Genet 2020;11:575776. [PMID: 33193690 DOI: 10.3389/fgene.2020.575776] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
409 Rupp LJ, Schumann K, Roybal KT, Gate RE, Ye CJ, Lim WA, Marson A. CRISPR/Cas9-mediated PD-1 disruption enhances anti-tumor efficacy of human chimeric antigen receptor T cells. Sci Rep. 2017;7:737. [PMID: 28389661 DOI: 10.1038/s41598-017-00462-8] [Cited by in Crossref: 296] [Cited by in F6Publishing: 288] [Article Influence: 59.2] [Reference Citation Analysis]
410 Stefani D, Plönes T, Viehof J, Darwiche K, Stuschke M, Schuler M, Aigner C. Lung Cancer Surgery after Neoadjuvant Immunotherapy. Cancers (Basel) 2021;13:4033. [PMID: 34439187 DOI: 10.3390/cancers13164033] [Reference Citation Analysis]
411 Liang H, Wang M. Prospect of immunotherapy combined with anti-angiogenic agents in patients with advanced non-small cell lung cancer. Cancer Manag Res 2019;11:7707-19. [PMID: 31616186 DOI: 10.2147/CMAR.S212238] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
412 Liu X, Jiang J, Liao YP, Tang I, Zheng E, Qiu W, Lin M, Wang X, Ji Y, Mei KC, Liu Q, Chang CH, Wainberg ZA, Nel AE, Meng H. Combination Chemo-Immunotherapy for Pancreatic Cancer Using the Immunogenic Effects of an Irinotecan Silicasome Nanocarrier Plus Anti-PD-1. Adv Sci (Weinh) 2021;8:2002147. [PMID: 33747719 DOI: 10.1002/advs.202002147] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
413 Modena A, Ciccarese C, Iacovelli R, Brunelli M, Montironi R, Fiorentino M, Tortora G, Massari F. Immune Checkpoint Inhibitors and Prostate Cancer: A New Frontier? Oncol Rev 2016;10:293. [PMID: 27471580 DOI: 10.4081/oncol.2016.293] [Cited by in Crossref: 27] [Cited by in F6Publishing: 27] [Article Influence: 4.5] [Reference Citation Analysis]
414 Guerrero AD, Moyes JS, Cooper LJ. The human application of gene therapy to re-program T-cell specificity using chimeric antigen receptors. Chin J Cancer 2014;33:421-33. [PMID: 25189715 DOI: 10.5732/cjc.014.10100] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
415 Tsai KK, Zarzoso I, Daud AI. PD-1 and PD-L1 antibodies for melanoma. Hum Vaccin Immunother. 2014;10:3111-3116. [PMID: 25625924 DOI: 10.4161/21645515.2014.983409] [Cited by in Crossref: 38] [Cited by in F6Publishing: 35] [Article Influence: 5.4] [Reference Citation Analysis]
416 Kalathil SG, Lugade AA, Miller A, Iyer R, Thanavala Y. PD-1+ and Foxp3+ T cell reduction correlates with survival of HCC patients after sorafenib therapy. JCI Insight 2016;1:e86182. [PMID: 27540594 DOI: 10.1172/jci.insight.86182] [Cited by in Crossref: 36] [Cited by in F6Publishing: 36] [Article Influence: 6.0] [Reference Citation Analysis]
417 Shaikh H, Kamran A, Monga DK. Immunotherapy in gastroesophageal cancers: Current state and future directions. J Oncol Pharm Pract 2021;27:395-404. [PMID: 33050805 DOI: 10.1177/1078155220963538] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
418 Chapuis AG, Afanasiev OK, Iyer JG, Paulson KG, Parvathaneni U, Hwang JH, Lai I, Roberts IM, Sloan HL, Bhatia S, Shibuya KC, Gooley T, Desmarais C, Koelle DM, Yee C, Nghiem P. Regression of metastatic Merkel cell carcinoma following transfer of polyomavirus-specific T cells and therapies capable of re-inducing HLA class-I. Cancer Immunol Res 2014;2:27-36. [PMID: 24432305 DOI: 10.1158/2326-6066.CIR-13-0087] [Cited by in Crossref: 62] [Cited by in F6Publishing: 31] [Article Influence: 7.8] [Reference Citation Analysis]
419 Sheng J, Zhang J, Baudelet C, Roy A. Clinical Benefit-Risk Assessment of Nivolumab 240 mg Every 2 Weeks in Chinese Patients With Advanced and Metastatic Solid Tumors. J Clin Pharmacol 2021;61:1045-53. [PMID: 33501654 DOI: 10.1002/jcph.1821] [Reference Citation Analysis]
420 Qin Q, Nan X, Miller T, Fisher R, Teh B, Pandita S, Farach AM, Pingali SR, Pandita RK, Butler EB, Pandita TK, Iyer SP. Complete Local and Abscopal Responses from a Combination of Radiation and Nivolumab in Refractory Hodgkin's Lymphoma. Radiat Res 2018;190:322-9. [PMID: 29949442 DOI: 10.1667/RR15048.1] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 5.0] [Reference Citation Analysis]
421 Lee KW, Lee DH, Kang JH, Park JO, Kim SH, Hong YS, Kim ST, Oh DY, Bang YJ. Phase I Pharmacokinetic Study of Nivolumab in Korean Patients with Advanced Solid Tumors. Oncologist 2018;23:155-e17. [PMID: 29158363 DOI: 10.1634/theoncologist.2017-0528] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 2.6] [Reference Citation Analysis]
422 Chen YF, Wang YH, Lei CS, Changou CA, Davis ME, Yen Y. Host immune response to anti-cancer camptothecin conjugated cyclodextrin-based polymers. J Biomed Sci 2019;26:85. [PMID: 31647037 DOI: 10.1186/s12929-019-0583-0] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
423 Aranda F, Vacchelli E, Eggermont A, Galon J, Fridman WH, Zitvogel L, Kroemer G, Galluzzi L. Trial Watch: Immunostimulatory monoclonal antibodies in cancer therapy. Oncoimmunology 2014;3:e27297. [PMID: 24701370 DOI: 10.4161/onci.27297] [Cited by in Crossref: 84] [Cited by in F6Publishing: 84] [Article Influence: 10.5] [Reference Citation Analysis]
424 Ribas A, Hu-Lieskovan S. What does PD-L1 positive or negative mean? J Exp Med. 2016;213:2835-2840. [PMID: 27903604 DOI: 10.1084/jem.20161462] [Cited by in Crossref: 150] [Cited by in F6Publishing: 148] [Article Influence: 25.0] [Reference Citation Analysis]
425 Brücher D, Kirchhammer N, Smith SN, Schumacher J, Schumacher N, Kolibius J, Freitag PC, Schmid M, Weiss F, Keller C, Grove M, Greber UF, Zippelius A, Plückthun A. iMATCH: an integrated modular assembly system for therapeutic combination high-capacity adenovirus gene therapy. Mol Ther Methods Clin Dev 2021;20:572-86. [PMID: 33665227 DOI: 10.1016/j.omtm.2021.01.002] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
426 Guo CX, Huang X, Xu J, Zhang XZ, Shen YN, Liang TB, Bai XL. Combined targeted therapy and immunotherapy for cancer treatment. World J Clin Cases 2021; 9(26): 7643-7652 [PMID: 34621816 DOI: 10.12998/wjcc.v9.i26.7643] [Reference Citation Analysis]
427 Singh BH, Gulley JL. Therapeutic vaccines as a promising treatment modality against prostate cancer: rationale and recent advances. Ther Adv Vaccines 2014;2:137-48. [PMID: 25177493 DOI: 10.1177/2051013614539478] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 1.8] [Reference Citation Analysis]
428 Zhou S, Sun Y, Chen T, Wang J, He J, Lyu J, Shen Y, Chen X, Yang R. The Landscape of the Tumor Microenvironment in Skin Cutaneous Melanoma Reveals a Prognostic and Immunotherapeutically Relevant Gene Signature. Front Cell Dev Biol 2021;9:739594. [PMID: 34660598 DOI: 10.3389/fcell.2021.739594] [Reference Citation Analysis]
429 El Sayed R, Haibe Y, Amhaz G, Bouferraa Y, Shamseddine A. Metabolic Factors Affecting Tumor Immunogenicity: What Is Happening at the Cellular Level? Int J Mol Sci 2021;22:2142. [PMID: 33670011 DOI: 10.3390/ijms22042142] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
430 Aqbi HF, Coleman C, Zarei M, Manjili SH, Graham L, Koblinski J, Guo C, Xie Y, Guruli G, Bear HD, Idowu MO, Habibi M, Wang XY, Manjili MH. Local and distant tumor dormancy during early stage breast cancer are associated with the predominance of infiltrating T effector subsets. Breast Cancer Res 2020;22:116. [PMID: 33115528 DOI: 10.1186/s13058-020-01357-9] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
431 Chen X, Chen X, Gao J, Yang H, Duan Y, Feng Y, He X, Gong X, Wang H, Wu X, Chang J. Astragaloside III Enhances Anti-Tumor Response of NK Cells by Elevating NKG2D and IFN-γ. Front Pharmacol 2019;10:898. [PMID: 31456687 DOI: 10.3389/fphar.2019.00898] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
432 Tanaka Y, Murata-Hirai K, Iwasaki M, Matsumoto K, Hayashi K, Kumagai A, Nada MH, Wang H, Kobayashi H, Kamitakahara H, Okamura H, Sugie T, Minato N, Toi M, Morita CT. Expansion of human γδ T cells for adoptive immunotherapy using a bisphosphonate prodrug. Cancer Sci 2018;109:587-99. [PMID: 29288540 DOI: 10.1111/cas.13491] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 4.3] [Reference Citation Analysis]
433 Kluger HM, Zito CR, Barr ML, Baine MK, Chiang VL, Sznol M, Rimm DL, Chen L, Jilaveanu LB. Characterization of PD-L1 Expression and Associated T-cell Infiltrates in Metastatic Melanoma Samples from Variable Anatomic Sites. Clin Cancer Res 2015;21:3052-60. [PMID: 25788491 DOI: 10.1158/1078-0432.CCR-14-3073] [Cited by in Crossref: 134] [Cited by in F6Publishing: 85] [Article Influence: 19.1] [Reference Citation Analysis]
434 Mito I, Takahashi H, Kawabata-Iwakawa R, Ida S, Tada H, Chikamatsu K. Comprehensive analysis of immune cell enrichment in the tumor microenvironment of head and neck squamous cell carcinoma. Sci Rep 2021;11:16134. [PMID: 34373557 DOI: 10.1038/s41598-021-95718-9] [Reference Citation Analysis]
435 Hirai M, Kitahara H, Kobayashi Y, Kato K, Bou-Gharios G, Nakamura H, Kawashiri S. Regulation of PD-L1 expression in a high-grade invasive human oral squamous cell carcinoma microenvironment. Int J Oncol. 2017;50:41-48. [PMID: 27922697 DOI: 10.3892/ijo.2016.3785] [Cited by in Crossref: 40] [Cited by in F6Publishing: 44] [Article Influence: 6.7] [Reference Citation Analysis]
436 Chandrasekaran D, Sundaram S, N K, R P. Programmed Death Ligand 1; An Immunotarget for Renal Cell Carcinoma. Asian Pac J Cancer Prev 2019;20:2951-7. [PMID: 31653140 DOI: 10.31557/APJCP.2019.20.10.2951] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
437 Gaur P, Hunt CR, Pandita TK. Emerging therapeutic targets in esophageal adenocarcinoma. Oncotarget 2016;7:48644-55. [PMID: 27102294 DOI: 10.18632/oncotarget.8777] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 2.5] [Reference Citation Analysis]
438 Parry HM, Dowell AC, Zuo J, Verma K, Kinsella FAM, Begum J, Croft W, Sharma-Oates A, Pratt G, Moss P. PD-1 is imprinted on cytomegalovirus-specific CD4+ T cells and attenuates Th1 cytokine production whilst maintaining cytotoxicity. PLoS Pathog 2021;17:e1009349. [PMID: 33662046 DOI: 10.1371/journal.ppat.1009349] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
439 Koopmans I, Hendriks D, Samplonius DF, van Ginkel RJ, Heskamp S, Wierstra PJ, Bremer E, Helfrich W. A novel bispecific antibody for EGFR-directed blockade of the PD-1/PD-L1 immune checkpoint. Oncoimmunology 2018;7:e1466016. [PMID: 30221065 DOI: 10.1080/2162402X.2018.1466016] [Cited by in Crossref: 21] [Cited by in F6Publishing: 16] [Article Influence: 5.3] [Reference Citation Analysis]
440 Schwörer S, Vardhana SA, Thompson CB. Cancer Metabolism Drives a Stromal Regenerative Response. Cell Metab 2019;29:576-91. [PMID: 30773467 DOI: 10.1016/j.cmet.2019.01.015] [Cited by in Crossref: 37] [Cited by in F6Publishing: 32] [Article Influence: 12.3] [Reference Citation Analysis]
441 Filosso PL, Guerrera F, Lausi PO, Ruffini E. Locally advanced non-small cell lung cancer treatment: another step forward. J Thorac Dis 2017;9:4908-11. [PMID: 29312689 DOI: 10.21037/jtd.2017.11.103] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
442 Isaacsson Velho P, Antonarakis ES. PD-1/PD-L1 pathway inhibitors in advanced prostate cancer. Expert Rev Clin Pharmacol 2018;11:475-86. [PMID: 29641940 DOI: 10.1080/17512433.2018.1464388] [Cited by in Crossref: 36] [Cited by in F6Publishing: 40] [Article Influence: 9.0] [Reference Citation Analysis]
443 Ahn DH, Goldberg RM. Colorectal clinical trials: what is on the horizon? Future Oncol 2016;12:525-31. [PMID: 26777152 DOI: 10.2217/fon.15.327] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
444 Tung N, Garber JE, Hacker MR, Torous V, Freeman GJ, Poles E, Rodig S, Alexander B, Lee L, Collins LC, Schnitt SJ. Prevalence and predictors of androgen receptor and programmed death-ligand 1 in BRCA1-associated and sporadic triple-negative breast cancer. NPJ Breast Cancer 2016;2:16002. [PMID: 28721372 DOI: 10.1038/npjbcancer.2016.2] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 3.2] [Reference Citation Analysis]
445 Hoffmann M, Pantazis N, Martin GE, Hickling S, Hurst J, Meyerowitz J, Willberg CB, Robinson N, Brown H, Fisher M, Kinloch S, Babiker A, Weber J, Nwokolo N, Fox J, Fidler S, Phillips R, Frater J; SPARTAC and CHERUB Investigators. Exhaustion of Activated CD8 T Cells Predicts Disease Progression in Primary HIV-1 Infection. PLoS Pathog 2016;12:e1005661. [PMID: 27415828 DOI: 10.1371/journal.ppat.1005661] [Cited by in Crossref: 86] [Cited by in F6Publishing: 86] [Article Influence: 14.3] [Reference Citation Analysis]
446 Wang Y, Sun SN, Liu Q, Yu YY, Guo J, Wang K, Xing BC, Zheng QF, Campa MJ, Patz EF Jr, Li SY, He YW. Autocrine Complement Inhibits IL10-Dependent T-cell-Mediated Antitumor Immunity to Promote Tumor Progression. Cancer Discov 2016;6:1022-35. [PMID: 27297552 DOI: 10.1158/2159-8290.CD-15-1412] [Cited by in Crossref: 78] [Cited by in F6Publishing: 52] [Article Influence: 13.0] [Reference Citation Analysis]
447 Santarpia M, Karachaliou N. Tumor immune microenvironment characterization and response to anti-PD-1 therapy. Cancer Biol Med 2015;12:74-8. [PMID: 26175922 DOI: 10.7497/j.issn.2095-3941.2015.0022] [Cited by in F6Publishing: 32] [Reference Citation Analysis]
448 Lamble AJ, Kosaka Y, Laderas T, Maffit A, Kaempf A, Brady LK, Wang W, Long N, Saultz JN, Mori M, Soong D, LeFave CV, Huang F, Adams H 3rd, Loriaux MM, Tognon CE, Lo P, Tyner JW, Fan G, McWeeney SK, Druker BJ, Lind EF. Reversible suppression of T cell function in the bone marrow microenvironment of acute myeloid leukemia. Proc Natl Acad Sci U S A 2020;117:14331-41. [PMID: 32513686 DOI: 10.1073/pnas.1916206117] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 7.0] [Reference Citation Analysis]
449 Azad N, Zahnow CA, Rudin CM, Baylin SB. The future of epigenetic therapy in solid tumours--lessons from the past. Nat Rev Clin Oncol. 2013;10:256-266. [PMID: 23546521 DOI: 10.1038/nrclinonc.2013.42] [Cited by in Crossref: 222] [Cited by in F6Publishing: 215] [Article Influence: 24.7] [Reference Citation Analysis]
450 Kakarla S, Gottschalk S. CAR T cells for solid tumors: armed and ready to go? Cancer J 2014;20:151-5. [PMID: 24667962 DOI: 10.1097/PPO.0000000000000032] [Cited by in Crossref: 123] [Cited by in F6Publishing: 77] [Article Influence: 15.4] [Reference Citation Analysis]
451 Wang PF, Chen Y, Song SY, Wang TJ, Ji WJ, Li SW, Liu N, Yan CX. Immune-Related Adverse Events Associated with Anti-PD-1/PD-L1 Treatment for Malignancies: A Meta-Analysis. Front Pharmacol. 2017;8:730. [PMID: 29093678 DOI: 10.3389/fphar.2017.00730] [Cited by in Crossref: 174] [Cited by in F6Publishing: 167] [Article Influence: 34.8] [Reference Citation Analysis]
452 Leite KR, Reis ST, Junior JP, Zerati M, Gomes Dde O, Camara-Lopes LH, Srougi M. PD-L1 expression in renal cell carcinoma clear cell type is related to unfavorable prognosis. Diagn Pathol 2015;10:189. [PMID: 26470780 DOI: 10.1186/s13000-015-0414-x] [Cited by in Crossref: 47] [Cited by in F6Publishing: 53] [Article Influence: 6.7] [Reference Citation Analysis]
453 Hong Y, Ding ZY. PD-1 Inhibitors in the Advanced Esophageal Cancer. Front Pharmacol 2019;10:1418. [PMID: 31920637 DOI: 10.3389/fphar.2019.01418] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 3.3] [Reference Citation Analysis]
454 Johnson DB, Peng C, Sosman JA. Nivolumab in melanoma: latest evidence and clinical potential. Ther Adv Med Oncol. 2015;7:97-106. [PMID: 25755682 DOI: 10.1177/1758834014567469] [Cited by in Crossref: 94] [Cited by in F6Publishing: 86] [Article Influence: 13.4] [Reference Citation Analysis]
455 Jimenez C, Armaiz-pena G, Dahia PLM, Lu Y, Toledo RA, Varghese J, Habra MA. Endocrine and Neuroendocrine Tumors Special Issue—Checkpoint Inhibitors for Adrenocortical Carcinoma and Metastatic Pheochromocytoma and Paraganglioma: Do They Work? Cancers 2022;14:467. [DOI: 10.3390/cancers14030467] [Reference Citation Analysis]
456 Peng W, Liu C, Xu C, Lou Y, Chen J, Yang Y, Yagita H, Overwijk WW, Lizée G, Radvanyi L, Hwu P. PD-1 blockade enhances T-cell migration to tumors by elevating IFN-γ inducible chemokines. Cancer Res 2012;72:5209-18. [PMID: 22915761 DOI: 10.1158/0008-5472.CAN-12-1187] [Cited by in Crossref: 235] [Cited by in F6Publishing: 158] [Article Influence: 23.5] [Reference Citation Analysis]
457 Naidoo J, Li BT, Schindler K, Page DB. What does the future hold for immunotherapy in cancer? Ann Transl Med 2016;4:177. [PMID: 27275490 DOI: 10.21037/atm.2016.04.05] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
458 Fisher R, Larkin J. Individualising treatment choices in a crowded treatment algorithm. EJC Suppl 2013;11:160-8. [PMID: 26217125 DOI: 10.1016/j.ejcsup.2013.07.019] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
459 Ezinne CC, Yoshimitsu M, White Y, Arima N. HTLV-1 specific CD8+ T cell function augmented by blockade of 2B4/CD48 interaction in HTLV-1 infection. PLoS One 2014;9:e87631. [PMID: 24505299 DOI: 10.1371/journal.pone.0087631] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 2.1] [Reference Citation Analysis]
460 Atefi M, Avramis E, Lassen A, Wong DJ, Robert L, Foulad D, Cerniglia M, Titz B, Chodon T, Graeber TG, Comin-Anduix B, Ribas A. Effects of MAPK and PI3K pathways on PD-L1 expression in melanoma. Clin Cancer Res 2014;20:3446-57. [PMID: 24812408 DOI: 10.1158/1078-0432.CCR-13-2797] [Cited by in Crossref: 206] [Cited by in F6Publishing: 151] [Article Influence: 25.8] [Reference Citation Analysis]
461 Ott PA, Piha-Paul SA, Munster P, Pishvaian MJ, van Brummelen EMJ, Cohen RB, Gomez-Roca C, Ejadi S, Stein M, Chan E, Simonelli M, Morosky A, Saraf S, Emancipator K, Koshiji M, Bennouna J. Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with recurrent carcinoma of the anal canal. Ann Oncol 2017;28:1036-41. [PMID: 28453692 DOI: 10.1093/annonc/mdx029] [Cited by in Crossref: 116] [Cited by in F6Publishing: 104] [Article Influence: 29.0] [Reference Citation Analysis]
462 Matsuki E, Younes A. Checkpoint Inhibitors and Other Immune Therapies for Hodgkin and Non-Hodgkin Lymphoma. Curr Treat Options Oncol. 2016;17:31. [PMID: 27193488 DOI: 10.1007/s11864-016-0401-9] [Cited by in Crossref: 41] [Cited by in F6Publishing: 31] [Article Influence: 8.2] [Reference Citation Analysis]
463 Jeyakumar G, Kim S, Bumma N, Landry C, Silski C, Suisham S, Dickow B, Heath E, Fontana J, Vaishampayan U. Neutrophil lymphocyte ratio and duration of prior anti-angiogenic therapy as biomarkers in metastatic RCC receiving immune checkpoint inhibitor therapy. J Immunother Cancer 2017;5:82. [PMID: 29041991 DOI: 10.1186/s40425-017-0287-5] [Cited by in Crossref: 46] [Cited by in F6Publishing: 43] [Article Influence: 9.2] [Reference Citation Analysis]
464 Kim JH, Kim BS, Lee SK. Regulatory T Cells in Tumor Microenvironment and Approach for Anticancer Immunotherapy. Immune Netw 2020;20:e4. [PMID: 32158592 DOI: 10.4110/in.2020.20.e4] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 10.5] [Reference Citation Analysis]
465 Saga K, Kaneda Y. Virosome presents multimodel cancer therapy without viral replication. Biomed Res Int 2013;2013:764706. [PMID: 24369016 DOI: 10.1155/2013/764706] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 1.6] [Reference Citation Analysis]
466 Wang Y, Yang G, You L, Yang J, Feng M, Qiu J, Zhao F, Liu Y, Cao Z, Zheng L, Zhang T, Zhao Y. Role of the microbiome in occurrence, development and treatment of pancreatic cancer. Mol Cancer. 2019;18:173. [PMID: 31785619 DOI: 10.1186/s12943-019-1103-2] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 4.7] [Reference Citation Analysis]
467 Kim MC, Jin Z, Kolb R, Borcherding N, Chatzkel JA, Falzarano SM, Zhang W. Updates on Immunotherapy and Immune Landscape in Renal Clear Cell Carcinoma. Cancers (Basel) 2021;13:5856. [PMID: 34831009 DOI: 10.3390/cancers13225856] [Reference Citation Analysis]
468 Lazarus J, Maj T, Smith JJ, Perusina Lanfranca M, Rao A, D'Angelica MI, Delrosario L, Girgis A, Schukow C, Shia J, Kryczek I, Shi J, Wasserman I, Crawford H, Nathan H, Pasca Di Magliano M, Zou W, Frankel TL. Spatial and phenotypic immune profiling of metastatic colon cancer. JCI Insight 2018;3:121932. [PMID: 30429368 DOI: 10.1172/jci.insight.121932] [Cited by in Crossref: 27] [Cited by in F6Publishing: 27] [Article Influence: 6.8] [Reference Citation Analysis]
469 Asmar R, Yang J, Carvajal RD. Clinical utility of nivolumab in the treatment of advanced melanoma. Ther Clin Risk Manag 2016;12:313-25. [PMID: 27013881 DOI: 10.2147/TCRM.S78039] [Cited by in Crossref: 5] [Cited by in F6Publishing: 10] [Article Influence: 0.8] [Reference Citation Analysis]
470 Lane RS, Femel J, Breazeale AP, Loo CP, Thibault G, Kaempf A, Mori M, Tsujikawa T, Chang YH, Lund AW. IFNγ-activated dermal lymphatic vessels inhibit cytotoxic T cells in melanoma and inflamed skin. J Exp Med 2018;215:3057-74. [PMID: 30381467 DOI: 10.1084/jem.20180654] [Cited by in Crossref: 57] [Cited by in F6Publishing: 50] [Article Influence: 14.3] [Reference Citation Analysis]
471 Wei F, Wang D, Wei J, Tang N, Tang L, Xiong F, Guo C, Zhou M, Li X, Li G, Xiong W, Zhang S, Zeng Z. Metabolic crosstalk in the tumor microenvironment regulates antitumor immunosuppression and immunotherapy resisitance. Cell Mol Life Sci 2021;78:173-93. [PMID: 32654036 DOI: 10.1007/s00018-020-03581-0] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 7.0] [Reference Citation Analysis]
472 Angelova M, Charoentong P, Hackl H, Fischer ML, Snajder R, Krogsdam AM, Waldner MJ, Bindea G, Mlecnik B, Galon J. Characterization of the immunophenotypes and antigenomes of colorectal cancers reveals distinct tumor escape mechanisms and novel targets for immunotherapy. Genome Biol. 2015;16:64. [PMID: 25853550 DOI: 10.1186/s13059-015-0620-6] [Cited by in Crossref: 280] [Cited by in F6Publishing: 270] [Article Influence: 40.0] [Reference Citation Analysis]
473 Ratain MJ, Peer CJ, Figg WD, Goldstein DA. Dose Optimization of Pembrolizumab: Less May Be More. Clin Pharmacol Ther 2021. [PMID: 34854077 DOI: 10.1002/cpt.2490] [Reference Citation Analysis]
474 Lin M, Liang S, Wang X, Liang Y, Zhang M, Chen J, Niu L, Xu K. Cryoablation combined with allogenic natural killer cell immunotherapy improves the curative effect in patients with advanced hepatocellular cancer. Oncotarget. 2017;8:81967-81977. [PMID: 29137237 DOI: 10.18632/oncotarget.17804] [Cited by in Crossref: 15] [Cited by in F6Publishing: 18] [Article Influence: 3.0] [Reference Citation Analysis]
475 Weenink B, Draaisma K, Ooi HZ, Kros JM, Sillevis Smitt PAE, Debets R, French PJ. Low-grade glioma harbors few CD8 T cells, which is accompanied by decreased expression of chemo-attractants, not immunogenic antigens. Sci Rep 2019;9:14643. [PMID: 31601888 DOI: 10.1038/s41598-019-51063-6] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
476 Jamil ML, Deebajah M, Sood A, Alanee S. Combination of pembrolizumab and BCG treatment after endoscopic ablation of high-risk superficial upper urinary tract urothelial carcinoma in patients not candidates for radical nephroureterectomy: protocol for phase-II study. BMJ Open 2019;9:e027066. [PMID: 31796469 DOI: 10.1136/bmjopen-2018-027066] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
477 Simon AK, Hollander GA, McMichael A. Evolution of the immune system in humans from infancy to old age. Proc Biol Sci. 2015;282:20143085. [PMID: 26702035 DOI: 10.1098/rspb.2014.3085] [Cited by in Crossref: 498] [Cited by in F6Publishing: 519] [Article Influence: 99.6] [Reference Citation Analysis]
478 Moynihan KD, Opel CF, Szeto GL, Tzeng A, Zhu EF, Engreitz JM, Williams RT, Rakhra K, Zhang MH, Rothschilds AM, Kumari S, Kelly RL, Kwan BH, Abraham W, Hu K, Mehta NK, Kauke MJ, Suh H, Cochran JR, Lauffenburger DA, Wittrup KD, Irvine DJ. Eradication of large established tumors in mice by combination immunotherapy that engages innate and adaptive immune responses. Nat Med 2016;22:1402-10. [PMID: 27775706 DOI: 10.1038/nm.4200] [Cited by in Crossref: 269] [Cited by in F6Publishing: 254] [Article Influence: 44.8] [Reference Citation Analysis]
479 De Sousa Linhares A, Leitner J, Grabmeier-Pfistershammer K, Steinberger P. Not All Immune Checkpoints Are Created Equal. Front Immunol 2018;9:1909. [PMID: 30233564 DOI: 10.3389/fimmu.2018.01909] [Cited by in Crossref: 69] [Cited by in F6Publishing: 63] [Article Influence: 17.3] [Reference Citation Analysis]
480 Housseau F, Llosa NJ. Immune checkpoint blockade in microsatellite instable colorectal cancers: Back to the clinic. Oncoimmunology 2015;4:e1008858. [PMID: 26155426 DOI: 10.1080/2162402X.2015.1008858] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.9] [Reference Citation Analysis]
481 Kamphorst AO, Araki K, Ahmed R. Beyond adjuvants: immunomodulation strategies to enhance T cell immunity. Vaccine 2015;33 Suppl 2:B21-8. [PMID: 26022562 DOI: 10.1016/j.vaccine.2014.12.082] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 3.3] [Reference Citation Analysis]
482 Li Z, Chen L, Rubinstein MP. Cancer immunotherapy: are we there yet? Exp Hematol Oncol 2013;2:33. [PMID: 24326015 DOI: 10.1186/2162-3619-2-33] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 1.9] [Reference Citation Analysis]
483 Bei D, Osawa M, Uemura S, Ohno T, Gobburu J, Roy A, Hasegawa M. Benefit-risk assessment of nivolumab 240 mg flat dose relative to 3 mg/kg Q2W regimen in Japanese patients with advanced cancers. Cancer Sci 2020;111:528-35. [PMID: 31773815 DOI: 10.1111/cas.14252] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
484 Triozzi PL, Fernandez AP. The role of the immune response in merkel cell carcinoma. Cancers (Basel) 2013;5:234-54. [PMID: 24216706 DOI: 10.3390/cancers5010234] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 2.4] [Reference Citation Analysis]
485 Feng GS, Hanley KL, Liang Y, Lin X. Improving the Efficacy of Liver Cancer Immunotherapy: The Power of Combined Preclinical and Clinical Studies. Hepatology 2021;73 Suppl 1:104-14. [PMID: 32715491 DOI: 10.1002/hep.31479] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 5.0] [Reference Citation Analysis]
486 Daud AI, Wolchok JD, Robert C, Hwu WJ, Weber JS, Ribas A, Hodi FS, Joshua AM, Kefford R, Hersey P, Joseph R, Gangadhar TC, Dronca R, Patnaik A, Zarour H, Roach C, Toland G, Lunceford JK, Li XN, Emancipator K, Dolled-Filhart M, Kang SP, Ebbinghaus S, Hamid O. Programmed Death-Ligand 1 Expression and Response to the Anti-Programmed Death 1 Antibody Pembrolizumab in Melanoma. J Clin Oncol 2016;34:4102-9. [PMID: 27863197 DOI: 10.1200/JCO.2016.67.2477] [Cited by in Crossref: 347] [Cited by in F6Publishing: 200] [Article Influence: 57.8] [Reference Citation Analysis]
487 Sanmamed MF, Chen L. Inducible expression of B7-H1 (PD-L1) and its selective role in tumor site immune modulation. Cancer J 2014;20:256-61. [PMID: 25098285 DOI: 10.1097/PPO.0000000000000061] [Cited by in Crossref: 78] [Cited by in F6Publishing: 50] [Article Influence: 11.1] [Reference Citation Analysis]
488 Byers J, Yin H, Rytting H, Logan S, He M, Yu Z, Wang D, Warren M, Mangray S, Dehner LP, Zhou S. PD-L1 expression in angiomatoid fibrous histiocytoma. Sci Rep 2021;11:2183. [PMID: 33500467 DOI: 10.1038/s41598-021-81746-y] [Reference Citation Analysis]
489 Solans BP, López-Díaz de Cerio A, Elizalde A, Pina LJ, Inogés S, Espinós J, Salgado E, Mejías LD, Trocóniz IF, Santisteban M. Assessing the impact of the addition of dendritic cell vaccination to neoadjuvant chemotherapy in breast cancer patients: A model-based characterization approach. Br J Clin Pharmacol 2019;85:1670-83. [PMID: 30933365 DOI: 10.1111/bcp.13947] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
490 Garg SK, Welsh EA, Fang B, Hernandez YI, Rose T, Gray J, Koomen JM, Berglund A, Mulé JJ, Markowitz J. Multi-Omics and Informatics Analysis of FFPE Tissues Derived from Melanoma Patients with Long/Short Responses to Anti-PD1 Therapy Reveals Pathways of Response. Cancers (Basel) 2020;12:E3515. [PMID: 33255891 DOI: 10.3390/cancers12123515] [Reference Citation Analysis]
491 Kimbara S, Kondo S. Immune checkpoint and inflammation as therapeutic targets in pancreatic carcinoma. World J Gastroenterol 2016; 22(33): 7440-7452 [PMID: 27672267 DOI: 10.3748/wjg.v22.i33.7440] [Cited by in CrossRef: 13] [Cited by in F6Publishing: 13] [Article Influence: 2.2] [Reference Citation Analysis]
492 Wei Y, Li Y, Du Q, Peng X, Jin J, Guo H, Li Y, Li Q. Effects of Clinicopathological Characteristics on the Survival of Patients Treated with PD-1/PD-L1 Inhibitor Monotherapy or Combination Therapy for Advanced Cancer: A Systemic Review and Meta-Analysis. J Immunol Res 2020;2020:5269787. [PMID: 33381603 DOI: 10.1155/2020/5269787] [Reference Citation Analysis]
493 Kantrowitz J, Sinjab A, Xu L, McDowell TL, Sivakumar S, Lang W, Nunomura-Nakamura S, Fukuoka J, Nemer G, Darwiche N, Chami H, Tfayli A, Wistuba II, Scheet P, Fujimoto J, Spira AE, Kadara H. Genome-Wide Gene Expression Changes in the Normal-Appearing Airway during the Evolution of Smoking-Associated Lung Adenocarcinoma. Cancer Prev Res (Phila) 2018;11:237-48. [PMID: 29382653 DOI: 10.1158/1940-6207.CAPR-17-0295] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
494 Huffaker TB, Lee SH, Tang WW, Wallace JA, Alexander M, Runtsch MC, Larsen DK, Thompson J, Ramstead AG, Voth WP, Hu R, Round JL, Williams MA, O'Connell RM. Antitumor immunity is defective in T cell-specific microRNA-155-deficient mice and is rescued by immune checkpoint blockade. J Biol Chem 2017;292:18530-41. [PMID: 28912267 DOI: 10.1074/jbc.M117.808121] [Cited by in Crossref: 42] [Cited by in F6Publishing: 27] [Article Influence: 8.4] [Reference Citation Analysis]
495 Jiang W, He Y, He W, Wu G, Zhou X, Sheng Q, Zhong W, Lu Y, Ding Y, Lu Q, Ye F, Hua H. Exhausted CD8+T Cells in the Tumor Immune Microenvironment: New Pathways to Therapy. Front Immunol 2020;11:622509. [PMID: 33633741 DOI: 10.3389/fimmu.2020.622509] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
496 Sandigursky S, Mor A. Immune-Related Adverse Events in Cancer Patients Treated With Immune Checkpoint Inhibitors. Curr Rheumatol Rep 2018;20:65. [PMID: 30191417 DOI: 10.1007/s11926-018-0770-0] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 4.0] [Reference Citation Analysis]
497 da Silva IP, Gallois A, Jimenez-Baranda S, Khan S, Anderson AC, Kuchroo VK, Osman I, Bhardwaj N. Reversal of NK-cell exhaustion in advanced melanoma by Tim-3 blockade. Cancer Immunol Res 2014;2:410-22. [PMID: 24795354 DOI: 10.1158/2326-6066.CIR-13-0171] [Cited by in Crossref: 200] [Cited by in F6Publishing: 142] [Article Influence: 25.0] [Reference Citation Analysis]
498 He H, Qi L, Xiao Y, Hou Y. [Tumor Associated Fibroblasts Promote PD-L1 Expression in Lung Cancer Cells]. Zhongguo Fei Ai Za Zhi 2017;20:293-7. [PMID: 28532535 DOI: 10.3779/j.issn.1009-3419.2017.05.01] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
499 Guo Y, Wang Y, Han W. Chimeric Antigen Receptor-Modified T Cells for Solid Tumors: Challenges and Prospects. J Immunol Res 2016;2016:3850839. [PMID: 26998495 DOI: 10.1155/2016/3850839] [Cited by in Crossref: 18] [Cited by in F6Publishing: 21] [Article Influence: 3.0] [Reference Citation Analysis]
500 Tomasello G, Ghidini M, Liguigli W, Ratti M, Toppo L, Passalacqua R. Targeted therapies in gastric cancer treatment: where we are and where we are going. Invest New Drugs. 2016;34:378-393. [PMID: 26873643 DOI: 10.1007/s10637-016-0330-2] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.8] [Reference Citation Analysis]
501 Li J, Liu X, Duan Y, Liu Y, Wang H, Lian S, Zhuang G, Fan Y. Combined Blockade of T Cell Immunoglobulin and Mucin Domain 3 and Carcinoembryonic Antigen-Related Cell Adhesion Molecule 1 Results in Durable Therapeutic Efficacy in Mice with Intracranial Gliomas. Med Sci Monit 2017;23:3593-602. [PMID: 28736431 DOI: 10.12659/msm.903098] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 2.8] [Reference Citation Analysis]
502 Ørskov AD, Treppendahl MB, Skovbo A, Holm MS, Friis LS, Hokland M, Grønbæk K. Hypomethylation and up-regulation of PD-1 in T cells by azacytidine in MDS/AML patients: A rationale for combined targeting of PD-1 and DNA methylation. Oncotarget 2015;6:9612-26. [PMID: 25823822 DOI: 10.18632/oncotarget.3324] [Cited by in Crossref: 109] [Cited by in F6Publishing: 108] [Article Influence: 18.2] [Reference Citation Analysis]
503 Kumar V, Chaudhary N, Garg M, Floudas CS, Soni P, Chandra AB. Current Diagnosis and Management of Immune Related Adverse Events (irAEs) Induced by Immune Checkpoint Inhibitor Therapy. Front Pharmacol. 2017;8:49. [PMID: 28228726 DOI: 10.3389/fphar.2017.00049] [Cited by in Crossref: 221] [Cited by in F6Publishing: 220] [Article Influence: 44.2] [Reference Citation Analysis]
504 Hashimoto M, Im SJ, Araki K, Ahmed R. Cytokine-Mediated Regulation of CD8 T-Cell Responses During Acute and Chronic Viral Infection. Cold Spring Harb Perspect Biol 2019;11:a028464. [PMID: 29101105 DOI: 10.1101/cshperspect.a028464] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 4.7] [Reference Citation Analysis]
505 Peng Q, Wang J. Non-coding RNAs in melanoma: Biological functions and potential clinical applications. Mol Ther Oncolytics 2021;22:219-31. [PMID: 34514101 DOI: 10.1016/j.omto.2021.05.012] [Reference Citation Analysis]
506 Mylvaganam G, Yanez AG, Maus M, Walker BD. Toward T Cell-Mediated Control or Elimination of HIV Reservoirs: Lessons From Cancer Immunology. Front Immunol 2019;10:2109. [PMID: 31552045 DOI: 10.3389/fimmu.2019.02109] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 6.0] [Reference Citation Analysis]
507 Yeo KP, Angeli V. Bidirectional Crosstalk between Lymphatic Endothelial Cell and T Cell and Its Implications in Tumor Immunity. Front Immunol 2017;8:83. [PMID: 28220121 DOI: 10.3389/fimmu.2017.00083] [Cited by in Crossref: 19] [Cited by in F6Publishing: 21] [Article Influence: 3.8] [Reference Citation Analysis]
508 Bai Y, Chen X, Hou L, Qian J, Jiang T, Zhou C, Ciebiada M. PD-L1 expression and its effect on clinical outcomes of EGFR-mutant NSCLC patients treated with EGFR-TKIs. Cancer Biol Med 2018;15:434-42. [PMID: 30766753 DOI: 10.20892/j.issn.2095-3941.2018.0223] [Cited by in Crossref: 9] [Cited by in F6Publishing: 12] [Article Influence: 2.3] [Reference Citation Analysis]
509 Li T, Zhang C, Zhao G, Zhang X, Hao M, Hassan S, Zhang M, Zheng H, Yang D, Liu L, Mehraein-Ghomi F, Bai X, Chen K, Zhang W, Yang J. IGFBP2 regulates PD-L1 expression by activating the EGFR-STAT3 signaling pathway in malignant melanoma. Cancer Lett 2020;477:19-30. [PMID: 32120023 DOI: 10.1016/j.canlet.2020.02.036] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
510 Martin-Liberal J, Hierro C, Ochoa de Olza M, Rodon J. Immuno-Oncology: The Third Paradigm in Early Drug Development. Target Oncol 2017;12:125-38. [PMID: 27995439 DOI: 10.1007/s11523-016-0471-4] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 3.4] [Reference Citation Analysis]
511 Naba NM, Tolay N, Erman B, Sayi Yazgan A. Doxorubicin inhibits miR-140 expression and upregulates PD-L1 expression in HCT116 cells, opposite to its effects on MDA-MB-231 cells. Turk J Biol 2020;44:15-23. [PMID: 32123492 DOI: 10.3906/biy-1909-12] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
512 Zidar DA, Al-Kindi SG, Liu Y, Krieger NI, Perzynski AT, Osnard M, Nmai C, Anthony DD, Lederman MM, Freeman ML, Bonomo RA, Simon DI, Dalton JE. Association of Lymphopenia With Risk of Mortality Among Adults in the US General Population. JAMA Netw Open 2019;2:e1916526. [PMID: 31790569 DOI: 10.1001/jamanetworkopen.2019.16526] [Cited by in Crossref: 28] [Cited by in F6Publishing: 24] [Article Influence: 9.3] [Reference Citation Analysis]
513 Oliveira-Costa JP, de Carvalho AF, da Silveira da GG, Amaya P, Wu Y, Park KJ, Gigliola MP, Lustberg M, Buim ME, Ferreira EN, Kowalski LP, Chalmers JJ, Soares FA, Carraro DM, Ribeiro-Silva A. Gene expression patterns through oral squamous cell carcinoma development: PD-L1 expression in primary tumor and circulating tumor cells. Oncotarget 2015;6:20902-20. [PMID: 26041877 DOI: 10.18632/oncotarget.3939] [Cited by in Crossref: 65] [Cited by in F6Publishing: 68] [Article Influence: 10.8] [Reference Citation Analysis]
514 Okuno D, Sugiura Y, Sakamoto N, Tagod MSO, Iwasaki M, Noda S, Tamura A, Senju H, Umeyama Y, Yamaguchi H, Suematsu M, Morita CT, Tanaka Y, Mukae H. Comparison of a Novel Bisphosphonate Prodrug and Zoledronic Acid in the Induction of Cytotoxicity in Human Vγ2Vδ2 T Cells. Front Immunol 2020;11:1405. [PMID: 32793196 DOI: 10.3389/fimmu.2020.01405] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
515 Berghoff AS, Fuchs E, Ricken G, Mlecnik B, Bindea G, Spanberger T, Hackl M, Widhalm G, Dieckmann K, Prayer D, Bilocq A, Heinzl H, Zielinski C, Bartsch R, Birner P, Galon J, Preusser M. Density of tumor-infiltrating lymphocytes correlates with extent of brain edema and overall survival time in patients with brain metastases. Oncoimmunology 2016;5:e1057388. [PMID: 26942067 DOI: 10.1080/2162402X.2015.1057388] [Cited by in Crossref: 149] [Cited by in F6Publishing: 100] [Article Influence: 21.3] [Reference Citation Analysis]
516 Willis JC, Lord GM. Immune biomarkers: the promises and pitfalls of personalized medicine. Nat Rev Immunol 2015;15:323-9. [PMID: 25814400 DOI: 10.1038/nri3820] [Cited by in Crossref: 62] [Cited by in F6Publishing: 56] [Article Influence: 8.9] [Reference Citation Analysis]
517 Karagiannis P, Fittall M, Karagiannis SN. Evaluating biomarkers in melanoma. Front Oncol 2014;4:383. [PMID: 25667918 DOI: 10.3389/fonc.2014.00383] [Cited by in Crossref: 25] [Cited by in F6Publishing: 26] [Article Influence: 3.6] [Reference Citation Analysis]
518 Liu SS, Yang YZ, Jiang C, Quan Q, Xie QK, Wang XP, He WZ, Rong YM, Chen P, Yang Q, Yang L, Zhang B, Xia XJ, Kong PF, Xia LP. Comparison of immunological characteristics between paired mismatch repair-proficient and -deficient colorectal cancer patients. J Transl Med 2018;16:195. [PMID: 30005666 DOI: 10.1186/s12967-018-1570-z] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
519 Kumar-Sinha C, Chinnaiyan AM. Precision oncology in the age of integrative genomics. Nat Biotechnol 2018;36:46-60. [PMID: 29319699 DOI: 10.1038/nbt.4017] [Cited by in Crossref: 62] [Cited by in F6Publishing: 49] [Article Influence: 15.5] [Reference Citation Analysis]
520 Girotti MR, Saturno G, Lorigan P, Marais R. No longer an untreatable disease: how targeted and immunotherapies have changed the management of melanoma patients. Mol Oncol 2014;8:1140-58. [PMID: 25178978 DOI: 10.1016/j.molonc.2014.07.027] [Cited by in Crossref: 39] [Cited by in F6Publishing: 32] [Article Influence: 4.9] [Reference Citation Analysis]
521 Ochoa CE, Joseph RW. Nivolumab in Renal Cell Carcinoma: Current Trends and Future Perspectives. J Kidney Cancer VHL 2018;5:15-8. [PMID: 29468108 DOI: 10.15586/jkcvhl.2018.102] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
522 Schalper KA, Carvajal-Hausdorf D, McLaughlin J, Altan M, Velcheti V, Gaule P, Sanmamed MF, Chen L, Herbst RS, Rimm DL. Differential Expression and Significance of PD-L1, IDO-1, and B7-H4 in Human Lung Cancer. Clin Cancer Res 2017;23:370-8. [PMID: 27440266 DOI: 10.1158/1078-0432.CCR-16-0150] [Cited by in Crossref: 87] [Cited by in F6Publishing: 66] [Article Influence: 14.5] [Reference Citation Analysis]
523 Li H, Bullock K, Gurjao C, Braun D, Shukla SA, Bossé D, Lalani AA, Gopal S, Jin C, Horak C, Wind-Rotolo M, Signoretti S, McDermott DF, Freeman GJ, Van Allen EM, Schreiber SL, Stephen Hodi F, Sellers WR, Garraway LA, Clish CB, Choueiri TK, Giannakis M. Metabolomic adaptations and correlates of survival to immune checkpoint blockade. Nat Commun 2019;10:4346. [PMID: 31554815 DOI: 10.1038/s41467-019-12361-9] [Cited by in Crossref: 55] [Cited by in F6Publishing: 61] [Article Influence: 18.3] [Reference Citation Analysis]
524 . 365 days: Nature's 10. Nature 2014;516:311-9. [PMID: 25519114 DOI: 10.1038/516311a] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
525 Woller N, Gürlevik E, Ureche CI, Schumacher A, Kühnel F. Oncolytic viruses as anticancer vaccines. Front Oncol 2014;4:188. [PMID: 25101244 DOI: 10.3389/fonc.2014.00188] [Cited by in Crossref: 45] [Cited by in F6Publishing: 48] [Article Influence: 5.6] [Reference Citation Analysis]
526 Gottschalk C, Damuzzo V, Gotot J, Kroczek RA, Yagita H, Murphy KM, Knolle PA, Ludwig-Portugall I, Kurts C. Batf3-dependent dendritic cells in the renal lymph node induce tolerance against circulating antigens. J Am Soc Nephrol 2013;24:543-9. [PMID: 23411785 DOI: 10.1681/ASN.2012101022] [Cited by in Crossref: 27] [Cited by in F6Publishing: 18] [Article Influence: 3.0] [Reference Citation Analysis]
527 Zanusso C, Dreussi E, Bortolus R, Romualdi C, Gagno S, De Mattia E, Romanato L, Sartor F, Quartuccio L, Cecchin E, Toffoli G. rs4143815-PDL1, a New Potential Immunogenetic Biomarker of Biochemical Recurrence in Locally Advanced Prostate Cancer after Radiotherapy. Int J Mol Sci 2019;20:E2082. [PMID: 31035590 DOI: 10.3390/ijms20092082] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
528 Trac NT, Chung EJ. Peptide-based targeting of immunosuppressive cells in cancer. Bioact Mater 2020;5:92-101. [PMID: 31956738 DOI: 10.1016/j.bioactmat.2020.01.006] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 6.0] [Reference Citation Analysis]
529 Zhang S, Zhong M, Wang C, Xu Y, Gao WQ, Zhang Y. CCL5-deficiency enhances intratumoral infiltration of CD8+ T cells in colorectal cancer. Cell Death Dis 2018;9:766. [PMID: 29991744 DOI: 10.1038/s41419-018-0796-2] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 4.5] [Reference Citation Analysis]
530 Luo F, Luo M, Rong QX, Zhang H, Chen Z, Wang F, Zhao HY, Fu LW. Niclosamide, an antihelmintic drug, enhances efficacy of PD-1/PD-L1 immune checkpoint blockade in non-small cell lung cancer. J Immunother Cancer 2019;7:245. [PMID: 31511071 DOI: 10.1186/s40425-019-0733-7] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 6.3] [Reference Citation Analysis]
531 Khan U, Ali F, Khurram MS, Zaka A, Hadid T. Immunotherapy-associated autoimmune hemolytic anemia. J Immunother Cancer 2017;5:15. [PMID: 28239468 DOI: 10.1186/s40425-017-0214-9] [Cited by in Crossref: 36] [Cited by in F6Publishing: 33] [Article Influence: 7.2] [Reference Citation Analysis]
532 Mamand S, Allchin RL, Ahearne MJ, Wagner SD. Comparison of interleukin-2-inducible kinase (ITK) inhibitors and potential for combination therapies for T-cell lymphoma. Sci Rep 2018;8:14216. [PMID: 30242208 DOI: 10.1038/s41598-018-32634-5] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
533 Han D, Lu X, Shih AH, Nie J, You Q, Xu MM, Melnick AM, Levine RL, He C. A Highly Sensitive and Robust Method for Genome-wide 5hmC Profiling of Rare Cell Populations. Mol Cell 2016;63:711-9. [PMID: 27477909 DOI: 10.1016/j.molcel.2016.06.028] [Cited by in Crossref: 62] [Cited by in F6Publishing: 56] [Article Influence: 10.3] [Reference Citation Analysis]
534 Biasci D, Smoragiewicz M, Connell CM, Wang Z, Gao Y, Thaventhiran JED, Basu B, Magiera L, Johnson TI, Bax L, Gopinathan A, Isherwood C, Gallagher FA, Pawula M, Hudecova I, Gale D, Rosenfeld N, Barmpounakis P, Popa EC, Brais R, Godfrey E, Mir F, Richards FM, Fearon DT, Janowitz T, Jodrell DI. CXCR4 inhibition in human pancreatic and colorectal cancers induces an integrated immune response. Proc Natl Acad Sci U S A 2020;117:28960-70. [PMID: 33127761 DOI: 10.1073/pnas.2013644117] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 9.0] [Reference Citation Analysis]
535 Salido Iniesta M, López López L, Carreras Costa F, Sionis A. A different type of acute myocarditis: a case report of acute autoimmune myocarditis mediated by anti-PD-1 T lymphocyte receptor (pembrolizumab). Eur Heart J Case Rep 2020;4:1-6. [PMID: 33204987 DOI: 10.1093/ehjcr/ytaa214] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
536 Yang B, Liu T, Qu Y, Liu H, Zheng SG, Cheng B, Sun J. Progresses and Perspectives of Anti-PD-1/PD-L1 Antibody Therapy in Head and Neck Cancers. Front Oncol 2018;8:563. [PMID: 30547012 DOI: 10.3389/fonc.2018.00563] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 4.0] [Reference Citation Analysis]
537 Shafirstein G, Battoo A, Harris K, Baumann H, Gollnick SO, Lindenmann J, Nwogu CE. Photodynamic Therapy of Non-Small Cell Lung Cancer. Narrative Review and Future Directions. Ann Am Thorac Soc 2016;13:265-75. [PMID: 26646726 DOI: 10.1513/AnnalsATS.201509-650FR] [Cited by in Crossref: 17] [Cited by in F6Publishing: 31] [Article Influence: 2.8] [Reference Citation Analysis]
538 Brassard J, Gill ME, Bernatchez E, Desjardins V, Roy J, Joubert P, Marsolais D, Blanchet MR. Countering the advert effects of lung cancer on the anticancer potential of dendritic cell populations reinstates sensitivity to anti-PD-1 therapy. PLoS One 2021;16:e0260636. [PMID: 34847189 DOI: 10.1371/journal.pone.0260636] [Reference Citation Analysis]
539 Chapman PB. Treating metastatic melanoma in 2014: what just happened and what is next? Am Soc Clin Oncol Educ Book 2014;:16-9. [PMID: 24857055 DOI: 10.14694/EdBook_AM.2014.34.16] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
540 Ji M, Liu Y, Li Q, Li X, Ning Z, Zhao W, Shi H, Jiang J, Wu C. PD-1/PD-L1 expression in non-small-cell lung cancer and its correlation with EGFR/KRAS mutations. Cancer Biol Ther 2016;17:407-13. [PMID: 26954523 DOI: 10.1080/15384047.2016.1156256] [Cited by in Crossref: 60] [Cited by in F6Publishing: 70] [Article Influence: 10.0] [Reference Citation Analysis]
541 Hurkmans DP, Basak EA, van Dijk T, Mercieca D, Schreurs MWJ, Wijkhuijs AJM, Bins S, Hoop EO, Debets R, Joerger M, Odink A, van der Veldt AAM, van der Leest CH, Aerts JGJV, Mathijssen RHJ, Koolen SLW. A prospective cohort study on the pharmacokinetics of nivolumab in metastatic non-small cell lung cancer, melanoma, and renal cell cancer patients. J Immunother Cancer 2019;7:192. [PMID: 31324223 DOI: 10.1186/s40425-019-0669-y] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 6.3] [Reference Citation Analysis]
542 Antonia SJ, Borghaei H, Ramalingam SS, Horn L, De Castro Carpeño J, Pluzanski A, Burgio MA, Garassino M, Chow LQM, Gettinger S, Crinò L, Planchard D, Butts C, Drilon A, Wojcik-Tomaszewska J, Otterson GA, Agrawal S, Li A, Penrod JR, Brahmer J. Four-year survival with nivolumab in patients with previously treated advanced non-small-cell lung cancer: a pooled analysis. Lancet Oncol 2019;20:1395-408. [PMID: 31422028 DOI: 10.1016/S1470-2045(19)30407-3] [Cited by in Crossref: 104] [Cited by in F6Publishing: 60] [Article Influence: 34.7] [Reference Citation Analysis]
543 Chocarro de Erauso L, Zuazo M, Arasanz H, Bocanegra A, Hernandez C, Fernandez G, Garcia-Granda MJ, Blanco E, Vera R, Kochan G, Escors D. Resistance to PD-L1/PD-1 Blockade Immunotherapy. A Tumor-Intrinsic or Tumor-Extrinsic Phenomenon? Front Pharmacol 2020;11:441. [PMID: 32317979 DOI: 10.3389/fphar.2020.00441] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 6.0] [Reference Citation Analysis]
544 Kong X, Kong Y. Evidence from a meta-analysis: is nivolumabneurotoxic in cancer patients? Onco Targets Ther 2017;10:1335-44. [PMID: 28280368 DOI: 10.2147/OTT.S120341] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
545 Johnson DB, Puzanov I, Kelley MC. Talimogene laherparepvec (T-VEC) for the treatment of advanced melanoma. Immunotherapy 2015;7:611-9. [PMID: 26098919 DOI: 10.2217/imt.15.35] [Cited by in Crossref: 72] [Cited by in F6Publishing: 74] [Article Influence: 10.3] [Reference Citation Analysis]
546 Li Q, Shi Z, Zhang F, Zeng W, Zhu D, Mei L. Symphony of nanomaterials and immunotherapy based on the cancer–immunity cycle. Acta Pharmaceutica Sinica B 2022;12:107-34. [DOI: 10.1016/j.apsb.2021.05.031] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
547 Sullivan RJ, Fisher DE. Understanding the biology of melanoma and therapeutic implications. Hematol Oncol Clin North Am 2014;28:437-53. [PMID: 24880940 DOI: 10.1016/j.hoc.2014.02.007] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 3.3] [Reference Citation Analysis]
548 Teng MW, Galon J, Fridman WH, Smyth MJ. From mice to humans: developments in cancer immunoediting. J Clin Invest 2015;125:3338-46. [PMID: 26241053 DOI: 10.1172/JCI80004] [Cited by in Crossref: 157] [Cited by in F6Publishing: 83] [Article Influence: 22.4] [Reference Citation Analysis]
549 Kong Y, Zhang J, Claxton DF, Ehmann WC, Rybka WB, Zhu L, Zeng H, Schell TD, Zheng H. PD-1(hi)TIM-3(+) T cells associate with and predict leukemia relapse in AML patients post allogeneic stem cell transplantation. Blood Cancer J 2015;5:e330. [PMID: 26230954 DOI: 10.1038/bcj.2015.58] [Cited by in Crossref: 80] [Cited by in F6Publishing: 68] [Article Influence: 11.4] [Reference Citation Analysis]
550 Yu Y, Huang S, Chen J, Yu F, Zhang L, Xiang X, Deng J, Fang Z, Li J, Xiong J. An Assessment of Combination of the Camrelizumab With Chemotherapy in Metastatic Biliary Tract Cancers. Cancer Control 2021;28:10732748211017165. [PMID: 33982628 DOI: 10.1177/10732748211017165] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
551 Kawana S, Saito R, Miki Y, Kimura Y, Abe J, Sato I, Endo M, Sugawara S, Sasano H. Suppression of tumor immune microenvironment via microRNA-1 after epidermal growth factor receptor-tyrosine kinase inhibitor resistance acquirement in lung adenocarcinoma. Cancer Med 2021;10:718-27. [PMID: 33305905 DOI: 10.1002/cam4.3639] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
552 Otoshi T, Nagano T, Tachihara M, Nishimura Y. Possible Biomarkers for Cancer Immunotherapy. Cancers (Basel) 2019;11:E935. [PMID: 31277279 DOI: 10.3390/cancers11070935] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 6.0] [Reference Citation Analysis]
553 Françoso A, Simioni PU. Immunotherapy for the treatment of colorectal tumors: focus on approved and in-clinical-trial monoclonal antibodies. Drug Des Devel Ther 2017;11:177-84. [PMID: 28138221 DOI: 10.2147/DDDT.S119036] [Cited by in Crossref: 13] [Cited by in F6Publishing: 5] [Article Influence: 2.6] [Reference Citation Analysis]
554 Taube JM, Galon J, Sholl LM, Rodig SJ, Cottrell TR, Giraldo NA, Baras AS, Patel SS, Anders RA, Rimm DL, Cimino-Mathews A. Implications of the tumor immune microenvironment for staging and therapeutics. Mod Pathol 2018;31:214-34. [PMID: 29192647 DOI: 10.1038/modpathol.2017.156] [Cited by in Crossref: 136] [Cited by in F6Publishing: 138] [Article Influence: 27.2] [Reference Citation Analysis]
555 Wyluda EJ, Cheng J, Schell TD, Haley JS, Mallon C, Neves RI, Robertson G, Sivik J, Mackley H, Talamo G, Drabick JJ. Durable complete responses off all treatment in patients with metastatic malignant melanoma after sequential immunotherapy followed by a finite course of BRAF inhibitor therapy. Cancer Biol Ther 2015;16:662-70. [PMID: 25806780 DOI: 10.1080/15384047.2015.1026507] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 3.8] [Reference Citation Analysis]
556 Kita T, Araya T, Sakai T, Uchida Y, Matsuoka H, Kasahara K. Nivolumab-Induced Polymyalgia Rheumatica in a Patient with Lung Adenocarcinoma. Am J Med Sci 2021;362:321-3. [PMID: 33905737 DOI: 10.1016/j.amjms.2021.04.010] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
557 Passiglia F, Cappuzzo F, Alabiso O, Bettini AC, Bidoli P, Chiari R, Defferrari C, Delmonte A, Finocchiaro G, Francini G, Gelsomino F, Giannarelli D, Giordano M, Illiano A, Livi L, Martelli O, Natoli C, Puppo G, Ricevuto E, Roca E, Turci D, Galetta D. Efficacy of nivolumab in pre-treated non-small-cell lung cancer patients harbouring KRAS mutations. Br J Cancer 2019;120:57-62. [PMID: 30377342 DOI: 10.1038/s41416-018-0234-3] [Cited by in Crossref: 24] [Cited by in F6Publishing: 26] [Article Influence: 6.0] [Reference Citation Analysis]
558 Frieling JS, Basanta D, Lynch CC. Current and emerging therapies for bone metastatic castration-resistant prostate cancer. Cancer Control 2015;22:109-20. [PMID: 25504285 DOI: 10.1177/107327481502200114] [Cited by in Crossref: 24] [Cited by in F6Publishing: 24] [Article Influence: 3.4] [Reference Citation Analysis]
559 Iwai Y, Hamanishi J, Chamoto K, Honjo T. Cancer immunotherapies targeting the PD-1 signaling pathway. J Biomed Sci. 2017;24:26. [PMID: 28376884 DOI: 10.1186/s12929-017-0329-9] [Cited by in Crossref: 261] [Cited by in F6Publishing: 266] [Article Influence: 52.2] [Reference Citation Analysis]
560 Ricca J, Turkekul M, Barlas A, Yarilin D, Fujisawa S, Fan N, Brendel M, Zamarin D, Wolchok JD, Manova-Todorova K. Validation of Anti-Mouse PDL-1 Goat Polyclonal Antibody Staining with Mouse PDL-1 In Situ Hybridization on Adjacent Sections of Cell Pellets and Mouse Tumors. Methods Mol Biol 2017;1554:253-62. [PMID: 28185198 DOI: 10.1007/978-1-4939-6759-9_18] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
561 Naing A, Infante J, Goel S, Burris H, Black C, Marshall S, Achour I, Barbee S, May R, Morehouse C, Pollizzi K, Song X, Steele K, Elgeioushi N, Walcott F, Karakunnel J, LoRusso P, Weise A, Eder J, Curti B, Oberst M. Anti-PD-1 monoclonal antibody MEDI0680 in a phase I study of patients with advanced solid malignancies. J Immunother Cancer 2019;7:225. [PMID: 31439037 DOI: 10.1186/s40425-019-0665-2] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
562 Prodeus A, Abdul-Wahid A, Fischer NW, Huang EH, Cydzik M, Gariépy J. Targeting the PD-1/PD-L1 Immune Evasion Axis With DNA Aptamers as a Novel Therapeutic Strategy for the Treatment of Disseminated Cancers. Mol Ther Nucleic Acids 2015;4:e237. [PMID: 25919090 DOI: 10.1038/mtna.2015.11] [Cited by in Crossref: 68] [Cited by in F6Publishing: 61] [Article Influence: 9.7] [Reference Citation Analysis]
563 Cooper ZA, Frederick DT, Juneja VR, Sullivan RJ, Lawrence DP, Piris A, Sharpe AH, Fisher DE, Flaherty KT, Wargo JA. BRAF inhibition is associated with increased clonality in tumor-infiltrating lymphocytes. Oncoimmunology 2013;2:e26615. [PMID: 24251082 DOI: 10.4161/onci.26615] [Cited by in Crossref: 76] [Cited by in F6Publishing: 69] [Article Influence: 8.4] [Reference Citation Analysis]
564 Weng TY, Wu HF, Li CY, Hung YH, Chang YW, Chen YL, Hsu HP, Chen YH, Wang CY, Chang JY, Lai MD. Homoharringtonine induced immune alteration for an Efficient Anti-tumor Response in Mouse Models of Non-small Cell Lung Adenocarcinoma Expressing Kras Mutation. Sci Rep 2018;8:8216. [PMID: 29844447 DOI: 10.1038/s41598-018-26454-w] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.5] [Reference Citation Analysis]
565 Drake CG, Sharma P, Gerritsen W. Metastatic castration-resistant prostate cancer: new therapies, novel combination strategies and implications for immunotherapy. Oncogene 2014;33:5053-64. [PMID: 24276248 DOI: 10.1038/onc.2013.497] [Cited by in Crossref: 32] [Cited by in F6Publishing: 30] [Article Influence: 3.6] [Reference Citation Analysis]
566 Speiser DE, Utzschneider DT, Oberle SG, Münz C, Romero P, Zehn D. T cell differentiation in chronic infection and cancer: functional adaptation or exhaustion? Nat Rev Immunol 2014;14:768-74. [PMID: 25257362 DOI: 10.1038/nri3740] [Cited by in Crossref: 163] [Cited by in F6Publishing: 154] [Article Influence: 20.4] [Reference Citation Analysis]
567 Miret JJ, Kirschmeier P, Koyama S, Zhu M, Li YY, Naito Y, Wu M, Malladi VS, Huang W, Walker W, Palakurthi S, Dranoff G, Hammerman PS, Pecot CV, Wong KK, Akbay EA. Suppression of Myeloid Cell Arginase Activity leads to Therapeutic Response in a NSCLC Mouse Model by Activating Anti-Tumor Immunity. J Immunother Cancer 2019;7:32. [PMID: 30728077 DOI: 10.1186/s40425-019-0504-5] [Cited by in Crossref: 39] [Cited by in F6Publishing: 39] [Article Influence: 13.0] [Reference Citation Analysis]
568 Kuang M, Cheng J, Zhang C, Feng L, Xu X, Zhang Y, Zu M, Cui J, Yu H, Zhang K, Yang A, Cheng S. A novel signature for stratifying the molecular heterogeneity of the tissue-infiltrating T-cell receptor repertoire reflects gastric cancer prognosis. Sci Rep 2017;7:7762. [PMID: 28798410 DOI: 10.1038/s41598-017-08289-z] [Cited by in Crossref: 14] [Cited by in F6Publishing: 8] [Article Influence: 2.8] [Reference Citation Analysis]
569 Berrien-Elliott MM, Jackson SR, Meyer JM, Rouskey CJ, Nguyen TL, Yagita H, Greenberg PD, DiPaolo RJ, Teague RM. Durable adoptive immunotherapy for leukemia produced by manipulation of multiple regulatory pathways of CD8+ T-cell tolerance. Cancer Res 2013;73:605-16. [PMID: 23188506 DOI: 10.1158/0008-5472.CAN-12-2179] [Cited by in Crossref: 36] [Cited by in F6Publishing: 23] [Article Influence: 3.6] [Reference Citation Analysis]
570 Crump NT, Hadjinicolaou AV, Xia M, Walsby-Tickle J, Gileadi U, Chen JL, Setshedi M, Olsen LR, Lau IJ, Godfrey L, Quek L, Yu Z, Ballabio E, Barnkob MB, Napolitani G, Salio M, Koohy H, Kessler BM, Taylor S, Vyas P, McCullagh JSO, Milne TA, Cerundolo V. Chromatin accessibility governs the differential response of cancer and T cells to arginine starvation. Cell Rep 2021;35:109101. [PMID: 33979616 DOI: 10.1016/j.celrep.2021.109101] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
571 Du Z, Lin JR, Rashid R, Maliga Z, Wang S, Aster JC, Izar B, Sorger PK, Santagata S. Qualifying antibodies for image-based immune profiling and multiplexed tissue imaging. Nat Protoc 2019;14:2900-30. [PMID: 31534232 DOI: 10.1038/s41596-019-0206-y] [Cited by in Crossref: 22] [Cited by in F6Publishing: 18] [Article Influence: 7.3] [Reference Citation Analysis]
572 McKendry RT, Spalluto CM, Burke H, Nicholas B, Cellura D, Al-Shamkhani A, Staples KJ, Wilkinson TM. Dysregulation of Antiviral Function of CD8(+) T Cells in the Chronic Obstructive Pulmonary Disease Lung. Role of the PD-1-PD-L1 Axis. Am J Respir Crit Care Med 2016;193:642-51. [PMID: 26517304 DOI: 10.1164/rccm.201504-0782OC] [Cited by in Crossref: 62] [Cited by in F6Publishing: 39] [Article Influence: 10.3] [Reference Citation Analysis]
573 Jomrich G, Silberhumer GR, Marian B, Beer A, Müllauer L. Programmed death-ligand 1 expression in rectal cancer. Eur Surg 2016;48:352-6. [PMID: 28058043 DOI: 10.1007/s10353-016-0447-8] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
574 Okuyama R, Aruga A, Hatori T, Takeda K, Yamamoto M. Immunological responses to a multi-peptide vaccine targeting cancer-testis antigens and VEGFRs in advanced pancreatic cancer patients. Oncoimmunology 2013;2:e27010. [PMID: 24498547 DOI: 10.4161/onci.27010] [Cited by in Crossref: 34] [Cited by in F6Publishing: 31] [Article Influence: 3.8] [Reference Citation Analysis]
575 Abdel-Wahab N, Shah M, Suarez-Almazor ME. Adverse Events Associated with Immune Checkpoint Blockade in Patients with Cancer: A Systematic Review of Case Reports. PLoS One. 2016;11:e0160221. [PMID: 27472273 DOI: 10.1371/journal.pone.0160221] [Cited by in Crossref: 242] [Cited by in F6Publishing: 235] [Article Influence: 40.3] [Reference Citation Analysis]
576 Tøndell A, Wahl SGF, Sponaas AM, Sørhaug S, Børset M, Haug M. Ectonucleotidase CD39 and Checkpoint Signalling Receptor Programmed Death 1 are Highly Elevated in Intratumoral Immune Cells in Non-small-cell Lung Cancer. Transl Oncol 2020;13:17-24. [PMID: 31733591 DOI: 10.1016/j.tranon.2019.09.003] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
577 Yang L, Li A, Lei Q, Zhang Y. Tumor-intrinsic signaling pathways: key roles in the regulation of the immunosuppressive tumor microenvironment. J Hematol Oncol 2019;12:125. [PMID: 31775797 DOI: 10.1186/s13045-019-0804-8] [Cited by in Crossref: 33] [Cited by in F6Publishing: 35] [Article Influence: 11.0] [Reference Citation Analysis]
578 Grambozov B, Wass R, Stana M, Gerum S, Karner J, Fastner G, Studnicka M, Sedlmayer F, Zehentmayr F. Impact of reirradiation, chemotherapy, and immunotherapy on survival of patients with recurrent lung cancer: A single-center retrospective analysis. Thorac Cancer 2021;12:1162-70. [PMID: 33586228 DOI: 10.1111/1759-7714.13884] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
579 Libutti SK. Genetically engineered lymphocytes and adoptive cell therapy: cancer immunotherapy’s smart bombs. Cancer Gene Ther. 2015;22:63. [PMID: 25753044 DOI: 10.1038/cgt.2015.1] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
580 Xu-Monette ZY, Zhang M, Li J, Young KH. PD-1/PD-L1 Blockade: Have We Found the Key to Unleash the Antitumor Immune Response? Front Immunol. 2017;8:1597. [PMID: 29255458 DOI: 10.3389/fimmu.2017.01597] [Cited by in Crossref: 116] [Cited by in F6Publishing: 114] [Article Influence: 23.2] [Reference Citation Analysis]
581 Wen XM, Xu ZJ, Jin Y, Xia PH, Ma JC, Qian W, Lin J, Qian J. Association Analyses of TP53 Mutation With Prognosis, Tumor Mutational Burden, and Immunological Features in Acute Myeloid Leukemia. Front Immunol 2021;12:717527. [PMID: 34745095 DOI: 10.3389/fimmu.2021.717527] [Reference Citation Analysis]
582 Gallois A, Bhardwaj N. Dendritic cell-targeted approaches to modulate immune dysfunction in the tumor microenvironment. Front Immunol 2013;4:436. [PMID: 24339825 DOI: 10.3389/fimmu.2013.00436] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 1.3] [Reference Citation Analysis]
583 John LB, Kershaw MH, Darcy PK. Blockade of PD-1 immunosuppression boosts CAR T-cell therapy. Oncoimmunology 2013;2:e26286. [PMID: 24353912 DOI: 10.4161/onci.26286] [Cited by in Crossref: 77] [Cited by in F6Publishing: 72] [Article Influence: 8.6] [Reference Citation Analysis]
584 Yan L. Molecular targeted agents--where we are and where we are going. Chin J Cancer 2013;32:225-32. [PMID: 23642906 DOI: 10.5732/cjc.013.10051] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
585 Maniyar RR, Chakraborty S, Jarboe T, Suriano R, Wallack M, Geliebter J, Tiwari RK. Interacting Genetic Lesions of Melanoma in the Tumor Microenvironment: Defining a Viable Therapy. Adv Exp Med Biol 2021;1350:123-43. [PMID: 34888847 DOI: 10.1007/978-3-030-83282-7_6] [Reference Citation Analysis]
586 Messeha SS, Zarmouh NO, Soliman KFA. Polyphenols Modulating Effects of PD-L1/PD-1 Checkpoint and EMT-Mediated PD-L1 Overexpression in Breast Cancer. Nutrients 2021;13:1718. [PMID: 34069461 DOI: 10.3390/nu13051718] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
587 Johnson DB, Sullivan RJ. Biomarkers in melanoma: where are we now? Melanoma Manag 2014;1:139-50. [PMID: 30190819 DOI: 10.2217/mmt.14.19] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
588 Kuritzkes DR. Why cure, why now? J Med Ethics 2017;43:67-70. [PMID: 27273887 DOI: 10.1136/medethics-2015-103113] [Cited by in Crossref: 10] [Cited by in F6Publishing: 13] [Article Influence: 1.7] [Reference Citation Analysis]
589 Hugo W, Zaretsky JM, Sun L, Song C, Moreno BH, Hu-Lieskovan S, Berent-Maoz B, Pang J, Chmielowski B, Cherry G, Seja E, Lomeli S, Kong X, Kelley MC, Sosman JA, Johnson DB, Ribas A, Lo RS. Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma. Cell. 2016;165:35-44. [PMID: 26997480 DOI: 10.1016/j.cell.2016.02.065] [Cited by in Crossref: 1279] [Cited by in F6Publishing: 1174] [Article Influence: 213.2] [Reference Citation Analysis]
590 Chen G, Kim YH, Li H, Luo H, Liu DL, Zhang ZJ, Lay M, Chang W, Zhang YQ, Ji RR. PD-L1 inhibits acute and chronic pain by suppressing nociceptive neuron activity via PD-1. Nat Neurosci 2017;20:917-26. [PMID: 28530662 DOI: 10.1038/nn.4571] [Cited by in Crossref: 76] [Cited by in F6Publishing: 71] [Article Influence: 15.2] [Reference Citation Analysis]
591 Ramos RI, Shaw MA, Foshag L, Stern SL, Rahimzadeh N, Elashoff D, Hoon DSB. Genetic Variants in Immune Related Genes as Predictors of Responsiveness to BCG Immunotherapy in Metastatic Melanoma Patients. Cancers (Basel) 2020;13:E91. [PMID: 33396862 DOI: 10.3390/cancers13010091] [Reference Citation Analysis]
592 Llosa NJ, Geis AL, Thiele Orberg E, Housseau F. Interleukin-17 and type 17 helper T cells in cancer management and research. Immunotargets Ther 2014;3:39-54. [PMID: 27471699 DOI: 10.2147/ITT.S56529] [Cited by in Crossref: 3] [Cited by in F6Publishing: 13] [Article Influence: 0.4] [Reference Citation Analysis]
593 Gok Yavuz B, Gunaydin G, Gedik ME, Kosemehmetoglu K, Karakoc D, Ozgur F, Guc D. Cancer associated fibroblasts sculpt tumour microenvironment by recruiting monocytes and inducing immunosuppressive PD-1+ TAMs. Sci Rep 2019;9:3172. [PMID: 30816272 DOI: 10.1038/s41598-019-39553-z] [Cited by in Crossref: 61] [Cited by in F6Publishing: 55] [Article Influence: 20.3] [Reference Citation Analysis]
594 Capasso C, Hirvinen M, Garofalo M, Romaniuk D, Kuryk L, Sarvela T, Vitale A, Antopolsky M, Magarkar A, Viitala T, Suutari T, Bunker A, Yliperttula M, Urtti A, Cerullo V. Oncolytic adenoviruses coated with MHC-I tumor epitopes increase the antitumor immunity and efficacy against melanoma. Oncoimmunology 2016;5:e1105429. [PMID: 27141389 DOI: 10.1080/2162402X.2015.1105429] [Cited by in Crossref: 42] [Cited by in F6Publishing: 26] [Article Influence: 6.0] [Reference Citation Analysis]
595 Boyerinas B, Jochems C, Fantini M, Heery CR, Gulley JL, Tsang KY, Schlom J. Antibody-Dependent Cellular Cytotoxicity Activity of a Novel Anti-PD-L1 Antibody Avelumab (MSB0010718C) on Human Tumor Cells. Cancer Immunol Res 2015;3:1148-57. [PMID: 26014098 DOI: 10.1158/2326-6066.CIR-15-0059] [Cited by in Crossref: 249] [Cited by in F6Publishing: 151] [Article Influence: 35.6] [Reference Citation Analysis]
596 Choi SH, Seong J. Stereotactic Body Radiotherapy: Does It Have a Role in Management of Hepatocellular Carcinoma? Yonsei Med J. 2018;59:912-922. [PMID: 30187697 DOI: 10.3349/ymj.2018.59.8.912] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 2.8] [Reference Citation Analysis]
597 Kovacsovics-Bankowski M, Chisholm L, Vercellini J, Tucker CG, Montler R, Haley D, Newell P, Ma J, Tseng P, Wolf R, Vetto JT, Hammill C, Hansen P, Weinberg AD. Detailed characterization of tumor infiltrating lymphocytes in two distinct human solid malignancies show phenotypic similarities. J Immunother Cancer 2014;2:38. [PMID: 25436113 DOI: 10.1186/s40425-014-0038-9] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 2.6] [Reference Citation Analysis]
598 Cheung LS, Fu J, Kumar P, Kumar A, Urbanowski ME, Ihms EA, Parveen S, Bullen CK, Patrick GJ, Harrison R, Murphy JR, Pardoll DM, Bishai WR. Second-generation IL-2 receptor-targeted diphtheria fusion toxin exhibits antitumor activity and synergy with anti-PD-1 in melanoma. Proc Natl Acad Sci U S A 2019;116:3100-5. [PMID: 30718426 DOI: 10.1073/pnas.1815087116] [Cited by in Crossref: 32] [Cited by in F6Publishing: 22] [Article Influence: 10.7] [Reference Citation Analysis]
599 Goldman N, Lomakova YD, Londregan J, Bucknum A, DePierri K, Somerville J, Riggs JE. High macrophage PD-L1 expression not responsible for T cell suppression. Cell Immunol 2018;324:50-8. [PMID: 29305065 DOI: 10.1016/j.cellimm.2017.12.013] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
600 Naidoo J, Page DB, Wolchok JD. Immune modulation for cancer therapy. Br J Cancer. 2014;111:2214-2219. [PMID: 25211661 DOI: 10.1038/bjc.2014.348] [Cited by in Crossref: 96] [Cited by in F6Publishing: 83] [Article Influence: 12.0] [Reference Citation Analysis]
601 Naidoo J, Schindler K, Querfeld C, Busam K, Cunningham J, Page DB, Postow MA, Weinstein A, Lucas AS, Ciccolini KT, Quigley EA, Lesokhin AM, Paik PK, Chaft JE, Segal NH, D'Angelo SP, Dickson MA, Wolchok JD, Lacouture ME. Autoimmune Bullous Skin Disorders with Immune Checkpoint Inhibitors Targeting PD-1 and PD-L1. Cancer Immunol Res 2016;4:383-9. [PMID: 26928461 DOI: 10.1158/2326-6066.CIR-15-0123] [Cited by in Crossref: 155] [Cited by in F6Publishing: 70] [Article Influence: 25.8] [Reference Citation Analysis]
602 Alessandrino F, Smith DA, Spierling A, Kikano E, Somarouthu B, Tirumani SH, Ramaiya NH. Cancer Clinical Trials: What Every Radiologist Wants to Know but Is Afraid to Ask. AJR Am J Roentgenol 2021;216:1099-111. [PMID: 33594911 DOI: 10.2214/AJR.20.22852] [Reference Citation Analysis]
603 Nagano M, Kohsaka S, Hayashi T, Ueno T, Kojima S, Shinozaki-Ushiku A, Morita S, Tsuda M, Tanaka S, Shinohara T, Omori Y, Sugaya F, Kato H, Narita Y, Nakajima J, Suzuki K, Takamochi K, Mano H. Comprehensive molecular profiling of pulmonary pleomorphic carcinoma. NPJ Precis Oncol 2021;5:57. [PMID: 34158601 DOI: 10.1038/s41698-021-00201-3] [Reference Citation Analysis]
604 Ong M, Ibrahim AM, Bourassa-Blanchette S, Canil C, Fairhead T, Knoll G. Antitumor activity of nivolumab on hemodialysis after renal allograft rejection. J Immunother Cancer 2016;4:64. [PMID: 27777773 DOI: 10.1186/s40425-016-0171-8] [Cited by in Crossref: 56] [Cited by in F6Publishing: 57] [Article Influence: 9.3] [Reference Citation Analysis]
605 Wang M, Busuttil RA, Pattison S, Neeson PJ, Boussioutas A. Immunological battlefield in gastric cancer and role of immunotherapies. World J Gastroenterol 2016; 22(28): 6373-6384 [PMID: 27605873 DOI: 10.3748/wjg.v22.i28.6373] [Cited by in CrossRef: 18] [Cited by in F6Publishing: 16] [Article Influence: 3.0] [Reference Citation Analysis]
606 McDermott DF, Cheng SC, Signoretti S, Margolin KA, Clark JI, Sosman JA, Dutcher JP, Logan TF, Curti BD, Ernstoff MS, Appleman L, Wong MK, Khushalani NI, Oleksowicz L, Vaishampayan UN, Mier JW, Panka DJ, Bhatt RS, Bailey AS, Leibovich BC, Kwon ED, Kabbinavar FF, Belldegrun AS, Figlin RA, Pantuck AJ, Regan MM, Atkins MB. The high-dose aldesleukin "select" trial: a trial to prospectively validate predictive models of response to treatment in patients with metastatic renal cell carcinoma. Clin Cancer Res 2015;21:561-8. [PMID: 25424850 DOI: 10.1158/1078-0432.CCR-14-1520] [Cited by in Crossref: 98] [Cited by in F6Publishing: 51] [Article Influence: 12.3] [Reference Citation Analysis]
607 Stukalin I, Alimohamed N, Heng DY. Contemporary Treatment of Metastatic Renal Cell Carcinoma. Oncol Rev. 2016;10:295. [PMID: 27471582 DOI: 10.4081/oncol.2016.295] [Cited by in Crossref: 19] [Cited by in F6Publishing: 26] [Article Influence: 3.2] [Reference Citation Analysis]
608 Kitano S, Nakayama T, Yamashita M. Biomarkers for Immune Checkpoint Inhibitors in Melanoma. Front Oncol 2018;8:270. [PMID: 30073150 DOI: 10.3389/fonc.2018.00270] [Cited by in Crossref: 32] [Cited by in F6Publishing: 29] [Article Influence: 8.0] [Reference Citation Analysis]
609 Samaan MA, Pavlidis P, Papa S, Powell N, Irving PM. Gastrointestinal toxicity of immune checkpoint inhibitors: from mechanisms to management. Nat Rev Gastroenterol Hepatol. 2018;15:222-234. [PMID: 29512649 DOI: 10.1038/nrgastro.2018.14] [Cited by in Crossref: 42] [Cited by in F6Publishing: 42] [Article Influence: 10.5] [Reference Citation Analysis]
610 Carbognin L, Pilotto S, Milella M, Vaccaro V, Brunelli M, Caliò A, Cuppone F, Sperduti I, Giannarelli D, Chilosi M. Differential Activity of Nivolumab, Pembrolizumab and MPDL3280A according to the Tumor Expression of Programmed Death-Ligand-1 (PD-L1): Sensitivity Analysis of Trials in Melanoma, Lung and Genitourinary Cancers. PLoS One. 2015;10:e0130142. [PMID: 26086854 DOI: 10.1371/journal.pone.0130142] [Cited by in Crossref: 294] [Cited by in F6Publishing: 283] [Article Influence: 42.0] [Reference Citation Analysis]
611 Johnpulle RA, Johnson DB, Sosman JA. Molecular Targeted Therapy Approaches for BRAF Wild-Type Melanoma. Curr Oncol Rep 2016;18:6. [PMID: 26743513 DOI: 10.1007/s11912-015-0485-6] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 3.3] [Reference Citation Analysis]
612 Zheng L. PD-L1 Expression in Pancreatic Cancer. J Natl Cancer Inst. 2017;109. [PMID: 28131993 DOI: 10.1093/jnci/djw304] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 3.4] [Reference Citation Analysis]
613 Lin Z, Chen X, Li Z, Luo Y, Fang Z, Xu B, Han M. PD-1 Antibody Monotherapy for Malignant Melanoma: A Systematic Review and Meta-Analysis. PLoS One 2016;11:e0160485. [PMID: 27483468 DOI: 10.1371/journal.pone.0160485] [Cited by in Crossref: 22] [Cited by in F6Publishing: 19] [Article Influence: 3.7] [Reference Citation Analysis]
614 Wang X, Wong K, Ouyang W, Rutz S. Targeting IL-10 Family Cytokines for the Treatment of Human Diseases. Cold Spring Harb Perspect Biol 2019;11:a028548. [PMID: 29038121 DOI: 10.1101/cshperspect.a028548] [Cited by in Crossref: 43] [Cited by in F6Publishing: 40] [Article Influence: 14.3] [Reference Citation Analysis]
615 Kashima Y, Togashi Y, Fukuoka S, Kamada T, Irie T, Suzuki A, Nakamura Y, Shitara K, Minamide T, Yoshida T, Taoka N, Kawase T, Wada T, Inaki K, Chihara M, Ebisuno Y, Tsukamoto S, Fujii R, Ohashi A, Suzuki Y, Tsuchihara K, Nishikawa H, Doi T. Potentiality of multiple modalities for single-cell analyses to evaluate the tumor microenvironment in clinical specimens. Sci Rep 2021;11:341. [PMID: 33431933 DOI: 10.1038/s41598-020-79385-w] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
616 Salik B, Smyth MJ, Nakamura K. Targeting immune checkpoints in hematological malignancies. J Hematol Oncol 2020;13:111. [PMID: 32787882 DOI: 10.1186/s13045-020-00947-6] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 6.5] [Reference Citation Analysis]
617 Rajan A, Schrump DS. Precision Therapy for Lung Cancer: Tyrosine Kinase Inhibitors and Beyond. Semin Thorac Cardiovasc Surg 2015;27:36-48. [PMID: 26074108 DOI: 10.1053/j.semtcvs.2015.04.002] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
618 Menon H, Ramapriyan R, Cushman TR, Verma V, Kim HH, Schoenhals JE, Atalar C, Selek U, Chun SG, Chang JY, Barsoumian HB, Nguyen QN, Altan M, Cortez MA, Hahn SM, Welsh JW. Role of Radiation Therapy in Modulation of the Tumor Stroma and Microenvironment. Front Immunol 2019;10:193. [PMID: 30828330 DOI: 10.3389/fimmu.2019.00193] [Cited by in Crossref: 48] [Cited by in F6Publishing: 47] [Article Influence: 16.0] [Reference Citation Analysis]
619 Wang F, Yang S, Palmer N, Fox K, Kohane IS, Liao KP, Yu KH, Kou SC. Real-world data analyses unveiled the immune-related adverse effects of immune checkpoint inhibitors across cancer types. NPJ Precis Oncol 2021;5:82. [PMID: 34508179 DOI: 10.1038/s41698-021-00223-x] [Reference Citation Analysis]
620 Sun Q, Barz M, De Geest BG, Diken M, Hennink WE, Kiessling F, Lammers T, Shi Y. Nanomedicine and macroscale materials in immuno-oncology. Chem Soc Rev 2019;48:351-81. [PMID: 30465669 DOI: 10.1039/c8cs00473k] [Cited by in Crossref: 74] [Cited by in F6Publishing: 18] [Article Influence: 24.7] [Reference Citation Analysis]
621 Zhao H, Luo F, Xue J, Li S, Xu RH. Emerging immunological strategies: recent advances and future directions. Front Med 2021. [PMID: 34874513 DOI: 10.1007/s11684-021-0886-x] [Reference Citation Analysis]
622 Fujiwara M, Komai Y, Yuasa T, Numao N, Yamamoto S, Fukui I, Yonese J. Pembrolizumab for a patient with metastatic castration-resistant prostate cancer with microsatellite instability-high. IJU Case Rep 2020;3:62-4. [PMID: 32743472 DOI: 10.1002/iju5.12144] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
623 Nguyen LT, Ohashi PS. Clinical blockade of PD1 and LAG3--potential mechanisms of action. Nat Rev Immunol. 2015;15:45-56. [PMID: 25534622 DOI: 10.1038/nri3790] [Cited by in Crossref: 339] [Cited by in F6Publishing: 320] [Article Influence: 48.4] [Reference Citation Analysis]
624 Doroshow DB, Bhalla S, Beasley MB, Sholl LM, Kerr KM, Gnjatic S, Wistuba II, Rimm DL, Tsao MS, Hirsch FR. PD-L1 as a biomarker of response to immune-checkpoint inhibitors. Nat Rev Clin Oncol 2021;18:345-62. [PMID: 33580222 DOI: 10.1038/s41571-021-00473-5] [Cited by in Crossref: 27] [Cited by in F6Publishing: 27] [Article Influence: 27.0] [Reference Citation Analysis]
625 Azuma T, Sugihara T, Honda S, Yoshizaki U, Niimi F, Tsuru I, Kume H. Metastatic renal cell carcinoma regains sensitivity to tyrosine kinase inhibitor after nivolumab treatment: A case report. Oncol Lett 2019;17:4011-5. [PMID: 30881514 DOI: 10.3892/ol.2019.10027] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
626 Wang Y, Liang Y, Xu H, Zhang X, Mao T, Cui J, Yao J, Wang Y, Jiao F, Xiao X, Hu J, Xia Q, Zhang X, Wang X, Sun Y, Fu D, Shen L, Xu X, Xue J, Wang L. Single-cell analysis of pancreatic ductal adenocarcinoma identifies a novel fibroblast subtype associated with poor prognosis but better immunotherapy response. Cell Discov 2021;7:36. [PMID: 34035226 DOI: 10.1038/s41421-021-00271-4] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
627 Sur D, Lungulescu C, Puscariu I, Volovat SR, Preda M, Mateianu EA, Lungulescu CV. Immunotherapy-Related Publications in Colorectal Cancer: A Bibliometric Analysis. Healthcare 2022;10:75. [DOI: 10.3390/healthcare10010075] [Reference Citation Analysis]
628 Shen H, Sun T, Hoang HH, Burchfield JS, Hamilton GF, Mittendorf EA, Ferrari M. Enhancing cancer immunotherapy through nanotechnology-mediated tumor infiltration and activation of immune cells. Semin Immunol 2017;34:114-22. [PMID: 28947107 DOI: 10.1016/j.smim.2017.09.002] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 3.8] [Reference Citation Analysis]
629 D'Souza NM, Fang P, Logan J, Yang J, Jiang W, Li J. Combining Radiation Therapy with Immune Checkpoint Blockade for Central Nervous System Malignancies. Front Oncol 2016;6:212. [PMID: 27774435 DOI: 10.3389/fonc.2016.00212] [Cited by in Crossref: 14] [Cited by in F6Publishing: 22] [Article Influence: 2.3] [Reference Citation Analysis]
630 Purroy N, Wu CJ. Coevolution of Leukemia and Host Immune Cells in Chronic Lymphocytic Leukemia. Cold Spring Harb Perspect Med 2017;7:a026740. [PMID: 28096240 DOI: 10.1101/cshperspect.a026740] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 2.4] [Reference Citation Analysis]
631 Osawa Y, Kojika E, Nishikawa K, Kimura M, Osakaya S, Miyauchi H, Kanto T, Kawakami Y, Kimura K. Programmed cell death ligand 1 (PD-L1) blockade attenuates metastatic colon cancer growth in cAMP-response element-binding protein (CREB)-binding protein (CBP)/β-catenin inhibitor-treated livers. Oncotarget 2019;10:3013-26. [PMID: 31105882 DOI: 10.18632/oncotarget.26892] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
632 Lin L, Huang K, Tu Z, Zhu X, Li J, Lei K, Luo M, Wang P, Gong C, Long X, Wu L. Integrin Alpha-2 as a Potential Prognostic and Predictive Biomarker for Patients With Lower-Grade Glioma. Front Oncol 2021;11:738651. [PMID: 34778054 DOI: 10.3389/fonc.2021.738651] [Reference Citation Analysis]
633 Hickmott L, De La Peña H, Turner H, Ahmed F, Protheroe A, Grossman A, Gupta A. Anti-PD-L1 atezolizumab-Induced Autoimmune Diabetes: a Case Report and Review of the Literature. Target Oncol 2017;12:235-41. [PMID: 28255845 DOI: 10.1007/s11523-017-0480-y] [Cited by in Crossref: 26] [Cited by in F6Publishing: 23] [Article Influence: 5.2] [Reference Citation Analysis]
634 Akella P, Loganathan S, Jindal V, Akhtar J, Lal A. Anti PD-1 immunotherapy related interstitial lung disease presenting as respiratory failure - A review with case series. Respir Med Case Rep 2019;26:17-22. [PMID: 30456167 DOI: 10.1016/j.rmcr.2018.11.005] [Cited by in Crossref: 4] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
635 Ma Q, Chen Y, Xiao F, Hao Y, Song Z, Zhang J, Okuda K, Um SW, Silva M, Shimada Y, Si C, Liang C. A signature of estimate-stromal-immune score-based genes associated with the prognosis of lung adenocarcinoma. Transl Lung Cancer Res 2021;10:1484-500. [PMID: 33889524 DOI: 10.21037/tlcr-21-223] [Reference Citation Analysis]
636 Galluzzi L, Eggermont A, Kroemer G. Doubling the blockade for melanoma immunotherapy. Oncoimmunology 2016;5:e1106127. [PMID: 26942094 DOI: 10.1080/2162402X.2015.1106127] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.1] [Reference Citation Analysis]
637 Lina TT, Alzahrani S, Gonzalez J, Pinchuk IV, Beswick EJ, Reyes VE. Immune evasion strategies used by Helicobacter pyloriWorld J Gastroenterol 2014; 20(36): 12753-12766 [PMID: 25278676 DOI: 10.3748/wjg.v20.i36.12753] [Cited by in CrossRef: 49] [Cited by in F6Publishing: 48] [Article Influence: 6.1] [Reference Citation Analysis]
638 García F, Plana M, Climent N, León A, Gatell JM, Gallart T. Dendritic cell based vaccines for HIV infection: the way ahead. Hum Vaccin Immunother 2013;9:2445-52. [PMID: 23912672 DOI: 10.4161/hv.25876] [Cited by in Crossref: 44] [Cited by in F6Publishing: 45] [Article Influence: 4.9] [Reference Citation Analysis]
639 Caswell DR, Swanton C. The role of tumour heterogeneity and clonal cooperativity in metastasis, immune evasion and clinical outcome. BMC Med 2017;15:133. [PMID: 28716075 DOI: 10.1186/s12916-017-0900-y] [Cited by in Crossref: 89] [Cited by in F6Publishing: 89] [Article Influence: 17.8] [Reference Citation Analysis]
640 Mei L, Du W, Ma WW. Targeting stromal microenvironment in pancreatic ductal adenocarcinoma: controversies and promises. J Gastrointest Oncol. 2016;7:487-494. [PMID: 27284483 DOI: 10.21037/jgo.2016.03.03] [Cited by in Crossref: 30] [Cited by in F6Publishing: 28] [Article Influence: 5.0] [Reference Citation Analysis]
641 Kroll AV, Jiang Y, Zhou J, Holay M, Fang RH, Zhang L. Biomimetic Nanoparticle Vaccines for Cancer Therapy. Adv Biosyst 2019;3:e1800219. [PMID: 31728404 DOI: 10.1002/adbi.201800219] [Cited by in Crossref: 32] [Cited by in F6Publishing: 29] [Article Influence: 8.0] [Reference Citation Analysis]
642 Lavoué V, Foucher F, Henno S, Bauville E, Catros V, Cabillic F, Levêque J. [Immunotherapy in epithelial ovarian carcinoma: hope and reality]. J Gynecol Obstet Biol Reprod (Paris) 2014;43:198-210. [PMID: 24230482 DOI: 10.1016/j.jgyn.2013.10.004] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
643 Fu Y, Liu S, Yin S, Niu W, Xiong W, Tan M, Li G, Zhou M. The reverse Warburg effect is likely to be an Achilles' heel of cancer that can be exploited for cancer therapy. Oncotarget 2017;8:57813-25. [PMID: 28915713 DOI: 10.18632/oncotarget.18175] [Cited by in Crossref: 105] [Cited by in F6Publishing: 100] [Article Influence: 21.0] [Reference Citation Analysis]
644 Aung PP, Sukswai N, Nejati R, Loghavi S, Chen W, Torres-Cabala CA, Yin CC, Konopleva M, Zheng X, Wang J, Tang Z, Medeiros LJ, Prieto VG, Pemmaraju N, Khoury JD. PD1/PD-L1 Expression in Blastic Plasmacytoid Dendritic Cell Neoplasm. Cancers (Basel) 2019;11:E695. [PMID: 31109153 DOI: 10.3390/cancers11050695] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
645 Wagner NB, Lenders MM, Kühl K, Reinhardt L, André F, Dudda M, Ring N, Ebel C, Stäger R, Zellweger C, Lang R, Paar M, Gussek P, Richtig G, Stürmer SH, Kimeswenger S, Oellinger A, Forschner A, Leiter U, Weide B, Gassenmaier M, Schraag A, Klumpp B, Hoetzenecker W, Berking C, Richtig E, Ziemer M, Mangana J, Terheyden P, Loquai C, Nguyen VA, Gebhardt C, Meier F, Diem S, Cozzio A, Flatz L, Röcken M, Garbe C, Eigentler TK. Pretreatment metastatic growth rate determines clinical outcome of advanced melanoma patients treated with anti-PD-1 antibodies: a multicenter cohort study. J Immunother Cancer 2021;9:e002350. [PMID: 33986126 DOI: 10.1136/jitc-2021-002350] [Reference Citation Analysis]
646 Gress RE, Miller JS, Battiwalla M, Bishop MR, Giralt SA, Hardy NM, Kröger N, Wayne AS, Landau DA, Wu CJ. Proceedings from the National Cancer Institute's Second International Workshop on the Biology, Prevention, and Treatment of Relapse after Hematopoietic Stem Cell Transplantation: Part I. Biology of relapse after transplantation. Biol Blood Marrow Transplant 2013;19:1537-45. [PMID: 24018395 DOI: 10.1016/j.bbmt.2013.08.010] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 1.8] [Reference Citation Analysis]
647 Hira-Miyazawa M, Nakamura H, Hirai M, Kobayashi Y, Kitahara H, Bou-Gharios G, Kawashiri S. Regulation of programmed-death ligand in the human head and neck squamous cell carcinoma microenvironment is mediated through matrix metalloproteinase-mediated proteolytic cleavage. Int J Oncol 2018;52:379-88. [PMID: 29345283 DOI: 10.3892/ijo.2017.4221] [Cited by in Crossref: 7] [Cited by in F6Publishing: 11] [Article Influence: 1.4] [Reference Citation Analysis]
648 Collet L, Delrieu L, Bouhamama A, Crochet H, Swalduz A, Nerot A, Marchal T, Chabaud S, Heudel PE. Association between Body Mass Index and Survival Outcome in Metastatic Cancer Patients Treated by Immunotherapy: Analysis of a French Retrospective Cohort. Cancers (Basel) 2021;13:2200. [PMID: 34063692 DOI: 10.3390/cancers13092200] [Reference Citation Analysis]
649 Muller L, Mitsuhashi M, Simms P, Gooding WE, Whiteside TL. Tumor-derived exosomes regulate expression of immune function-related genes in human T cell subsets. Sci Rep. 2016;6:20254. [PMID: 26842680 DOI: 10.1038/srep20254] [Cited by in Crossref: 176] [Cited by in F6Publishing: 181] [Article Influence: 29.3] [Reference Citation Analysis]
650 Brenner E, Schörg BF, Ahmetlić F, Wieder T, Hilke FJ, Simon N, Schroeder C, Demidov G, Riedel T, Fehrenbacher B, Schaller M, Forschner A, Eigentler T, Niessner H, Sinnberg T, Böhm KS, Hömberg N, Braumüller H, Dauch D, Zwirner S, Zender L, Sonanini D, Geishauser A, Bauer J, Eichner M, Jarick KJ, Beilhack A, Biskup S, Döcker D, Schadendorf D, Quintanilla-Martinez L, Pichler BJ, Kneilling M, Mocikat R, Röcken M. Cancer immune control needs senescence induction by interferon-dependent cell cycle regulator pathways in tumours. Nat Commun 2020;11:1335. [PMID: 32165639 DOI: 10.1038/s41467-020-14987-6] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 11.0] [Reference Citation Analysis]
651 Erickson JJ, Rogers MC, Hastings AK, Tollefson SJ, Williams JV. Programmed death-1 impairs secondary effector lung CD8⁺ T cells during respiratory virus reinfection. J Immunol 2014;193:5108-17. [PMID: 25339663 DOI: 10.4049/jimmunol.1302208] [Cited by in Crossref: 26] [Cited by in F6Publishing: 26] [Article Influence: 3.3] [Reference Citation Analysis]
652 Serrano Nájera G, Narganes Carlón D, Crowther DJ. TrendyGenes, a computational pipeline for the detection of literature trends in academia and drug discovery. Sci Rep 2021;11:15747. [PMID: 34344904 DOI: 10.1038/s41598-021-94897-9] [Reference Citation Analysis]
653 Khair DO, Bax HJ, Mele S, Crescioli S, Pellizzari G, Khiabany A, Nakamura M, Harris RJ, French E, Hoffmann RM, Williams IP, Cheung A, Thair B, Beales CT, Touizer E, Signell AW, Tasnova NL, Spicer JF, Josephs DH, Geh JL, MacKenzie Ross A, Healy C, Papa S, Lacy KE, Karagiannis SN. Combining Immune Checkpoint Inhibitors: Established and Emerging Targets and Strategies to Improve Outcomes in Melanoma. Front Immunol 2019;10:453. [PMID: 30941125 DOI: 10.3389/fimmu.2019.00453] [Cited by in Crossref: 88] [Cited by in F6Publishing: 77] [Article Influence: 29.3] [Reference Citation Analysis]
654 Jin J, Si J, Liu Y, Wang H, Ni R, Wang J. Elevated serum soluble programmed cell death ligand 1 concentration as a potential marker for poor prognosis in small cell lung cancer patients with chemotherapy. Respir Res 2018;19:197. [PMID: 30290817 DOI: 10.1186/s12931-018-0885-x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
655 Russell L, Peng KW, Russell SJ, Diaz RM. Oncolytic Viruses: Priming Time for Cancer Immunotherapy. BioDrugs 2019;33:485-501. [PMID: 31321623 DOI: 10.1007/s40259-019-00367-0] [Cited by in Crossref: 43] [Cited by in F6Publishing: 38] [Article Influence: 21.5] [Reference Citation Analysis]
656 MacLachlan BJ, Mason GH, Greenshields-Watson A, Triebel F, Gallimore A, Cole DK, Godkin A. Molecular characterization of HLA class II binding to the LAG-3 T cell co-inhibitory receptor. Eur J Immunol 2021;51:331-41. [PMID: 32920841 DOI: 10.1002/eji.202048753] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
657 Jiang H, Cui N, Yang L, Liu C, Yue L, Guo L, Wang H, Shao Z. Altered follicular helper T cell impaired antibody production in a murine model of myelodysplastic syndromes. Oncotarget 2017;8:98270-9. [PMID: 29228688 DOI: 10.18632/oncotarget.21548] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
658 Lu X, Horner JW, Paul E, Shang X, Troncoso P, Deng P, Jiang S, Chang Q, Spring DJ, Sharma P, Zebala JA, Maeda DY, Wang YA, DePinho RA. Effective combinatorial immunotherapy for castration-resistant prostate cancer. Nature 2017;543:728-32. [PMID: 28321130 DOI: 10.1038/nature21676] [Cited by in Crossref: 202] [Cited by in F6Publishing: 202] [Article Influence: 40.4] [Reference Citation Analysis]
659 Dai Y, Zhao W, Yue L, Dai X, Rong D, Wu F, Gu J, Qian X. Perspectives on Immunotherapy of Metastatic Colorectal Cancer. Front Oncol 2021;11:659964. [PMID: 34178645 DOI: 10.3389/fonc.2021.659964] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
660 Palmer JD, Zaorsky NG, Witek M, Lu B. Molecular markers to predict clinical outcome and radiation induced toxicity in lung cancer. J Thorac Dis 2014;6:387-98. [PMID: 24688783 DOI: 10.3978/j.issn.2072-1439.2013.12.04] [Cited by in F6Publishing: 15] [Reference Citation Analysis]
661 Pennock GK, Chow LQ. The Evolving Role of Immune Checkpoint Inhibitors in Cancer Treatment. Oncologist. 2015;20:812-822. [PMID: 26069281 DOI: 10.1634/theoncologist.2014-0422] [Cited by in Crossref: 108] [Cited by in F6Publishing: 101] [Article Influence: 15.4] [Reference Citation Analysis]
662 McLaughlin J, Han G, Schalper KA, Carvajal-Hausdorf D, Pelekanou V, Rehman J, Velcheti V, Herbst R, LoRusso P, Rimm DL. Quantitative Assessment of the Heterogeneity of PD-L1 Expression in Non-Small-Cell Lung Cancer. JAMA Oncol. 2016;2:46-54. [PMID: 26562159 DOI: 10.1001/jamaoncol.2015.3638] [Cited by in Crossref: 431] [Cited by in F6Publishing: 460] [Article Influence: 71.8] [Reference Citation Analysis]
663 Fuertes Marraco SA, Neubert NJ, Verdeil G, Speiser DE. Inhibitory Receptors Beyond T Cell Exhaustion. Front Immunol. 2015;6:310. [PMID: 26167163 DOI: 10.3389/fimmu.2015.00310] [Cited by in Crossref: 122] [Cited by in F6Publishing: 115] [Article Influence: 17.4] [Reference Citation Analysis]
664 Shao Z, Wang AZ, George DJ, Zhang T. Novel immunotherapy approaches for metastatic urothelial and renal cell carcinoma. Asian J Urol 2016;3:268-77. [PMID: 29264195 DOI: 10.1016/j.ajur.2016.08.013] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
665 Simon R. Immunotherapy is different: Implications for vaccine clinical trial design. Hum Vaccin Immunother 2017;13:2179-84. [PMID: 28498733 DOI: 10.1080/21645515.2017.1316910] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
666 Ernst MPT, Broeders M, Herrero-Hernandez P, Oussoren E, van der Ploeg AT, Pijnappel WWMP. Ready for Repair? Gene Editing Enters the Clinic for the Treatment of Human Disease. Mol Ther Methods Clin Dev 2020;18:532-57. [PMID: 32775490 DOI: 10.1016/j.omtm.2020.06.022] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 10.5] [Reference Citation Analysis]
667 Sun Z, Fourcade J, Pagliano O, Chauvin JM, Sander C, Kirkwood JM, Zarour HM. IL10 and PD-1 Cooperate to Limit the Activity of Tumor-Specific CD8+ T Cells. Cancer Res 2015;75:1635-44. [PMID: 25720800 DOI: 10.1158/0008-5472.CAN-14-3016] [Cited by in Crossref: 82] [Cited by in F6Publishing: 57] [Article Influence: 11.7] [Reference Citation Analysis]
668 Woods K, Knights AJ, Anaka M, Schittenhelm RB, Purcell AW, Behren A, Cebon J. Mismatch in epitope specificities between IFNγ inflamed and uninflamed conditions leads to escape from T lymphocyte killing in melanoma. J Immunother Cancer 2016;4:10. [PMID: 26885372 DOI: 10.1186/s40425-016-0111-7] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 2.7] [Reference Citation Analysis]
669 Dai M, Yip YY, Hellstrom I, Hellstrom KE. Curing mice with large tumors by locally delivering combinations of immunomodulatory antibodies. Clin Cancer Res 2015;21:1127-38. [PMID: 25142145 DOI: 10.1158/1078-0432.CCR-14-1339] [Cited by in Crossref: 45] [Cited by in F6Publishing: 26] [Article Influence: 5.6] [Reference Citation Analysis]
670 Liechtenstein T, Perez-Janices N, Blanco-Luquin I, Goyvaerts C, Schwarze J, Dufait I, Lanna A, Ridder M, Guerrero-Setas D, Breckpot K, Escors D. Anti-melanoma vaccines engineered to simultaneously modulate cytokine priming and silence PD-L1 characterized using ex vivo myeloid-derived suppressor cells as a readout of therapeutic efficacy. Oncoimmunology 2014;3:e945378. [PMID: 25954597 DOI: 10.4161/21624011.2014.945378] [Cited by in Crossref: 20] [Cited by in F6Publishing: 23] [Article Influence: 2.5] [Reference Citation Analysis]
671 Snahnicanova Z, Kasubova I, Kalman M, Grendar M, Mikolajcik P, Gabonova E, Laca L, Caprnda M, Rodrigo L, Ciccocioppo R, Kruzliak P, Plank L, Lasabova Z. Genetic and epigenetic analysis of the beta-2-microglobulin gene in microsatellite instable colorectal cancer. Clin Exp Med 2020;20:87-95. [PMID: 31853669 DOI: 10.1007/s10238-019-00601-7] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
672 Meyers DE, Thakur S, Thirukkumaran CM, Morris DG. Oncolytic virotherapy as an immunotherapeutic strategy for multiple myeloma. Blood Cancer J 2017;7:640. [PMID: 29208938 DOI: 10.1038/s41408-017-0020-0] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 2.6] [Reference Citation Analysis]
673 Xu L, Chen X, Shen M, Yang DR, Fang L, Weng G, Tsai Y, Keng PC, Chen Y, Lee SO. Inhibition of IL-6-JAK/Stat3 signaling in castration-resistant prostate cancer cells enhances the NK cell-mediated cytotoxicity via alteration of PD-L1/NKG2D ligand levels. Mol Oncol 2018;12:269-86. [PMID: 28865178 DOI: 10.1002/1878-0261.12135] [Cited by in Crossref: 33] [Cited by in F6Publishing: 33] [Article Influence: 8.3] [Reference Citation Analysis]
674 Hurez V, Padrón ÁS, Svatek RS, Curiel TJ. Considerations for successful cancer immunotherapy in aged hosts. Clin Exp Immunol 2017;187:53-63. [PMID: 27690272 DOI: 10.1111/cei.12875] [Cited by in Crossref: 42] [Cited by in F6Publishing: 35] [Article Influence: 7.0] [Reference Citation Analysis]
675 Mishra DK, Rocha HJ, Miller R, Kim MP. Immune cells inhibit the tumor metastasis in the 4D cellular lung model by reducing the number of live circulating tumor cells. Sci Rep 2018;8:16569. [PMID: 30410108 DOI: 10.1038/s41598-018-34983-7] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
676 Lutz-Nicoladoni C, Wolf D, Sopper S. Modulation of Immune Cell Functions by the E3 Ligase Cbl-b. Front Oncol 2015;5:58. [PMID: 25815272 DOI: 10.3389/fonc.2015.00058] [Cited by in Crossref: 44] [Cited by in F6Publishing: 44] [Article Influence: 6.3] [Reference Citation Analysis]
677 Overacre-Delgoffe AE, Vignali DAA. Treg Fragility: A Prerequisite for Effective Antitumor Immunity? Cancer Immunol Res 2018;6:882-7. [PMID: 30068755 DOI: 10.1158/2326-6066.CIR-18-0066] [Cited by in Crossref: 32] [Cited by in F6Publishing: 20] [Article Influence: 10.7] [Reference Citation Analysis]
678 Palena C, Hamilton DH. Immune Targeting of Tumor Epithelial-Mesenchymal Transition via Brachyury-Based Vaccines. Adv Cancer Res 2015;128:69-93. [PMID: 26216630 DOI: 10.1016/bs.acr.2015.04.001] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.6] [Reference Citation Analysis]
679 Yang X, Lei P, Huang L, Tang X, Wei B, Wei H. Prognostic value of LRRC4C in Colon and Gastric Cancers correlates with Tumour Microenvironment Immunity. Int J Biol Sci 2021;17:1413-27. [PMID: 33867855 DOI: 10.7150/ijbs.58876] [Reference Citation Analysis]
680 Abdel-Rahman O. Combination or single-agent ipilimumab as immunotherapy of advanced melanoma: a critical review. Melanoma Manag 2016;3:231-43. [PMID: 30190892 DOI: 10.2217/mmt-2016-0011] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
681 Lee SM, Wages NA, Goodman KA, Lockhart AC. Designing Dose-Finding Phase I Clinical Trials: Top 10 Questions That Should Be Discussed With Your Statistician. JCO Precis Oncol 2021;5:317-24. [PMID: 34151131 DOI: 10.1200/PO.20.00379] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
682 Mehta A, Oklu R, Sheth RA. Thermal Ablative Therapies and Immune Checkpoint Modulation: Can Locoregional Approaches Effect a Systemic Response? Gastroenterol Res Pract. 2016;2016:9251375. [PMID: 27051417 DOI: 10.1155/2016/9251375] [Cited by in Crossref: 41] [Cited by in F6Publishing: 39] [Article Influence: 6.8] [Reference Citation Analysis]
683 Chaudhri A, Xiao Y, Klee AN, Wang X, Zhu B, Freeman GJ. PD-L1 Binds to B7-1 Only In Cis on the Same Cell Surface. Cancer Immunol Res 2018;6:921-9. [PMID: 29871885 DOI: 10.1158/2326-6066.CIR-17-0316] [Cited by in Crossref: 61] [Cited by in F6Publishing: 40] [Article Influence: 15.3] [Reference Citation Analysis]
684 Murakami D, Harada H, Yamato M, Amano Y. Cytomegalovirus-associated esophagitis on early esophageal cancer in immunocompetent host: a case report. Gut Pathog 2021;13:24. [PMID: 33863376 DOI: 10.1186/s13099-021-00418-4] [Reference Citation Analysis]
685 Shi Y, Li Z, Zhou Z, Liao S, Wu Z, Li J, Yin J, Wang M, Weng M. Identification and validation of an epithelial mesenchymal transition-related gene pairs signature for prediction of overall survival in patients with skin cutaneous melanoma. PeerJ 2022;10:e12646. [DOI: 10.7717/peerj.12646] [Reference Citation Analysis]
686 Mackall CL, Merchant MS, Fry TJ. Immune-based therapies for childhood cancer. Nat Rev Clin Oncol 2014;11:693-703. [PMID: 25348789 DOI: 10.1038/nrclinonc.2014.177] [Cited by in Crossref: 64] [Cited by in F6Publishing: 55]